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EQUIPMENT TO ADDRESS INFRASTRUCTURE AND HUMAN RESOURCE  
CHALLENGES FOR RADIOTHERAPY IN LOW-RESOURCE SETTINGS 
Abstract  
Rachel Elizabeth McCarroll, B.S. 
 
Advisory Professor: Laurence E. Court, Ph.D. 
 
Millions of people in low- and middle- income countries (LMICs) are without access to 
radiation therapy and as rate of population growth in these regions increase and lifestyle 
factors which are indicative of cancer increase; the cancer burden will only rise. There are a 
multitude of reasons for lack of access but two themes among them are the lack of access to 
affordable and reliable teletherapy units and insufficient properly trained staff to deliver high 
quality care.  The purpose of this work was to investigate to two proposed efforts to improve 
access to radiotherapy in low-resource areas; an upright radiotherapy chair (to facilitate low-
cost treatment devices) and a fully automated treatment planning strategy.  
A fixed-beam patient treatment device would allow for reduced upfront and ongoing 
cost of teletherapy machines.  The enabling technology for such a device is the 
immobilization chair.  A rotating seated patient not only allows for a low-cost fixed treatment 
machine but also has dosimetric and comfort advantages. We examined the inter- and intra- 
fraction setup reproducibility, and showed they are less than 3mm, similar to reports for the 
supine position. 
The head-and-neck treatment site, one of the most challenging treatment planning, 
greatly benefits from the use of advanced treatment planning strategies. These strategies, 
however, require time consuming normal tissue and target contouring and complex plan 
optimization strategies. An automated treatment planning approach could reduce the 
additional number of medical physicists (the primary treatment planners) in LMICs by up to 
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half.  We used in-house algorithms including mutli-atlas contouring and quality assurance 
checks, combined with tools in the Eclipse Treatment Planning System®, to automate every 
step of the treatment planning process for head-and-neck cancers. Requiring only the patient 
CT scan, patient details including dose and fractionation, and contours of the gross tumor 
volume, high quality treatment plans can be created in less than 40 minutes. 
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Chapter 1: Introduction 
Cancer is a worldwide and growing epidemic; projected to kill nearly 13 million people 
by 2030. It is a fallacy that cancer is a disease only of the developed world; the most recent 
statistics showed more than two thirds of cancer-related deaths occur in low- and middle-
income countries (LMICs)(1). As the population of LMICs ages and as risk factors such as 
smoking, poor dietary habits, and sedentary lifestyles increase, the cancer burden will only 
rise(2).  
Though colloquially referred to as a single disease, cancer is a class of diseases 
which share common traits, and, therefore, the treatment of cancer is necessarily very varied. 
Treatment options often involve one or more of three common techniques; surgery, 
chemotherapy, and/or radiation therapy. Surgical intervention has the longest history with 
records dating back to Greek physicians in the first and second centuries A.D.(3) and may be 
required for up to 80% of cancer patients(4). Surgery, however, is often insufficient for 
metastatic disease. Chemotherapy, introduced at the beginning of the 20th century, uses 
drugs to combat cancer growth and spread at the molecular level and can only be 
administered if sufficient laboratory facilities are also available (5). Finally, radiation therapy, 
introduced at the end of the 19th century and available for both the palliative and curative 
treatment of cancer uses energetic subatomic particles due induce DNA damage and kill 
cancer cells(6). Radiotherapy is required for the treatment of more than 50% of the cancer 
population (7).  
Radiation and its use in medicine have been intertwined from the start; in late 1895 
Wilhelm Röntgen designed an experiment to identify the source of flouresence on a painted 
cardboard screen and it was only two weeks later he took the famed first radiograph of his 
wife’s hand, which he included in the first manuscript describing this new kind of rays(8). The 
use of radiation to treat cancers came shortly thereafter, for stomach cancer in 1896, for basal 
15 | P a g e  
 
cell carcinoma in 1899, and many others to follow(9). Radiation therapy has advanced quickly 
since its introduction and an improved understanding of how to harness the biological effect of 
radiation on cancer cells, improvements in the safe and accurate delivery of radiation 
throughout the body, and, more recently, advances in computing power and have led to rapid 
changes in treatment delivery and improved patient outcomes. 
Radiation therapy has been shown to be cost-effective for both palliative and curative 
cancer treatment in LMICs (10, 11); one study showed that the cost of an entire course of 
radiation therapy in Senegal is only $300USD (12). However, due in part to the substantial 
capital investment and the ever-increasing pace of technological advancements, the practice 
of radiation oncology in developed and less developed regions rapidly is rapidly diverging. In 
low- and middle-income countries, defined as those countries with a gross national income 
per capita less than $12,235 USD and where 84% of the world’s population (13) and 57% of 
the cancer population lives(1), there exist only 30% of the world’s radiation therapy equipment 
(14). It is not only the equipment for treatment that is lacking – so too are trained personnel 
required to safely and effectively deliver treatment. It is estimated that by 2020 LMICs will 
need an additional 9,169 radiation therapy machines (3.2 times what was available in 2014), 
9,915 medical physicists (3.9 times 2014 availability), 12,149 radiation oncologists (2 times 
2014 availability), and 29,140 radiation therapists (3.7 times 2014 availability)(15). In order to 
bridge the gap in cancer care around the world, and to provide safe, effective, and possibility 
lifesaving treatment to 6.3 million people, urgent and innovative solutions are needed. 
In order to address the overwhelming demand for radiotherapy, a multi-thronged 
approach is necessary. Efforts should seek to utilize technology and ideas at the forefront of 
the field, should be developed in concert with professionals for which the solutions are aimed, 
and should utilize and build upon previous efforts. Current initiatives underway to bridge the 
gap in radiotherapy needs worldwide include efforts to provide necessary equipment and 
ancillary supplies to less developed regions, programs for the training (initial and ongoing) of 
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radiotherapy professionals, systems for peer-to-peer collaborations which encourage 
professional growth and promote high quality care, the development of low-cost and effective 
solutions, and there are many others. Despite these efforts, there remains a significant 
challenge to provide radiotherapy services worldwide. The work herein represents two 
proposed efforts; an upright radiotherapy chair and a fully automated treatment planning 
strategy. 
An Upright Radiotherapy Chair 
 External beam radiation therapy machines have been in use since the 1950s and 
early treatments had reports of patients treated in lying, seated, and standing positions (16, 
17). The invention of the computed tomography (CT) scanner in 1972 gave physicians the 
ability to accurately visualize each patient’s anatomy and, in the context of radiation therapy, 
optimize treatment delivery. The incorporation of CT image acquisition for treatment planning 
represented a breakthrough in radiation therapy and the acquisition of pre-treatment CT 
scans for use in treatment planning has become routine practice in radiation oncology clinics. 
The orientation of CT scanners is such that the patient lies, generally supine, on a treatment 
couch inside a bore with a diameter of up to 90cm (18), and this effectively requires that 
radiation treatment plans are developed for and delivered to patients in a lying position. 
Further, it requires that teletherapy machines accommodate this treatment position. 
Unfortunately, some patients, particularly those with head-and-neck or lung cancers, may 
develop orthopnea, dyspnea, dysphagia, or other conditions that make lying flat for the 
duration of treatment difficult or impossible. Further, it has been shown that dosimetric 
advantages can be had in other position; for example, when patients assume a seated or 
upright position lung volume and motion are reduced, allowing for sparing of normal tissues 
and fewer radiation-induced symptoms (19-21). 
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To accommodate the lying position during treatment delivery radiotherapy machines 
most commonly feature a rotating gantry around a stationary isocenter and this contributes 
greatly to the considerable cost of teletherapy units. In an effort to reduce the cost of 
teletherapy treatment machines and with added benefits of patient comfort and limited 
dosimetric improvement; we propose the development and validation of a treatment chair for 
use in radiation therapy. The use of treatment chair which rotates around the patient’s axis 
would allow for a fixed radiation field and tremendously reduce machine cost. In addition, 
such a treatment paradigm would allow for a reduction in cost due to shielding, set-up, 
treatment delivery, machine downtime, and other factors of which are currently under 
investigation (22-24). This lower cost machine is of interest to machine vendors and would be 
highly applicable in areas with limited resources. 
 The work herein represents an important step in the assessment of the clinical utility of 
a radiotherapy treatment chair; set-up reproducibility. As radiation treatment often occurs in 
small fractions over the course of many weeks and the prescribed treatment is developed 
from a single pre-treatment image it is critical that the patient be positioned in very similar 
positions each day; this is known as inter-fraction set-up reproducibility. Further, as radiation 
treatment, especially advanced techniques, may take more than ten minutes for delivery(25) it 
is important the patient maintains the same position for the duration of treatment; this is 
known and intra-fraction reproducibility. Both inter- and intra- fraction reproducibility are 
important aspects when considering the implementation of new patient positions into clinical 
practice. The traditional supine position has been shown to have inter- and intra- fraction 
reproducibility less than 5mm on average for treatment of the breast (26, 27), prostate (28), 
head and neck (29), and whole brain (30). The main goal of this study was to assess the 
setup reproducibility of a novel treatment chair design, paving the way for clinical use and 
supporting further investigation into a fixed-beam low-cost radiotherapy treatment machine.  
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Automated Treatment Planning 
Treatment planning is a mainstay in the field of radiation oncology. During the required 
treatment planning process a representation of the patient, most often a simulation CT, is 
used to design or select beam arrangements, shapes, energies, and combinations which will 
best deliver the prescribed therapeutic dose to the target volume while sparing as much 
normal tissue possible. The practice of treatment planning has evolved quite dramatically in 
the past thirty years. In the 1990s the practice of acquiring a computed tomography scan of 
the patient, on which the target and organs at risk are delineated and the dose delivery is 
visualized and optimized, became common practice. Compared to conventional techniques, 
3D conformal treatment allowed tumor dose to be escalated without a significant increase in 
normal tissue dose (31), thus improving tumor control (32, 33) while reducing normal tissue 
complication (34). The use of 3D conformal techniques did, however, also increase the cost, 
complexity, burden on equipment and personnel, and time needed to plan and deliver 
radiation therapy (31, 35, 36).  
Treatment planning and delivery further improved with the introduction of intensity 
modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) which rely 
on the use of non-uniform beam fluences and an inverse approach to the dose optimization 
problem. Through the use of optimization criteria and a search algorithm beam parameters 
are optimized in order to meet the constraints set by the user through the minimization (or 
maximization) of an objective function. The beam fluence variations in IMRT and VMAT offer 
distinct advantages over simpler beam shaping devices for irregularly shaped targets and 
those in close proximity to critical organs at risk. The advantages of these advanced 
techniques is underlined in the treatment of cancers in the head-and-neck. Cancers in this 
region are in close proximity of up to 25 organs at risk, and advanced planning techniques 
have been shown to significantly increase planned target coverage and conformality while 
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decreasing normal tissue complications including xerostomia and fibrosis (37-40). More than 
two thirds of the head-and-neck cancer population lives in less developed regions(1) where 
access to these advanced techniques is severely limited and while, for many clinics, the lack 
of advanced equipment is the primary barrier in the delivery of advanced treatments, there 
are many others for whom the machinery exists but treatment delivery is limited due to 
staffing considerations, this is the scenario for our partner clinics in South Africa and the 
Philippines. 
In low-resource areas the time and cost required for treatment planning, especially for 
these advanced techniques, contribute to the limited number of patients able to receive 
advanced treatment (41). The cost of personnel, including highly skilled treatment planners, 
while less than in high-income countries, represent 10% of the total cost of radiotherapy (6). 
Combined with the well documented “brain drain” on human resources in low-income areas 
(42) the need for tools which can relieve part of the staffing burden while maintaining a 
standard of care is tremendous. 
The increasing complexity of treatment planning has also brought other challenges. 
Complex treatments often involve many decisions and tradeoffs during the planning process 
and it has been shown that every IMRT and VMAT treatment plan may not offer the same 
benefits; in a study on treatment plan quality investigators found the plan quality was not 
significantly correlated with the treatment planning system, modality of delivery, plan 
complexity, education or certification of the planner, planner confidence or experience, the 
number of beams, or the number of monitor units. Instead, it was concluded, plan quality was 
most contributable to general “planner skill” (43). An automated planning strategy may also 
standardize treatment plan quality which are prone to significant variability; this variability 
represents a significant challenge when comparing patient outcomes (44) and when 
optimizing plan delivery parameters. Additionally, these advanced IMRT and VMAT 
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techniques come with a significant increase in technical burden including infrastructure 
required for plan development, quality assurance checks, and delivery.  
We propose a solution which would automate the treatment planning process for 
head-and-neck cancers; removing a time intensive aspect of the treatment planning process; 
standardizing treatment across patients, and relieving highly trained staff for other duties, 
ultimately reducing the tremendous deficit in the numbers of these staff. 
Automated methods are emerging throughout the radiotherapy process. From beam 
commissioning to patient plan checks, researchers and vendors alike are exploring 
automated methods of improving radiotherapy (45, 46), and this includes treatment planning 
(47-49). At the forefront of automated plan optimization is knowledge based planning (KBP) 
which uses information gathered from previously treated patients to generate treatment plans 
for new patients and was first reported in 1990 for its potential to organize and harness the 
current state of knowledge of treatment planning in order to improve treatment planning (50). 
With technological advancement and improved computing power, the interest in KBP has 
increased dramatically and has found recent success in the planning of breast, prostate and 
head-and-neck cancer showing an improvement in plan quality and a reduction in plan 
variability (51-54). Unfortunately, these studies fall short of full plan automation, as often 
these KBP algorithms require manual inputs. One of the most time intensive requirements of 
advanced planning techniques is the delineation of normal tissues and targets. The automatic 
contouring of these structures is an area of ongoing research; technologies ranging from 
traditional atlas based deformable solutions to newer deep learning pixel-wise classification 
methods are finding success in the contouring of both normal tissues and targets for a variety 
of treatment sites (55-57). These approaches, however are limited in scope and are not fully 
integrated into routine clinical practice. The full validation of automatic contouring for clinical 
use and oversight of the use of an autocontouring technique in an automated treatment 
planning system has not yet been presented in the literature. Together automatic plan 
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optimization and autocontouring represent a majority of the tasks required for treatment 
planning. 
Ideally, a fully automated planning approach would eliminate the need for human 
intervention, would produce clinically acceptable or superior plans, would include methods to 
assure the quality and safety of each step, and would do so while reducing the time and 
human effort needed for planning. Such an automated planning technique would not only be 
tremendously helpful in low resource areas but would prove an essential tool in all clinics, 
may improve the standard of care, and would be a reliable tool for comparing planning 
techniques within and among patients. 
Towards realizing the benefits of full automation in treatment planning, we propose a 
fully automated treatment planning approach for head-and-neck cancer. This system would 
decrease the time required to generate a high quality plan, would reduce the training needed 
for plan production, would reduce plan variability, and may facilitate the transition to advanced 
planning techniques. We envision a system for which the user must only provide an approved 
CT scan, patient information including information about the prescribed dose and 
fractionation, and the identification of the primary target through the contouring of either a 
high dose CTV or gross tumor volume(s) including both the primary and nodal disease as 
indicated. The system would then use this information to generate a treatment plan through 
many, validated steps including plan preparation, automatic contouring of normal tissues, 
automatic contouring of target volumes, plan optimization, dose calculation, and plan 
finalization. Secondary and independent checks of each step should be implemented for 
redundancy and to ensure the safe use of an automated system. An overview of the system 
can be seen in Figure 1. The work herein represents validation and development of three key 
components, the knowledge based plan optimization, the contouring of normal tissues and 
the generation of targets volumes.
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 Figure 1. Schematic of the proposed automatic treatment planning strategy. Presented in this work are the development and validation 
of automatic contouring of both normal tissues and targets and the knowledge based plan optimization technique and associated quality 
assurance checks.
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2. Patient CT Scan 
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Chapter 2: Purpose and Central Hypothesis 
Central Hypothesis 
Equipment can be developed which may partially alleviate the staff and infrastructure burden 
of radiotherapy in low- resource settings and are feasible and clinically appropriate. 
Specific Aim 1: An Upright Radiotherapy Chair 
Aim: To preclinically validate the use of an upright radiotherapy chair for head-and-neck 
patients 
Hypothesis: An upright radiotherapy chair has clinically acceptable inter- and intra- fraction 
reproducibility  
Experiment 1.1: Establish the inter- and intra- fraction setup variation of an upright 
radiotherapy chair 
Experiment 1.2: Assess patient experience in an upright radiotherapy chair 
Specific Aim 2: A Fully Automated Treatment Planning Strategy 
Aim: To develop and validate a single optimization treatment planning strategy for the head-
and-neck 
Hypothesis: Single optimization head and neck treatment plans perform with equal quality to 
clinically acceptable plans and 90% are accepted by radiation oncologists for use without edit. 
Experiment 2.1: Quantitative and physician review of treatment plan quality 
Specific Aim 3: Automatic Delineation of Normal Structures in the Head-and-
Neck 
Aim: The assess the feasibility of the use of automatically contoured normal structures in the 
head and neck in a fully automated treatment planning strategy 
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Hypothesis: Automatically contoured normal structures can be used for treatment planning 
purposes without significant impact on plan quality. 
Experiment 3.1: Evaluation of automatic contouring algorithms for normal structures 
in the head and neck 
Experiment 3.2: Clinical use of an autocontouring algorithm for normal structures in 
the head and neck 
Experiment 3.3: Development of a random forest model for assessment of 
anatomical errors in autocontours of normal structures in the head and neck 
Experiment 3.4: Assessment of dosimetric impact of using autocontoured normal 
structures for treatment planning in the head and neck 
Specific Aim 4: Automatic Delineation of Target Volumes in the Head-and-Neck 
Aim: To assess the feasibility of the use of automatically countered intermediate and low 
dose target volumes in the head and neck 
Hypothesis: Automatically contoured clinical target volumes can safely be safely used for 
treatment planning purposes. 
Experiment 4.1: Quantitative and physician review of an automatically contoured 
clinical target volumes in the head and neck 
Experiment 4.2: Assessment of dosimetric impact of using autocontoured clinical 
target volumes for treatment planning in the head and neck 
Experiment 4.3: Development of a method to ensure quality of autocontoured clinical 
target volumes 
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Chapter 3: An Upright Radiotherapy Chair 
A substantial portion of this chapter is written or based on the following publication: 
McCarroll RE, Beadle BM, Fullen D, Balter Pa, Followill DS, Stingo FC, Yang J, Court LE. 
Reproducibility of patient setup in the seated treatment position: A novel treatment chair design. 
Journal of Applied Clinical Medical Physics. DOI: 10.1002/acm2.12024 Volume 18, Issue 1, Pages 
223-229 © John Wiley & Sons 
The permission for reuse of this material was obtained from John Wiley & Sons ©. 
 
In this chapter we describe the results for Specific Aim 1 which pertains to the 
development and clinical validation of an upright treatment approach. Our working 
hypothesis is that an upright radiotherapy chair has clinically acceptable inter- and 
intra- fraction reproducibility equal to or less than that in the traditional supine position. 
Introduction 
The majority of patients treated with radiation therapy are positioned supine on the 
treatment couch, with a small proportion prone. These positions are supported by decades of 
experience and are suited for the routine practice of 3-dimensional treatment planning with 
imaging from computed tomography (CT) scanners which utilize horizontal bores. However, 
some patients, particularly those with head-and-neck or lung cancers, may develop 
orthopnea, dyspnea, dysphagia, or other conditions that make lying flat for the duration of 
treatment difficult or impossible. Further, an upright treatment allows for an increase in lung 
volume and decrease in lung motion which allow for the sparing of normal tissues and fewer 
radiation-induced symptoms (19-21). In addition to the comfort and dosimetric advantages of 
treatment in the upright position, this treatment position could allow for the development of a 
treatment paradigm centered on a fixed treatment beam and seated rotating radiotherapy 
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patient. This delivery approach would prove advantageous in the development of a low-cost 
linear accelerator system, applicable to low- and middle- income countries. Advantages of this 
approach in terms of cost, shielding, set-up, treatment delivery, machine downtime, and 
others factors are under investigation (22-24). Interest from vendors in a fixed beam system 
has further supported this work.  
Historically, chairs for radiation therapy are used primarily as an exception for patients 
unable to tolerate the lying position and have involved temporary replacement of the 
treatment couch with an upright unit(58-60) Additionally, these previous studies are from an 
era in which treatment planning was carried out primarily using 2D image acquisition(61-63) 
and margins which were much more tolerant of positional inaccuracies. The degree of these 
uncertainties is not well documented in the literature; only one description of an upright 
system included an assessment of the reproducibility of patient position(61) and found that for 
all patients shifts of the treatment blocks of at least 5mm were required. 
Concerning treatment planning in the upright position, traditional CT scanner 
geometries do not allow for image acquisition in the seated position. Recent studies, however, 
have explored the feasibility of acquiring cone beam CT (CBCT) scans of seated patients 
using the on-board imaging capabilities of modern medical linear accelerators by positioning 
the gantry at 0° degrees, and then rotating the patient couch instead of the gantry (64, 65). 
Studies have also demonstrated the feasibility of using cone beam CT images acquired at the 
treatment unit for treatment planning (64, 66-68).  This work supports our expectation that we 
will soon be able to take CBCT images of patients in an upright position for the purpose of 
treatment planning, by rotating the treatment couch. It has been reported that acquisition of a 
field of view of 40 cm x 26 cm at isocenter is possible (64).  
Given the above, we have developed a treatment chair suitable for use with standard 
gantry based linear accelerator geometries for head-and-neck cancer regions, incorporating 
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measures designed to optimize the reproducibility of inter- and intra- fraction patient setup. 
Herein we report the details of the chair design, inter- and intra- fraction reproducibility 
measurements for five head-and-neck cancer patients under simulated treatment scenarios, 
and patient feedback and discuss considerations for future development. 
Preclinical validation of a treatment chair is necessary for the development of a 
treatment approach centered on treatment chair and paired with a fixed radiation beam; such 
a treatment paradigm could greatly reduce the upfront and ongoing cost of radiation therapy 
make the treatment more available in low-resource settings. 
Methods 
Chair Design 
The chair was initially designed by engineering students at Rice University (Houston, 
TX), with major refinement to improve patient comfort and ease of patient positioning.  The 
general concept was based on a massage chair, as the forward leaning position was 
expected to give better stability than a regular chair design. Additionally, this forward leaning 
position is beneficial for patients with an excess accumulation of saliva.  The chair was 
constructed in two major parts: (i) the seat with the back rest was constructed such that it slid 
onto the end of the treatment couch and was securely fastened to avoid shifts in position, and 
(ii) a unit consisting of footrests (15 x 30 x 2 cm acrylic), a chest plate (T-shaped acrylic), a 
face piece, and a wooden support post. Once the patient sat down, the second unit slid into 
position between the patients’ legs and securely tightened into position. Having the chair 
attach to the couch allowed us to make use of the couch’s remote motions to correct patient 
position based on pre-treatment imaging. Additionally, set-up of the chair fits smoothly into 
patient treatment workflow, where therapists gather and position any accessories needed for 
treatment shortly before the patient enters the treatment vault. The chair allows for many 
positional variations due to patient size, height, and comfort. Figure 2 shows the available 
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chair adjustments, including adjustment of the seat depth (A), the chest plate height (B), the 
chest plate angle (C), the face piece angle (D), and the footrest height (E). The chair was 
manufactured in-house, primarily from wood and acrylic materials. Limiting the use of metal 
was important to avoid affecting beam or imaging quality. Further, the construction allowed for 
easy maneuverability into position. For setup and reproducibility, indexing measures including 
notches and angle identifiers were incorporated. 
 
Figure 2. Treatment chair setup. For 
simulation, a flattop bench was used to 
mimic the treatment couch in the 
treatment vault. For image acquisition, 
the seat was securely fastened to the 
treatment couch. The setup is 
adjustable for patient size and comfort 
including adjustment of the seat depth 
(A), chest plate height (B), chest plate 
angle (C), face piece angle (D), and 
footrest height (E). 
 
 
 
Intra- and Inter-Fraction Imaging  
Six head-and-neck cancer patients undergoing radiotherapy (in a supine position) 
were accrued with approval from our institutional review board. Five patients completed the 
study and are included in the analysis. The seated patients were first set-up in the treatment 
chair outside of the treatment room using a flattop bench in lieu of the treatment couch 
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(Figure 2). For setup, the chair position was established and a Vac-Lok cushion (MTVLG35C; 
Civco Medical Solutions, Coralville, IA) and thermoplastic head mask (MTAPU; Civco Medical 
Solutions, Coralville, IA) were made. The Vac-Lok cushion was used to fill any space between 
the patient’s chest and the chest piece, to create pseudo arm rests for patient comfort, and to 
facilitate set-up reproducibility, especially lateral stabilization (Figure 3). The head mask was 
secured over the back of the patient’s head, in contrast to typical head-and-neck cancer 
treatment for which a thermoplastic mask is generally placed over the patient’s face and 
secured to the treatment table. Additionally, the patients were assessed for the need of 
additional accessories, including an A-bar for arm and hand positioning and comfort and a 
pillow behind the back for added support. 
 
 
 
Figure 3. Patient setup for lateral image 
acquisition in the treatment vault , with kV 
imagers extended and couch positioned at 0°. 
The Vac-Lok cushion was shaped so as to 
create armrests for patient comfort, the head 
mask was secured of the back of the patient’s 
head. 
 
 
 
 
30 | P a g e  
 
For imaging, the chair position was duplicated in the treatment vault. For two patients, 
acrylic shims were needed to loosen the thermoplastic mask at the face, after the mask had 
hardened. A TrueBeam® linear accelerator (Varian Medical Systems, Palo Alto, CA) was 
used for this study, primarily due to the couch end load limit of 200 kg, which allows for 
positioning of the treatment seat and patient at the couch’s end. With the gantry at 330°, 
kilovoltage imagers retracted, and the patient couch lowered to the full extent and positioned 
at 270°, the patient was set up as in simulation.  The gantry rotation to 330° was necessary to 
improve access in this relatively tight space.  We also inserted a custom tray into the physical 
wedge slot to protect the exit window in case of accidental contact.  
The longitudinal table position was selected so that the patient’s vertebrae were 
approximately at the beam’s isocenter. Using orthogonal lasers, the patient’s position was 
marked on the thermoplastic mask. The gantry was rotated to 0° and kilovoltage imagers 
were extended outward. The position of kilovoltage imagers varied between patients due to 
patient size and couch location, to which the chair was attached. The superior-inferior, left-
right, and anterior-posterior positions of the imagers relative to the patient ranged 10, 3, and 
5cm respectively. The position of the imagers was such that anatomical regions captured in 
the image were similar between patients. Posterior-anterior images were acquired first (couch 
at 90°, gantry at 0°, kV imagers extended), the couch was rotated to 0° and then lateral 
images were acquired. All mechanical motions occurred under supervision inside the 
treatment vault.  
After image acquisition and under supervision, the couch was rotated for 5 minutes to 
simulate treatment delivery. Two additional images (lateral and P-A) were then acquired. 
Image registration of these two sets of images was used to calculate the first intra-fraction 
reproducibility measurement. The patient then got out of the treatment chair and rested for a 
few minutes, and the process was repeated to acquire 2 more sets of images, providing one 
inter-fraction reproducibility measurement and one additional intra-fraction measurement. 
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Upon completion, the patient was asked to complete a questionnaire (see supplemental 
materials, page 180) regarding both their supine treatments and their experience in the chair.  
Image Registration 
The head-and-neck region has many degrees of motion, so inter- and intra-fraction 
alignment was evaluated for several sub-regions of the acquired images.  We used a method 
similar to that used previously to evaluate setup reproducibility in patients with head-and-neck 
cancer after cone beam CT guidance (69). Sub-regions of interest on kV projection lateral 
images were cervical vertebrae 1-3 (C1C3), C3C5, the mandible, and the occipital bone. The 
sub-regions of interest on P-A images were the left temporomandibular joint and the nasal 
sinuses. These regions were chosen to facilitate accurate evaluation of patient motion, to 
match those studied previously (69), and to obtain high visibility on the acquired images. The 
images were processed via histogram normalization and sub-regions were chosen by hand to 
include the area of interest, see Figure 4. Rigid 3-dimensional image registration (bi-
directional translation and rotation) was carried out between the two 2-dimensional kilovoltage 
images in Matlab (MathWorks, Natick, MA) using the gradient descent method with the mean 
square error as the registration metric.  All registration results were verified visually.  
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Figure 4. Histogram-normalized kilovoltage image of a representative patient , outlining the 
sub-regions selected on the lateral image (A) and PA image (B) for registration. C1C3 and 
C3C5, cervical vertebrae 1–3 and 3–5, respectively. 
 
Simulated Image Guidance 
The use of image guidance for patient positioning and tumor localization in head-and-
neck cancer patients receiving radiotherapy is a routine procedure in many clinics and is 
necessary for the delivery of advanced treatment techniques such as IMRT and VMAT. We 
therefore simulated the use of image guidance in our inter-fraction displacement images, as 
done by others, which were acquired without patient realignment prior to the simulated 
treatment delivery. The two images were first registered according to the position of C1C3 
(lateral images) or the spinal column (posterior-anterior images). Then, the remaining sub-
regions were registered as previous. This approach provided a measure of the residual error 
in inter-fraction displacement given the use of image guidance.  
C1C
 
C3C
 
Mandibl
 
Occipita
l Bone 
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Measurement of Registration Uncertainty 
To best approximate the possible uncertainty in the rigid registration, we placed an 
Alderson Radiation Therapy phantom (ART-210, Radiology Support Devices, Ramsey, NJ) in 
the treatment chair, and images were acquired within the range of imaging parameters used 
to acquire patient images. The chair and phantom were shifted by a known amount and the 
images were registered. The difference between the registration and the true table positon 
provides a measure of the uncertainty in our rigid registration technique.  
Development of an Updated Chair 
 Results from this study and feedback from the patient questionnaire indicated several 
features of the current chair design which could be improved for both patient comfort and 
radiotherapeutic use. A second treatment chair was developed in-house using primarily 
acrylic pieces and an increased number of indexing options.  
Results 
Patient Cohort 
The 5 patients in this study were all male, with a median age of 65 years (range: 55–
78 years), mean height of 181.1 cm (range: 180–183 cm), and mean weight of 88 kg (range: 
76–111 kg). Female subjects (n > 8) were positioned in the chair during trial development and 
found no difficulties in positioning or comfort. On the basis of the feedback from the first two 
patients imaged, the face piece was changed from the bolus-based chin-and-forehead piece, 
to a suctionable cushion which conforms to the patient’s face (Figure 5). Further, a small 
piece of loop fastener was applied to the top of the face piece as a barrier between the seam 
of the plastic and the patient’s forehead. 
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 Figure 5. Face piece of the chair before and after the change implemented after feedback 
from the first two patients. Before the change, the chin and forehead pieces were covered 
with bolus material for comfort, and the inferior chin piece was arched for anatomical 
conformity. 
Image Registration 
Table 1 lists the intra- and inter- fraction displacement for the 6 sub-regions measured. 
Rotation displacement was found to be small, ranging between -0.2° and 0.7°. The error in 
the registration, as measured with the phantom measurements was found to be no more than 
0.4 mm. Average intra- fraction displacements were less than 2 mm across all patients. 
Average inter-fraction displacements were less than 3 mm. The largest displacements were 
seen in the anterior-posterior direction. Image guidance improved inter-fraction patient set-up 
in the anterior-posterior and left-right directions by an average of 1mm. 
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Table 1. Intra-fraction and inter-fraction displacements with and without image guidance in the treatment chair 
 Mean displacement (mm) ± SE [Range] (n=5) 
 
Intra-fraction 
Inter-fraction 
 Without IGRT With IGRT 
 S-I A-P L-R S-I A-P L-R S-I A-P L-R 
C1C3 
0.1±1.2 1.2±2.5  0.5±2.0 -2.5±5.3  Used for 
IGRT 
Used for 
IGRT 
 
[-1.8-1.9] [-3.3-4.7]  [-1.8-3.3] [-6.8-6.1]   
C3C5 
-0.1±1.1 1.2±3.3  0.2±2.4 -2.0±5.7  -0.3±0.7 0.3±0.5  
[-1.8-1.1] [-4.9-5.9]  [-3.2-3.4] [-6.8-7.1]  [-1.3-0.4] [-0.1-1.0]  
Mandible 
0.1±1.1 0.5±1.6  1.0±1.8 -1.2±4.3  0.5±1.3 1.1±3.6  
[-1.1-2.3] [-1.7-3.6]  [-1.1-3.7] [-7.1-4.0]  [-1.6-2.0] [-2.1-7.0]  
Occipital Bone 
0.2±1.4 0.3±2.5  -0.3±2.3 -2.7±4.3  -0.8±0.4 -0.4±2.6  
[-2.3-1.6] [-5.5-3.5]  [-3.2-3.0] [-7.4-1.5]  [-1.4--0.3] [-4.6-2.3]  
Nasal Cavity 
0.4±1.8  -0.7±1.2 0.4±2.0  2.1±3.4 -1.1±0.9  1.7±6.8 
[-3.2-2.4]  [-3.2-1.0] [-1.9-3.5]  [-1.0-7.3] [-1.9-0.3]  [-9.1-7.6] 
Left TMJ 
0.6±1.6  -0.8±1.8 0.3±1.9  3.0±4.1 -1.3±1.1  2.6±4.5 
[-2.5-3.0]  [-4.7-1.2] [-2.1-3.0]  [-1.5-8.4] [-2.4--0.1]  [-4.0-7.8] 
SE, standard error; S-I, superior-inferior; A-P, anterior-posterior; L-R, left-right; IGRT, image-guided radiation therapy; C1C3 and 
C3C5, cervical vertebrae 1–3 and 3–5, respectively; TMJ, temporomandibular joint
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Table 2. Comparison of inter-fraction displacements in the seated and supine treatment 
positions for simulated image guidance with respect to cervical vertebrae 1–3 
 
Region of interest 
Mean displacement (mm) ± SE 
Upright position 
(this study) 
Supine position 
Kapanen et al(70)* 
van Kranen et 
al(69) 
Cranial-caudal    
C3C5 -0.3 ± 0.7   1.2* 0.10 ± 0.00 
Mandible 0.5 ± 1.3 2.9 1.30 ± 2.50 
Occipital bone -0.8 ± 0.4 1.3 0.60 ± 2.0 0 
Anterior-posterior    
C3C5 0.3 ± 0.5   3.1* 0.10 ± 0.50 
Mandible -1.1 ± 3.6 2.2 -0.30 ± 1.20 
Occipital bone -0.4 ± 2.6 1.9 0.30 ± 0.60 
*Standard errors (SE) were not reported by Kapanen et al. Additionally, cervical vertebrae 1–
2 (C1C2) were used as a reference, and C5C7 data were reported instead of C3C5 data. 
 
Patient Questionnaire 
Patients were asked to rate various aspects of their treatment in the supine and 
seated positions by completing a questionnaire consisting of 15 items. Fourteen of the fifteen 
resultant comparisons were less than one point apart on a 6 point (0-5) scale.  In Figure 6, the 
questions separated by 4 tenths of a point or more are illustrated. Regarding comfort in the 
arms during treatment, patients preferred the seated position over the supine position, with a 
mean score of 4.6, compared with 3.6 for the supine position (a score of 5 corresponded to 
“perfectly comfortable”). Patients also had the opportunity to provide written and verbal 
feedback about the treatment experience. Verbal feedback included discomfort at the chin 
and lips, which was partially alleviated with the change in the face piece, as indicated by 
fewer verbal reports of discomfort after the change was made. Pressure from the head mask 
and pressure at the chest from the Vac-Lok cushion were also noted. Several patients 
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expressed the expected benefit of a deeper seat cushion. One patient requested a strap 
around the back to help prevent slouching and to remind the patient to relax forward into the 
chair.  
 
Figure 6. The results of the patient questionnaire. Only questions separated by an average of 
0.4 points (5 point scale) or more are shown. The full questionnaire can be found in the 
supplemental materials. The questionnaire alternated the score assigned to a positive 
response. For example, a rating of 5 was assigned to answers of “I felt calm” and “Getting on 
the chair (couch) was difficult”. In this figure all positive responses are correlated to a ratings 
of 5 and text has been altered for clarity. 
 
Development of an Updated Chair 
We modified the chair design to reflect patient feedback and our accumulated 
experience. Changes include an increase in seat depth (from 23 cm to 45 cm), the 
footrest/chest/face piece no longer attaches to of the seat portion between the patients’ legs 
but rather on the outside of one’s hips, and for dosimetric consideration the thick supportive 
materials at the chest piece were removed. A schematic and picture of the new treatment 
chair can be found in Figure 7. 
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Figure 7. New radiotherapy chair design. Shown are the pre-build schematic (panel A) and 
photos of the seat only (Panel B) and the full chair (Panel C). The new chair design features 
adjustments for the angle of the face piece (a), a back strap for patient comfort (b), 
adjustments for chest plate depth and angle (c), and adjustments for chest plate height (d). 
 
Discussion 
As radiation therapy treatment planning has moved almost entirely to 3-dimensional 
methods, the acquisition of CT scans for planning has become routine in many clinics around 
the world. The horizontal bore of such scanners is a limiting factor for possible patient 
positions and therefore nearly all patients are treated lying in a prone or supine position. 
However, this position may not be suitable for all patients, especially those suffering from 
orthopnea, dyspnea, or dysphagia. Further, dosimetric considerations may indicate upright or 
A B C 
a b 
c d 
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seated patient positioning.  As techniques for image acquisition at the treatment unit continue 
to advance, for treatment paradigms still reliant on 2-dimensional planning techniques, for 
patients unable to tolerate a lying treatment position, and for the development of a fixed-beam 
low-cost system an upright treatment chair may prove optimal for treatment. We have 
designed a treatment chair compatible with current linear accelerator geometries and have 
tested patient intra- and inter- fraction displacement for the head and neck region. Patient 
displacement was on average less than 2 mm in the intra- and 3 mm in the inter- fraction 
scenarios. These raw inter- fraction measurements prove much better than those found for a 
previous upright setup for mantle treatments, for which all patients required block shifts of at 
least 5 mm, and 35% requiring shifts greater than or equal to 1 cm(61).  
We also evaluated inter-fraction displacements in a scenario of simulated image 
guidance. While in clinical scenarios the radiation therapist would typically compare the whole 
acquired image to a planning image for use in image guidance, we have used only a sub-
region of the acquired image to simulate image guidance. This approach is consistent with 
techniques used previously (69) and both the mean and standard deviation of inter-fraction 
displacement in the seated position in our study are on the same order as those reported for 
the traditional supine-position techniques (Table 2). 
There are limitations to this technique.  One patient was not able to complete the 
testing, and review of his images before the trial was aborted suggests that he had significant 
intra-fractional displacement (up to 3.3 cm).  This was likely due to the fact that he was falling 
asleep and not feeling well, resulting in significant positional changes.  While this only 
affected one patient, this may be more widespread; our attempts to create a treatment chair 
that is better tolerated than the supine position may not be tolerated by some patients.  
Furthermore, we largely enrolled “healthy” patients who tolerated the supine position quite 
well, and they also tolerated the upright position quite well.  It remains to be seen how 
patients with significant medical issues (for instance, orthopnea, dyspnea, thick secretions) 
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and for patient nearing the end of treatment may tolerate the upright treatment, and whether it 
reflects an improvement over the supine position.  These issues will be investigated in future 
studies. 
The tight geometry of the gantry system and the chair tested in our study is partially a 
result of a minimum vertical height of the treatment couch and seat height; therefore, care 
must be taken when positioning the patient. We estimate that by the sixth patient setup took 
approximately 8 minutes including marking of lasers on head mask, similar to that for supine 
positioning. A complete assessment of the shift accuracy of the used registration algorithm 
was completed. However, while the rotational displacement of patient images was small, less 
than 1°, a similar analysis was not completed for the rotational accuracy of the registration 
algorithm and is potential source of error in this study. 
The ability to acquire treatment planning images in the upright position, mirroring that 
of treatment, is an important aspect of the complete treatment process in the upright position. 
Using onboard imaging systems or other techniques, the acquisition of planning images in the 
treatment position is possible. Herein we have explored the set-up reproducibility of the 
upright treatment position in an in-house built chair. The results show the chair to have inter- 
and intra- fraction set-up reproducibility similar to current supine techniques. This works 
support the further investigation of the use of this position in the development of a fixed beam 
and rotating patient treatment paradigm. Such a position could dramatically reduce the 
upfront and ongoing cost of radiotherapy machines which may aide in their implementation in 
low-resource and LMIC settings. 
Conclusion 
In conclusion, our preliminary tests indicate that it is feasible to create an upright 
treatment chair with geometry suitable for 3-D imaging (with cone beam CT) and robust 
reproducible patient position between and within radiotherapy fractions.  This work supports 
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this vision of the a system whereby patients can be simulated and treated in an upright 
position without degradation of a conformal, modern radiation treatment plan towards a fixed-
beam low-cost radiotherapy system. 
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Chapter 4: A Single Optimization Treatment Planning 
Strategy in the Head-and-Neck 
In this chapter we describe the results for Specific Aim 2 which pertains to the 
development of a fully automated single optimization head-and-neck treatment planning 
approach. Our working hypothesis is that a single optimization head-and-neck treatment 
planning approach produces plans which perform with equal quality to clinically acceptable 
plans and 90% of which are accepted by radiation oncologists for clinical use without edit. 
Introduction 
Towards a fully automated treatment planning approach for the head-and-neck an 
optimized and validated plan optimization approach is the most important aspect. The 
treatment of head-and-neck tumors; in close proximity of up to 25 organs at risk and divided 
into multiple target dose levels, represents one of the most challenging sites in treatment 
planning. Interest in automated plan optimization strategies has increased dramatically and 
researchers have identified several approaches which have found success for prostate, lung, 
and the head-and-neck cancers (54, 71-74). These approaches, however are subject many 
limitations, including their evaluation for only a small subset of patients, the need for manual 
adjustment or fine-tuning after automatic optimization, and the need for manual input 
including beam parameters or patient-specific dose parameters.  
We seek to develop a fully automated planning strategy in the head-and-neck which 
produces plans of equal or superior quality compared to clinically treated plans, does not 
require the user to select beam angles, or modify the final treatment plan. Such a technique 
could dramatically reduce the human effort needed to generate treatment plans and ultimately 
reduce the deficient of highly trained radiotherapy staff in LMICs and represents a critical 
component of a fully automated treatment planning system. 
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 Methods 
Patient Cohort 
For this analysis, 54 patients treated at The University of Texas MD Anderson 
Cancer Center selected as to represent seven head-and-neck subsites; larynx, 
nasopharynx, oral cavity, oropharynx, paranasal sinuses and cavity, and salivary 
glands and 30 patients from other institutions treated on a clinical trial were 
retrospectively collected. The clinical trial data was obtained through The Cancer 
Imaging Archive (75) and was originally derived from the Radiation Therapy Oncology 
Group 0522 study (76). Selection criteria for both patient cohorts included a maximum 
of three planned target volume dose levels, the use of IMRT or VMAT treatment 
delivery, and availability of the treated dose distribution for comparison. Autoplans 
were generated for each of the patients and compared against clinical plans at clinical 
dose constraints and relevant endpoints. Additionally, 20 patient CTs, 10 collected 
from each of 2 partner institutions in South Africa, were used to evaluate the single 
optimization treatment planning approach but were not compared to the clinically 
treated plans. 
Planning Strategy 
The planning strategy mirrors the clinical planning approach but competes each step 
automatically and without human intervention. 
Plan Initialization 
Primarily developed by other members of our group, plan initialization steps includes 
assignment of the target prescription dose levels, removal of the treatment couch, selected of 
the treatment isocenter, initial setup of beam parameters, and contouring of any structures 
(planning or otherwise) required for treatment planning but not included in the clinical 
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treatment plan. Target prescription dose levels were matched to the clinically delivered plan. 
The treatment isocenter was selected to be at the center of all combined planning target 
volumes (PTVs). Either three or four 360-degree treatment arcs were selected depending on 
target size and orientation. The collimator angles for the first two arcs were set to be 30 and 
330 degrees and jaws were determined such that the entire target remained in the beam’s 
eye view (BEV) as the gantry rotates through 360 degrees.  If the field size exceeded 18 cm 
in the x-direction (the direction of travel of the multi-leaf collimators (MLCs)) then the jaw was 
set to be symmetric with a field size of 18 cm. This constraint was imposed on the jaw 
settings due to mechanical constraints of the MLCs modeled in the treatment planning system 
(Varian 2100 series linear accelerator, Millennium 120 MLCs) which have a maximum 
distance of travel of 14.5cm, and in an effort to design a planning approach widely applicable 
to many machine types which, for example, may not have jaw tracking capabilities. The 
collimator was then set to 90 degrees and the jaws set such that all PTVs remained in the 
field of view with a 1cm margin over 360 degrees of rotation. If this required that the x jaw size 
exceed 18 cm, a fourth field was added such that the two fields cover the PTVs, one from the 
most superior extent and from the most inferior and both with a maximum size of 18cm. 
Structures required for plan optimization which were not included in the original treatment 
plan, including planning and normal structures, were automatically contoured using an in-
house multi-atlas deformable image registration technique, details of which are described in 
Chapter 5. 
Dose Optimization and Knowledge Based Planning 
A knowledge based treatment planning module, RapidPlan®, has been implemented 
and is available for clinical use in the Eclipse Treatment Planning system (Varian Associates, 
Palo Alto, CA). Using a number of previously treated plans, from which both the geometries of 
the targets and organs at risk as well as the planned dose distributions are extracted, DVH 
estimation models are used to parameterize a DVH estimation algorithm which sets the 
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constraints for new patients. The methodology employed by the proprietary RapidPlan® 
software is based primarily on work from Duke University Medical Center which characterizes 
inter-patient organ at risk sparing (77). To estimate the DVH for each organ at risk, 
quantitative metrics are used which include the distance to target histogram, the relative 
relationship between the OAR and the targets, and additional anatomical features including; 
the relative volume overlap, the relative out-of-field volume, the absolute OAR volume and the 
absolute target volume (78). In RapidPlan® the user has the capability to create their own 
DVH estimation models based on patients selected by the user, though there are two vendor 
provided DVH estimation models for the head-and-neck – the “CancerCare Manitoba Head 
and Neck” and the “Washington University Head & Neck models”. The latter served as the 
basis for this work. The details of the data set used to develop the Washington University 
Head & Neck Model can be found in the provided model description. In short, the model was 
trained and tested on plans with targets delineated in the nasopharynx, oral cavity, 
oropharynx, hypopharynx, larynx, or other unknown head-and-neck primary anatomical 
locations. The model allows for one, two, or three targets and estimates the DVH curve for the 
brain, brainstem, upper esophagus, larynx, lips, spinal cord, mandible, middle ear, oral cavity, 
parotid glands, pharyngeal constrictors, and submandibular glands. Provided in the model 
description are contouring guidelines for both targets and organs at risk. The model was 
trained and validated on unilateral and bilateral cases planned as head first, supine, 6-9 field 
IMRT cases with 6x photons, couch rotation of 0 degrees and fields with allowable gantry 
angles in increments of 40 degrees from 0 to 320 degrees. The objectives and relative 
priorities used for clinical training cases can be found in the model description.  
For this study we used the model-provided line constraints for normal structures and 
modified or added new templated constraints for both structures with model provided line 
constraints and other structures. Through iterative testing structure constraints and priorities 
were optimized based on quadrative analysis and physician feedback.  The final constraints 
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used for the planning strategy presented here can be found in the Appendix. As is currently 
mandatory in the Eclipse TPS when using RapidPlan®, the Photon Optimizer (PO) algorithm 
(version 13.5.35) was used to optimize VMAT plans. Dose was calculated using the 
anisotropic analytic algorithm (version 13.5.35) implemented in the Eclipse treatment planning 
system.  
To ensure adequate coverage of each target autoplans were normalized such that 
95% of the target volume received at least 98% of the prescribed dose. To reduce plan 
sensitivity to normalization, normalization criteria were implemented. Structures with volume 
less than 20cc, which can greatly effect plan normalization especially if the structure is in a 
high gradient area, and structures with more than 20% of the target volume having Hounsfield 
unit less than -800, in which high doses are not theoretically achievable and the uncertainty in 
dose calculation algorithms is high, were excluded for normalization purposes, unless it was 
the only target. 
Quantitative Plan Analysis 
For evaluation, 4 patient groups were considered; (1) all patients with corresponding 
clinical plans, (2) only patients treated at MD Anderson, (3) only patients treated at other 
institutions as part of a clinical trial, and (4) only patients from partner institutions in South 
Africa for which corresponding clinical plans were not available. The autoplans were 
evaluated at typical clinical constraints and those outlined in RTOG protocol 1016. Autoplans 
were assessed as the mean, standard deviation, minimum and maximum values across 
patients at dosimetric points of interest, and the percentage of plans meeting the clinical 
constraint.  
For plans with corresponding clinically delivered plans, autoplans were also compared 
against the corresponding clinical plans at many DVH endpoints using the Wilcoxon signed 
rank test, a nonparametric statistical hypothesis test based on rank orders for two planning 
groups. The two planning techniques were also compared using the Brown-Forsythe test, a 
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non-parametric test which tests for the equality of the variances in the two planning groups by 
examining the absolute distance of each point from the median of the distribution(79). For 
both tests, significance was established as a p-value of less than 0.05. When comparing 
plans using the Wilcoxon signed rank test, plans were normalized such that DVHs were 
matched at the dose received by 95% of the high dose PTV, allowing for a fair comparison of 
OAR sparing and target coverage.  
Physician Review of Autoplans 
Throughout the process, specialized head-and-neck radiation oncologists were 
consulted concerning plan quality. Feedback was used to improve the planning strategy. 
Once the planning strategy was finalized, plan review documents were created for 40 
patients, 20 from the cohort of patients treated at MD Anderson and 20 from the cohort of 
patients treated on a clinical trial. Review documentation included CT slices with overlaid 
dose distributions, beam and field information, patient information and DVH curves for target 
and normal structures. A head-and-neck radiation oncologist was asked to rate the plans on a 
three point scale, either needing no edit for clinical use, needing minor edit, or needing major 
edit. 
Results 
VMAT optimization of plans took 5.5 ± 2.0 minutes (average ± standard deviation) and 
dose calculation took 9.0 ± 3.3 minutes, an additional 1 minute was required for additional 
steps including opening the plan and setting the prescription. Other pre-planning activities 
were not systematically recorded for this study, but for a sample of ten patients automated 
tasks which include the removal of the treatment couch, detection of the body, selection of the 
isocenter, determination of the field parameters, contouring of planning structures, data 
format conversion, and import of DICOM files into Eclipse took 22.5±1.1 minutes, with the 
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largest time commitment (on average, 18 minutes) coming from contouring. The entire 
planning process is therefore estimated to require an average of 37 minutes. 
Patient Cohort 
Patient characteristics can be found in Table 3. One of the thirty patients collected and 
treated on the clinical trial had a CT scan with variable slice spacing, which is not compatible 
with the necessary autocontouring and was thus excluded from analysis. 
 
Table 3. Characteristics of patients used to validate the treatment planning strategy. In 
parenthesis are additional statistics of the 20 patients collected from the South African partner 
institutions 
Characteristic Number 
Number of Target Dose 
Levels 
3 
2 
1 
 
56 (4) 
18 (9) 
9 (7) 
Gender 
Male 
Female 
Unknown 
 
38 
16 
29 (20) 
Sub-site 
Hypopharynx 
Larynx 
Nasopharynx 
Oral Cavity 
Oropharynx 
Paranasal Sinuses 
Salivary Glands 
Unknown 
 
3(1) 
12(3) 
5(1) 
12(3) 
41(2) 
5 
5 
20(10) 
 
Quantitative Plan Analysis 
 Plans were normalized such that 95% of each of the PTVs received at least 98% of 
the prescribed dose, excluding structures with volume less than 20cc or for which more than 
20% of the PTV had Hounsfield unit less than -800, as previously discussed. Of 250 total 
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targets, 2 had more than 20% of the volume with Hounsfield unit less than -800 (22% and 
26%) and 8 had volume less than 20cc [range 4-19 cc]. All ten of these exceptions were from 
the MD Anderson patient data set. Of the ten exceptions only four targets received less than 
98% of the prescribed dose to 95% of the volumes after plan normalization. The structure 
chosen for normalization as well as the percentage of dose covering 95% of the target volume 
can be found for all targets in Figure 8. Forty six of the 103 autoplans were normalized to the 
high dose PTV, 25 to the intermediate dose PTV, and 32 to the low dose PTV. 
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Figure 8. Coverage of 95% of target volumes , used for normalization. High dose PTVs are 
shown in red, intermediate dose in blue, and low dose in yellow. Patients from the MD 
Anderson data set in squares, from the clinical trial data set are displayed as circles, and from 
the South African data set in diamonds. The target receiving 98% of the prescription dose to 
95% of the volume was chosen for normalization. 
 
 
South Africa data Set MD Anderson data Set 
Clinical Trial data Set 
High Dose PTV 
Intermediate Dose PTV 
Low Dose PTV 
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Quantitative metrics describing the autoplan and corresponding clinical plans including 
the mean, standard deviation, and minimum and maximum value at clinically relevant 
dosimetric endpoints can be found in Table 4 and the fraction of both clinical and autoplans 
meeting clinical constraints in Table 5. Clinical constraints were, on average, met in clinical 
plans more often for patient cohort from MD Anderson (86%) than those treated on a clinical 
trial (72%).  
 Constraints least often met were the mean dose less than 39 Gy the submandibular 
glands, for which of 83 clinical plans 16% and 35% met for ipsilateral and contralateral 
glands, respectively, and autoplans met less often with rates of 12% and 28%, respectively. 
Next least often met was the clinical constraint of a mean dose less than 26 Gy to the parotid 
glands, for which clinical plans met with a rate of 46% and 83% for contralateral and 
ipsilateral glands respectively. Autoplans met these constraints more often at rates of 51% 
and 88%.  
Of the 103 autoplans, all but two had maximum spinal cord dose less than 45Gy. One 
plan, from the MD Anderson data set had a spinal cord maximum dose of 45.1Gy and while 
exceeding a 45Gy constraint, meets a constraint of less than 0.03cc with dose greater than 
48Gy which has been reported in the literature(80, 81). The other plan not meeting this 
constraint had the spinal cord contour within 1.3mm of the high dose PTV, and had a 
maximum dose of 48.44Gy, this patient, from the cohort of patients from South Africa, did not 
have a corresponding clinical plan. Similarly, two patients from the South African data set did 
not meet the clinical constraint of brainstem maximum dose less than 54 Gy, having 
maximum doses of 60.2 Gy and 57.4 Gy. For these patients the brainstem contour and high 
dose PTV overlapped with volumes of 0.3 and 0.1cc. These patients failing to meet brainstem 
and spinal cord constraints can be seen in Figure 9.  
52 | P a g e  
 
Table 4. Quantitative evaluation of autoplans and corresponding clinical plans (when available) at clinically relevant dosimetric points.
 AutoPlans Clinical Plans AutoPlans Clinical Plans 
 mean±std [min-max] mean±std [min-max] mean±std [min-max] mean±std [min-max] 
Structure Spinal Cord, Maximum Dose [Gy] Brainstem, Maximum Dose [Gy] 
All Patients (n=83) 39.2±5.2 [4.8-45.1] 32.2±11.6 [2.8-48.9] 33.6±15.3 [0.0-48.3] 28.6±18.5 [0.0-71.6] 
MDACC Patients (n=54) 38.0±6.2 [4.8-45.1] 26.0±9.6 [2.8-48.9] 29.3±16.7 [0.0-48.3] 18.5±14.5 [0.0-49.1] 
Clinical Trial Patients (n=29) 41.1±0.8 [40.2-43.7] 43.7±3.0 [38.8-48.9] 41.6±7.3 [16.5-47.7] 47.2±6.9 [33.5-71.6] 
South Africa Patients (n=20) 41.0±3.8 [32.0-48.4]   28.7±20.2 [1.7-60.2]   
Structure Ipsilateral Parotid, Mean Dose [Gy] Contralateral Parotid, Mean Dose [Gy] 
All Patients (n=83) 27.6±16.2 [0.1-67.8] 30.4±17.7 [0.0-70.5] 16.5±7.6 [0.1-34.9] 16.1±9.8 [0.0-33.2] 
MDACC Patients (n=54) 26.6±18.8 [0.1-67.8] 27.4±19.6 [0.0-70.5] 14.0±7.5 [0.1-34.9] 11.0±7.9 [0.0-23.4] 
Clinical Trial Patients (n=29) 29.5±9.9 [16.5-57.3] 36.0±12.1 [23.3-66.0] 21.2±5.1 [12.9-29.2] 25.6±4.6 [15.3-33.2] 
South Africa Patients (n=20) 38.5±17.7 [6.0-64.3]   24.3±14.2 [5.6-50.7]   
Structure Ipsilateral Parotid, Volume Receiving > 30Gy [%] Contralateral Parotid, Volume Receiving > 30Gy [%] 
All Patients (n=83) 37.1±29.1 [0.0-100.0] 44.4±31.0 [0.0-100.0] 14.6±13.6 [0.0-52.7] 18.2±14.4 [0.0-49.0] 
MDACC Patients (n=54) 35.9±33.5 [0.0-100.0] 40.2±33.3 [0.0-100.0] 10.4±12.1 [0.0-52.7] 11.4±11.3 [0.0-32.6] 
Clinical Trial Patients (n=29) 39.2±18.8 [16.5-57.3] 51.9±25.0 [12.7-100.0] 22.5±13.0 [0.8-43.0] 30.5±10.6 [3.7-49.0] 
South Africa Patients (n=20) 56.6±29.4 [6.0-64.3]   31.8±27.7 [0.0-86.7]   
Structure Ipsilateral Submandibular Gland, Mean Dose [Gy] Contralateral Submandibular Gland, Mean Dose [Gy] 
All Patients (n=83) 57.9±19.6 [0.5-72.4] 58.2±19.2 [0.5-74.9] 48.6±19.9 [0.4-72.1] 43.8±24.9 [0.5-73.0] 
MDACC Patients (n=54) 53.4±22.1 [0.5-72.4] 53.1±20.8 [0.5-72.3] 42.6±21.3 [0.4-72.1] 34.2±24.9 [0.5-72.1] 
Clinical Trial Patients (n=29) 66.2±9.9 [20.2-72.3] 67.9±10.5 [17.3-74.9] 59.7±10.3 [23.6-71.9] 61.810.7 [19.7-73.0] 
South Africa Patients (n=20) 58.1±15.8 [26.4-75.3]   49.3±18.3 [11.9-73.0]   
Structure Cochleae, Maximum Dose [Gy] Brain, Maximum Dose [Gy] 
All Patients (n=83) 13.1±15.1 [0.0-69.5] 13.6±14.8 [0.0-72.9] 38.2±19.1 [0.0-69.5] 41.019.9 [0.0-71.9] 
MDACC Patients (n=54) 14.8±17.2 [0.0-69.5] 10.0±13.5 [0.0-72.9] 35.6±22.1 [0.0-69.5] 34.521.4 [0.0-70.3] 
Clinical Trial Patients (n=29) 10.1±9.2 [2.2-44.5] 20.5±14.6 [2.1-57.4] 43.2±9.9 [13.3-57.1] 53.27.5 [37.3-71.9] 
South Africa Patients (n=20) 19.6±23.5 [0.6-75.2]   34.2±9.9 [1.5-78.5]   
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Table 4. Continued from previous page. 
Structure Optic Chiasm, Maximum Dose [Gy] Optic Nerves, Maximum Dose [Gy] 
All Patients (n=83) 5.1±10.0 [0.0-62.0] 4.9±10.5 [0.0-52.5] 5.5±11.2 [0.0-61.7] 5.6±12.2 [0.0-57.8] 
MDACC Patients (n=54) 6.6±12.2 [0.0-62.0] 6.2±12.0 [0.0-52.5] 7.4±13.5 [0.0-61.7] 7.2±13.8 [0.0-57.8] 
Clinical Trial Patients (n=29) 2.1-0.9 [1.0-4.2] 1.4±1.2 [0.0-4.7] 2.1±0.8 [0.9-4.1] 1.2±1.3 [0.0-4.6] 
South Africa Patients (n=20) 9.8±16.6 [0.5-64.6]   12.5±22.1 [0.5-71.4]   
Structure Lens, Maximum Dose [Gy] Eyes, Maximum Dose [Gy] 
All Patients (n=83) 2.1±2.5 [0.0-15.6] 1.7±2.5 [0.0-12.2] 5.4±10.8 [0.0-59.7] 4.8±10.0 [0.0-56.9] 
MDACC Patients (n=54) 2.4±3.0 [0.0-15.6] 1.9±2.6 [0.0-12.2] 7.1±13.0 [0.0-59.7] 6.3±12.0 [0.0-56.9] 
Clinical Trial Patients (n=29) 1.5±0.5 [0.7-3.4] 1.1±1.7 [0.0-7.1] 2.2±1.1 [0.8-7.0] 1.9±2.3 [0.0-12.8] 
South Africa Patients (n=20) 3.5±5.0 [0.3-21.4]   8.7±14.6 [0.4-49.0]   
Structure High Dose PTV, Dose Received by hottest 1cc [% of Rx] High Dose PTV, Volume Receiving 95%Rx [%] 
All Patients (n=83) 106.4±2.1 [102.7-113.5] 106.6±2.7 [97.5-114.5] 98.7±1.0 [98.0-102.8] 100.2±1.6 [89.8-102.0] 
MDACC Patients (n=54) 106.7±2.3 [102.7-113.5] 105.2±1.5 [97.5-107.6] 98.7±0.9 [98.0-101.6] 100.1±1.9 [89.8-102.0] 
Clinical Trial Patients (n=29) 105.9±1.5 [103.9-110.1] 109.1±2.5 [104.1-114.5] 98.8±1.3 [98.0-102.8] 100.3±0.5 [99.0-101.1] 
South Africa Patients (n=20) 108.7±3.4 [106.1-119.4]   99.5±2.5 [98.0-107.5]   
Structure Intermediate Dose PTV, Volume Receiving 95%Rx [%] Low Dose PTV, Volume Receiving 95%Rx [%] 
All Patients (n=83) 99.1±1.6 [91.8-104.0] 100.6±1.7 [93.3-106.6] 98.4±2.0 [87.5-105.7] 100.6±1.9 [93.0-107.7] 
MDACC Patients (n=54) 99.1±1.8 [91.8-103.1] 100.5±1.5 [93.3-102.7] 98.5±2.3 [87.5-105.7] 100.6±1.6 [93.0-107.7] 
Clinical Trial Patients (n=29) 99.1±1.4 [98.0-104.0] 100.7±2.0 [97.5-106.6] 98.2±0.3 [98.0-99.0] 100.5±2.6 [97.2-107.7] 
South Africa Patients (n=20) 98.4±0.8 [98.0-100.6]   99.8±2.7 [98.1-103.8]   
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Table 5. Fraction of clinical and autoplans meeting clinical dosimetric constraints
  MDACC & CT Patients 
(n=83) 
Clinical Trial (CT) 
Patients (n=29) 
MDACC Patients  
(n=54) 
South Africa 
Patients (n=20) 
Structure Constraint Clinical Plans  Autoplans 
Clinical 
Plans  Autoplans 
Clinical 
Plans  Autoplans Autoplans 
Spinal Cord Dmax<45Gy 88% 99% 66% 100% 100% 98% 90% 
Brainstem Dmax<54Gy 96% 100% 90% 100% 100% 100% 85% 
Ipsilateral Parotid Dmean<26Gy 46% 51% 24% 38% 57% 57% 25% 
Contralateral 
Parotid Dmean<26Gy 83% 88% 52% 76% 100% 94% 50% 
Ipsilateral Parotid V30Gy<50% 64% 75% 55% 79% 69% 72% 40% 
Contralateral 
Parotid V30Gy<50% 100% 99% 100% 100% 100% 98% 75% 
Ipsilateral 
Submandibular 
Gland 
Dmean<39Gy 
16% 12% 3% 3% 22% 17% 20% 
Contralateral 
Submandibular 
Gland 
Dmean<39Gy 
35% 28% 3% 7% 52% 39% 25% 
Cochleae Dmax<35Gy 91% 89% 83% 97% 95% 85% 73% 
Optic Chiasm Dmax<54Gy 100% 99% 100% 100% 100% 98% 95% 
Optic Nerve Dmax<54Gy 99% 99% 100% 100% 98% 98% 89% 
Lens Dmax<7Gy 95% 95% 96% 100% 94% 93% 81% 
Eyes Dmax<35Gy 98% 98% 100% 100% 97% 97% 88% 
Brain Dmax<54Gy 70% 84% 59% 97% 76% 78% 70% 
High Dose PTV V1cc<110% 87% 93% 62% 97% 100% 91% 85% 
High Dose PTV V1cc<117% 100% 100% 100% 100% 100% 100% 95% 
High Dose PTV V95%>95% 74% 24% 72% 17% 76% 29% 100% 
Intermediate Dose 
PTV V95%>100% 100% 100% 100% 100% 100% 100% 8% 
Intermediate Dose 
PTV V95>80% 71% 9% 43% 0% 81% 12% 100% 
Low Dose PTV V95>100% 100% 100% 100% 100% 100% 100% 25% 
Low Dose PTV V95%>78% 98% 100% 100% 100% 96% 100% 100% 
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 Figure 9. Examples of normal structures not meeting clinical constraints . In only these three 
patients did spinal and brainstem structures fail to meet clinical maximum dose constraints. In 
all cases the critical structure in question was in very near proximity or overlapping with the 
high dose target volume. In panel A, the spinal cord and high dose planning target volume are 
separated by only 1.3mm, in panels B and C the brainstem overlaps with the high dose 
planning target volume. These cases underline the need for sanity checks on contours prior to 
plan optimization. 
 
A paired Wilcoxon signed rank test was used to compare the clinical and autoplans for 
three groups – all 83 patients with available clinical plans, 54 patients from MD Anderson, and 
29 patients treated at on a clinical trial protocol. The p-value of the Wilcoxon signed rank test 
for each DVH metric can be found in Table 6. Considering all 83 patients with corresponding 
clinical plans, the autoplans significantly outperformed their clinical counterparts considering 
the volume of spinal cord receiving more than 45 Gy, the maximum dose and the volume 
receiving more than the clinical threshold of 54 Gy to the brain, the mean dose to the 
ipsilateral parotid and volume receiving 30 Gy to the ipsilateral and contralateral parotids. The 
clinical plans performed better considering the maximum dose to the spinal cord, brainstem, 
optic chiasm, optic nerves, eyes, and lens. However, for all these the plans were not 
significantly different considering the volume receiving more than the clinical maximum dose 
threshold.  The clinical plans had significantly better sparing of the submandibular glands with 
Brainstem 
Spinal Cord 
High Dose PTV 
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a lower average mean dose and significantly better coverage of the low dose PTVs at 95% of 
the prescription dose and a lower dose to 1cc of the high dose PTV. Similarly, when 
considering only the patients from the MDACC data set the clinical plans outperformed the 
autoplans on all these categories. The autoplans only outperformed the cohort of patients 
from MD Anderson considering the volume receiving more than 30Gy to the ipsilateral 
parotid, the mean dose to the contralateral parotid, and the volume of the intermediate dose 
PTV receiving more than 95% of the prescribed dose. 
When considering the cohort of patients treated on a clinical trial, the autoplans 
significantly outperformed the clinical plans for a majority of evaluated constraints. The 
autoplans outperformed the clinical plans in terms of maximum dose and volume exceeding 
the maximum dose to the spinal cord, brainstem, brain, and cochlea, mean dose and V30Gy 
to both the contralateral and ipsilateral parotids, and dose to the hottest 1cc of the high dose 
PTV. The only categories in which the 29 clinical plans treated on a clinical trial outperformed 
the autoplans were the maximum dose to the optic nerves, chiasm, lens, and eyes, though for 
none of these did the clinical plans outperform the autoplans when considering the volume of 
the structure exceeding the clinical constraints and the maximum dose constraints were met 
for all patients. 
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Table 6. Comparison of autoplan performance to clinically treated plans. Shown are p-values 
of the paired Wilcoxon signed rank test. In green are parameters for which the autoplans 
outperformed the clinical plans, and in red which the clinical plans outperformed the 
autoplans. 
  p-value, Wilcoxon signed rank 
Structure Test Point 
All Patients 
(n=83) 
Clinical Trial 
Patients (n=29) 
MDACC Patients 
(n=54) 
Spinal Cord 
D_max <0.01 <0.01 <0.00 
V_45Gy <0.01 <0.01 1.00 
Brainstem 
D_max <0.01 <0.01 <0.01 
V_54Gy 0.25 0.25 1.00 
Ipsilateral Parotid 
Gland 
D_mean <0.01 <0.01 0.23 
V_30Gy <0.01 <0.01 <0.01 
Contralateral Parotid 
Gland 
D_mean 0.27 <0.01 <0.01 
V_30Gy <0.01 <0.01 0.39 
Ipsilateral 
Submandibular Gland D_mean 0.02 0.15 <0.01 
Contralateral 
Submandibular Gland D_mean <0.01 0.28 <0.01 
Cochleae 
D_max 0.51 <0.01 <0.01 
V_35Gy 0.11 0.01 <0.01 
Optic Chiasm 
D_max <0.01 <0.01 <0.01 
V_54Gy 1.00 1.00 1.00 
Optic Nerves 
D_max <0.01 <0.01 <0.01 
V_54Gy 0.50 1.00 0.50 
Lens 
D_max <0.01 <0.01 <0.01 
V_7Gy 0.13 1.00 0.08 
Eyes 
D_max <0.01 <0.01 <0.01 
V_50Gy 0.50 1.00 0.50 
Brain 
D_max 0.01 <0.01 0.01 
V_54Gy 0.01 <0.01 0.54 
High Dose PTV 
D_1cc <0.01 <0.01 <0.01 
V_95% 0.69 1.00 1.00 
Intermediate Dose 
PTV V_95% 0.06 0.77 0.02 
Low Dose PTV V_95% 0.02 0.07 0.26 
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Considering the variance between the two planning strategies, the results of the 
Brown-Forsythe test for all patient with corresponding clinical plans are shown in Table 7. A 
significant p-value, as for maximum dose to the spinal cord and brainstem; and mean doses 
to the contralateral parotid and submandibular glands, indicates that the two distributions 
come from distributions with different variances. When considering all 83 patients, the 
standard deviation across plans was less for autoplans than clinical plans, suggesting the 
autoplanning technique provides plans with decreased inter-patient variability. 
 
Table 7. Brown-Forsyth test of equal variance between autoplans and clinical plans. A 
significant p-value (p<0.05, shaded green) indicate that the distributions of clinically relevant 
DVH points have different variances. For each tissue the RPA plan distribution had a 
significantly smaller variation than the clinical plans. 
  p value, Brown-Forsythe Test 
Structure Test Point All Patients (n=83) 
Spinal Cord D_max <0.01 
Brainstem D_max <0.01 
Ipsilateral Parotid 
D_mean 0.40 
V_30Gy 0.61 
Contralateral Parotid 
D_mean 0.01 
V_30Gy 0.63 
Ipsilateral Submandibular Gland D_mean 0.81 
Contralateral Submandibular Gland D_mean 0.04 
Cochleae D_max 0.73 
Optic Chiasm D_max 0.74 
Optic Nerves D_max 0.50 
Lens D_max 0.37 
Eyes D_max 0.99 
Brain D_max 0.48 
High Dose PTV 
D_1cc 0.11 
V_95% 0.95 
Intermediate Dose PTV V_95% 0.82 
Low Dose PTV V_95% 0.34 
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Figure 10 describes the layout of Figure 11 in which the performance of the 
autoplanning strategy against the corresponding clinical plan for all 83 patients is considered 
at many clinically relevant dosimetric points. Over 83 patients and 18 structures, 4 bilaterally, 
for a total of 1719 DVH points considered (36 target volumes did not exist, and 71 structures 
were outside of the dose calculation region in the clinical plan), 610 (35%) had improved DVH 
metric for the autoplans, but the improvement did not change the whether the plans met 
clinical constraints. For 989 structures (58%), the clinical plan performed better at the 
endpoint, but the difference was not beyond the clinical threshold. However, for 76 structures 
(4%) the autoplan outperformed the clinical plan and this difference was beyond clinical 
thresholds, this is compared to 44 structures (3%) of endpoints for which the clinical plan 
performed better and was beyond clinical limits. Of the 4% of endpoints for which the 
autoplan provided an improvement at the dosimetric endpoint and this resulted in the plan 
meeting clinical constraints whereas the clinical plan had not met that constraint, 91% came 
from the population of patients treated on the clinical trial.  
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 Figure 10. Explanation of clinical and autoplan comparison. For structures with an upper DVH 
constraint (i.e. spinal cord maximum dose less than 45Gy) (right), plan quality was improved if 
the DVH metric of the autoplan was less than the DVH metric of the clinical plan, these plans 
will be reflected in the shaded green regions. Plans for which an improvement was seen but 
both plans met the clinical constraint (e.g. spinal cord maximum dose of 43 Gy in the clinical 
plan and 42 Gy in the autoplan) are reflected in a, when both fail to meet the clinical 
constraint (e.g. spinal cord maximum dose of 47 Gy in the clinical plan and 46 Gy in the 
autoplan) in panel b. In the darker green region, panel c, the autoplan met the clinical 
constraint but the clinical plan did not (e.g. spinal cord maximum dose of 46 Gy in the clinical 
plan and 44 Gy in the autoplan). Similarly if the clinical plan outperformed the autoplan, this is 
reflected in the red shaded regions. If both plans met the constraint in panel d and if both 
missed the constraint in panel e. Importantly, if the clinical plan met the clinical constraint but 
the autoplan did not, the plan will be reflected in panel f. On the left, the same schema is used 
but for structures with a lower DVH constraint (e.g. volume of the PTV receiving 95% of the 
prescribed dose). An improvement in plan quality, shaded green, are seen when the autoplan 
has a higher value than the clinical plan. Color and letter definition are as previously 
described.  
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 Figure 11. Distribution of autoplan and clinical plan performance at relevant dosimetric points. 
Autoplan values are shown along the x-axis and corresponding clinical plan value along the y-
axis. Shades of green indicate improvement in the dosimetric descriptor for the autoplan, 
shades of red indicate poorer performance due to autoplanning. Darker shades delineate 
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common clinical thresholds for each dosimetric descriptor, with darker green indicating an 
improvement beyond the clinical threshold and darker red indicating a poorer performance 
beyond the clinical threshold. Twenty nine patients treated on a clinical trial are shown in 
magenta circles, and 54 patients from our institution shown in cyan squares. The number of 
patients in each group are shown (continued of following pages). 
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Figure 11, continued from previous page.  
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Figure 11, continued from previous page. 
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 Finally, when considering DVHs curves of target and organs at risk, the autoplans 
show significant improvement over clinical plans treated on a clinical trial. Shown in Figure 12 
are average DVH curves for the two planning techniques and the negative of the log of the p-
value of the Wilcoxon signed rank test which is significant for values greater than or equal to 
3. For all structures, the autoplans significantly outperformed the clinical plans in DVH 
analysis. 
 
 
Figure 12. DVH comparison of autoplans and clinical plans treated as part of a clinical trial . 
The average DVH over all 20 patients is shown for both the clinical plan (red) and the 
autoplan (blue). Overlaid is negative of the log of the p value of the Wilcoxon signed sum test, 
significant in the green shaded region at values greater than or equal to 3. Autoplans routinely 
outperform clinical plans. 
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Physician Review of Autoplans 
During the development of the planning approach, four head-and-neck site specific 
radiation oncologists review the autoplans and assessed them for clinical utility. When 
presented with 8 plans, 2 radiation oncologists from South Africa approved 100% of the 
autoplans. Upon presentation of the autoplans for 20 patients treated on a clinical trial XX 
were approved for use without and one required only minor edits. However, of 20 patients 
treated at MD Anderson Cancer Center only 7 (35%) were approved for use without edit and 
one required only minor edits. These patients included patients from subsites which differ in 
treatment strategy from those primarily used for strategy development including patients with 
disease of the oral cavity in which dose prescription levels (typically 60 ,57 and 54 Gy) are 
much closer than, for example, for oropharynx cases (70, 63 and 57Gy or 66, 60 and 54 gy). 
Further, the strategy was tested for patients with primary disease of the larynx for which, in 
scenarios of low-resource, advanced techniques are unlikely to be used. While for this cohort 
of patients, clinical dose constraints were met at rates similar to clinical plans as seen in 
Table 5, other features of the plans including dose heterogeneity and relative location of 
hotspots with underlying anatomy result in major modification needed for treatment planning. 
This suggests that, while the strategy is high performing for some subsites (particularly 
disease of the oropharynx), further investigation is likely needed for other subsites. 
Discussion 
In summary, we have developed an automated single-optimization approach for 
VMAT planning in the head-and-neck. Using a full automated approach based on in-house 
algorithms and commercial solutions, head-and-neck VMAT plans are created without human 
intervention. After manual contouring of targets and organs at risk, algorithms are used to set 
beam parameters including the jaw and collimator, identify the isocenter, and automatically 
contour planning structures. Finally, using a validated RapidPlan ® model in combination with 
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added population optimization objectives, VMAT plans were optimized and dose was 
calculated automatically. The entre process takes, on average, less than 40 minutes.  
This autoplanning technique represents the first fully automated approach which 
requires no human intervention aside from the contouring of targets and organs at risk.  DVH 
analysis of 29 patients treated on a clinical trial showed considerable improvement to the 
dose to organs as risk with limited impact of dose coverage and as rated by a head-and-neck 
specific radiation oncologist, XX% of plans were clinically acceptable without edit. A decrease 
in plan variability at clinically relevant dosimetric endpoints between plans was seen for four 
organs at risk when the autoplanning approach was used. A reduction in plan variability is 
often cited as desired for quality management purposes (82), though a reduction in variability 
should not come with a reduction in quality. The plans are generated in less than 40 minutes 
and this represents time during which the user does not need to intervene or be present and 
during which other tasks (i.e. contouring, plan approval, etc.) may occur. This time includes 
that needed for the autocontouring of structures not included in the treatment plan, which if 
supplied by the attending physician would not be required. Built on clinically implemented 
tools including the Eclipse Treatment Planning system (VMAT optimizer, dose calculation 
engine) and autocontouring algorithms the autoplanning technique can easily be expanded 
for use with other treatment machines and at other institutions. Evaluated on 20 patients from 
international partner institutions, the autoplanner performed well and radiation oncologists 
from these institutions found the plans clinically acceptable. 
This autoplanning approach does, however, have limitations. First, when compared 
against clinically delivered plans from our institution, the clinical plans outperformed the 
autoplans for 10 of 26 DVH metrics analyzed, including having a lower maximum dose to the 
spinal cord, brainstem, optic chiasm, nerves, eyes and lens, better coverage at the 95% dose 
level of the low dose PTV and a lower hotspot to 1cc of the high dose PTV. The autoplans 
only outperformed for 6/26 including volume receiving 30Gy to the ipsilateral and contralateral 
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parotid glands, mean dose to the ipsilateral parotid gland, and maximum dose to the brain. It 
is known, and a fundamental characteristic of knowledge based planning, that the autoplans 
will represent the quality of the knowledge base on which the approach was designed. Also, 
as rated by a head-and-neck specific radiation oncologist, all rated plans for disease of the 
oral cavity and salivary glands needed major edit for clinical use, it is likely a subs-site specific 
optimization strategy is needed. A model built based wholly or partly on the sample of the 54 
MD Anderson patients herein, may represent an improvement in plan quality over the current 
knowledge base and therefore allow for an improvement in the autoplans.  
Similarly, while the current knowledge based schema does consider the spatial 
geometry of the patients’ targets and normal tissues the use of a single model for the planning 
of many head-and-neck subsite may limit to performance of the autoplanner. Investigation in 
subsite specific knowledge based planning techniques for the head-and-neck may allow for 
incremental improvement in plan quality. Finally, the autoplanner performance was noticeably 
poor for patients which met certain criteria including very large tumor volumes, tumor volumes 
which include large volumes with very low density, and targets in very close proximity to 
critical normal structures. Many times, in these cases, compromises in plan quality must be 
identified by highly trained staff and therefore are not suitable to a fully automated approach. 
This could be implemented through a feedback system which analyzes spatial geometry of 
the plan prior to optimization. 
In addition to general performance, the autoplanning schema used here has 
fundamental limitations. The limitation of 3 discrete target volume prescriptions which, while 
acceptable for the majority of patients, may exclude some patients who have disease very 
close to the brain or brachial plexus and generally require a fourth prescriptions volume to 
shape the dose around these critical structures. Additionally, as seen for one patient, the use 
of the current autocontouring technique requires consistent CT slice spacing, a requirement 
which does not apply to manual contouring or traditional treatment planning approaches. 
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As with any automated approach rule base objectives and tradeoffs must be 
implemented which may need revising over time. It is critical that characteristics of the 
incoming data are known and systems, which warn the user or may halt the process when a 
result is outside of standard values are implemented. For example, herein we implemented a 
normalization approach meant to ensure adequate coverage of all target volumes, which was 
realized by normalizing the final plan such that at least 98% of each target volume received 
95% of the prescribed dose. However for some patients this resulted in very small 
normalization values and unacceptable plans. Evaluation of the characteristics of the target 
volumes used for normalization revealed the normalization to very small or very low density 
target volumes could drastically effect the plan quality. Towards this, pre-normalization rules 
were implemented to avoid these scenarios and over time new scenarios may arise which 
require the revaluation of the assumptions on which the algorithms were developed. 
There are many opportunities for further study concerning this automated treatment 
planning approach. As mentioned, refinement of the knowledge based model may improve 
plan quality or may allow for tailoring to each individual site for implementation. Further, an 
iterative approach which may involve re-optimization with added constraints on hot or cold 
spots has seen success (83) and could be implemented without requiring human intervention.  
Additionally, though the current use of 3-4 arcs is not desired as the use of additional arcs 
increases the time needed for delivery, dose calculation, and plan quality assurance. 
Optimization of the planning approach including jaw and collimator selection algorithms may 
allow for the use of two arcs. Further refinement of the normalization algorithm to 
accommodate additional head-and-neck subsites, and not yet encountered circumstances, 
and in order to satisfy individual treating physicians may be required. The time needed for 
plan development may also be reduced by increasing processing power or using improved 
dose calculation algorithms including Acuros® (84) which is available in the Eclipse TPS but 
requires additional investigation including how to handle dental artifacts. Other considerations 
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for planning/overrise structures such as dental artifacts or bridges may be required and result 
in an improvement plan quality. Finally, and most importantly, the clinical use of the 
autoplanning approach will reveal how the system will be integrated into a radiation oncology 
clinic, will likely reveal the need for further refinement, and may prove to be an essential tool 
to help reduce the human infrastructure burden of radiotherapy in low-resource settings. 
Conclusion 
In conclusion, a single optimization treatment planner along with automatic field 
settings can generate clinically acceptable autoplans in under 40 minutes without the need for 
human intervention.  
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Chapter 5: Automatic Contours of Normal Structures in the 
Head-and-Neck 
A substantial portion of this chapter is written or based on the following publications: 
Placeholder – Paper under 2nd round revision. 
 
 
In this chapter we describe the results for Specific Aim 3 in which, through four 
experiments, we evaluate the feasibility of automatic delineation of normal structures for 
treatment planning in the head-and-neck. Our working hypothesis is automatically contoured 
normal structures can be used for treatment planning purposes without significant impact on 
plan quality. 
Introduction  
Advanced techniques including 3D conformal radiotherapy, IMRT, and VMAT which 
have been widespread in high-resource clinics since the 1990s, have made the process of 
contouring an essential step in the treatment planning process. Contouring, however, is 
known to be time consuming, plagued by considerable inter-physician variability (85-89), and 
the component of radiation therapy treatment planning which introduces the most error (90, 
91). For head-and-neck cancer, the contouring of 3 or more target volumes and as many as 
25 normal structures may be required (92). For any clinic, but particularly for those in low-
resource clinics the enormous time, human resource, and training burden of contouring may 
prohibit the transition to these advanced techniques, which are particularly critical for the 
treatment of head-and-neck cancer. 
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In the context of an automated treatment planning approach for head-and-neck 
cancer, automatic contouring would increase the time savings, reduce plan variability, and 
may eliminate some of the barriers prohibiting the transition to advanced delivery techniques. 
Many efforts to automate the contouring process for normal structures have been reported – 
techniques include image registration atlas based segmentation, machine learning, and 
shape modelling (57). Findings indicate that for head-and-neck treatment plans, automatic 
segmentation of normal structures can significantly reduce inter-observer variability and 
contouring time (93-95). Authors have reported on the limited implementation of automated 
contouring for small structure sets (e.g., brachial plexus(96), heart chambers(97),etc.) and for 
other anatomical sites (e.g. the prostate(98)). However, use of autocontouring for only a 
subset of structures requires a deviation in workflow, if contours require manual editing the 
time saving advantages are partially lost, and importantly, and the long term clinical use of 
autocontoured normal tissues has not been reported. 
Further, reports on the clinical implementation of automatic contouring methods note 
that automatic contours should be carefully reviewed and edited by the physician (99), which 
may take up to 60 minutes (100). The use of automatically contoured normal structures for 
treatment planning without edit would offer increased time savings and would be interest not 
only for a fully automated treatment planning approach but also for adaptive planning in which 
treatment plans are made under tight time constraints and for general clinical practice. 
However, using unedited automatically contoured normal structures should be considered 
with great caution and after comprehensive analysis. 
In this chapter we describe four experiments which assess the viability of using 
unedited normal structures in the head-and-neck for treatment planning. First, several 
autocontouring algorithms were retrospectively assessed for accuracy compared to physician 
drawn structures and were qualitatively rated by head-and-neck radiation oncologists. Then, 
the best performing algorithm was implemented into our head-and-neck clinic with careful 
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physician review and editing for clinical use. Next, a technique to ensure safe use in an 
automated process was developed in order to detect both gross errors in autocontours and 
autocontours which required physician edit for clinical use. Finally, treatment plans were 
created on autocontours without edit and DVH analysis revealed the impact planning on these 
structures, as opposed to physician derived structure, had on the treatment plan. 
Methods 
Analysis of Autocontouring Algorithms 
In this first experiment we sought to evaluate automatic contouring algorithms for 
normal structures in the head-and-neck. 
Patient Cohort 
For this study, we collected 128, the latest in our database, treated for head-and-neck 
cancer at MD Anderson Cancer Center, and who had physician approved contours. Normal 
structure contours were identified manually by naming convention and visual assessment. 
From the 128 patients, the 8 contours most often included in the final treatment plan, and thus 
included in this analysis, were the brain, brainstem, cochleae, eyes, lungs, mandible, parotid 
glands, and spinal cord. Limited analysis of the autocontouring of others structures, including 
lens, optic chiasm, optic nerves, and submandibular glands was also performed. 
A subset of 10 patients was randomly selected for initial review of four autocontouring 
techniques. For the highest performing algorithm on initial review the 118 remaining patients 
were selected to further analyze the autocontouring algorithm’s performance.  
Autocontouring Algorithms 
Of the four autocontouring algorithms used for this study, three are based on two 
commercially available autocontouring algorithms available in the Eclipse Treatment Planning 
system; Smart Detection® and Smart Segmentation®(101). Smart Detection® is a heuristic 
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solution available for a select number of structures and requires only the selection of desired 
contours. Available structures included brain, eyes, lungs, mandible, and spinal canal. The 
second algorithm, Smart Segmentation®, is a deformable image registration based technique 
which, in Eclipse TPS version 13.2, requires the user to select one of many available expert 
cases from which the autocontours will be propagated. According to the manufacturer: 
“Users match their patient case to one of the hundreds of expert cases in the 
library, and through a sequence of co-registration and proprietary deformation 
algorithms, the contours of an expert case are deformed to fit the CT images of 
the patients”(101) 
 
The Smart Segmentation software offers guidance on which expert case should be selected 
through a 5 star rating system. Expert cases for each structure for each patient were selected 
in order of star rating, with up to 14 expert cases selected for each structure for each patient, 
though not all expert cases were available for all 8 normal structures considered. Later 
versions of the Eclipse TPS software allows the selection of multiple atlas and fuses the 
contours using a majority voting algorithm. To simulate this and based on physician feedback, 
up to 12 individual contours were used as inputs to an in-house majority voting algorithm 
outside of the treatment planning system, resulting in a single fused contour per structure. 
The fused contours represent the third autocontouring approach. 
The fourth autocontouring method was based on an in-house multi atlas deformable 
image registration technique termed multi-atlas contouring service (MACS) (96, 97), was 
previously developed (102, 103) and consists of three distinct steps. First, rigid registration is 
performed between the test patient’s simulation CT and the CT of each of twelve atlas 
patients, using 2D sagittal and coronal projections. Second, the test patient is deformably 
registered to each of the atlas patients using dual-force Demons deformable registration 
(104). Using the resultant deformation vector fields, the contours from each atlas patient are 
mapped to the test patient(105); resulting in a number of individual contours equal to the 
number of atlas patients. Finally, the STAPLE algorithm with a built-in tissue appearance 
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model(106) is used to combine the individual segmentations, generating a fusion contour 
approximating a true segmentation.  Central to the MACS algorithm is the building of an atlas 
of patient CTs, which is representative of the patients for which the algorithm will be used. To 
build the atlas used in this work, 12 patients recently treated at our institution for head-and-
neck cancer were selected. The contours used for atlas building were either extracted from 
patient treatment plans (reviewed prior to treatment by head-and-neck quality assurance peer 
review clinic (107)) or created using thresholding tools (brain, lung, and mandible). All 
contours were carefully reviewed by a medical dosimetrist and head-and-neck radiation 
oncologist with 13 and 8 years of experience, respectively.  The autocontouring process of 
multi-atlas DIR based methods can be seen in Figure 13.
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Figure 13. Schematic of the multi-atlas deformable image registration autocontouring process. 
For each new patient, a deformable image registration algorithm is used to link the test patient 
to each of the chosen atlas patients, which have validated contours already drawn. The 
deformation vector field is used to map the contours from each of the atlas patients to the test 
patients, which results in a number of contours for each structure equal to the number of atlas 
patients. A fusion algorithm is used to combine the contours into a single contour. The in-
house contouring algorithm uses 12 atlas patients, a deamons dual force DIR algorithms and 
STAPLE as the fusion algorithm. For the fused Smart Segmentation contours a proprietary 
DIR and contours from up to 12 patients were used with a majority voting algorithm. A third 
algorithm, discussed in the next sections, used a Deeds deformable image registration 
algorithm, 10 atlas patients, and a majority voting algorithm. 
 
Quantitative Contour Assessment 
Contours of the 8 normal structures from each of the 4 autocontouring techniques 
were quantitatively compared to independently physician drawn contours, when available. 
The Dice similarity coefficient, mean surface distance, and Hausdorff distance were 
measured to assess contour accuracy. The Dice similarity coefficient (DSC) measures the 
volume overlap of the physician drawn contour, P, with the autocontour, A, as a ratio to their 
total volume, with a minimum value of 0 when the contours have no overlap and a maximum 
value of 1 when the contours agree perfectly, as in Equation 1. 
Equation 1 – Dice Similarity Coefficient 
𝐷𝐷𝐷𝐷𝐷𝐷(𝑃𝑃,𝐴𝐴) = 2 |𝑃𝑃 ∩ 𝐴𝐴||𝑃𝑃| + |𝐴𝐴|. 
The mean surface distance was calculated as a symmetric 3D mean surface distance 
between two volumes (P and A) and has a minimum value of 0 when the contours agree 
completely and no maximum value, as in Equation 2. 
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Equation 2 – Mean Surface Distance 
𝑀𝑀𝐷𝐷𝐷𝐷(𝑃𝑃,𝐴𝐴) = 12 � 1|𝑃𝑃|�min (𝑑𝑑(𝑝𝑝, 𝑎𝑎))
𝑝𝑝∈𝑃𝑃
+ 1|𝐴𝐴|�min (𝑑𝑑(𝑎𝑎,𝑝𝑝))
𝑎𝑎∈𝐴𝐴
�. 
The Hausdorff distance (HD) was used to measure the maximum Euclidean distance 
from the points both contours to the nearest point in the other and has a minimum value of 0 
when the contours agree completely and no maximum value, as in Equation 3. 
Equation 3 – Hausdorff Distance 
𝐻𝐻𝐷𝐷(𝑃𝑃,𝐴𝐴) = 𝑚𝑚𝑎𝑎𝑚𝑚 �max
𝑝𝑝∈𝑃𝑃
min
𝑎𝑎∈𝐴𝐴
𝑑𝑑(𝑝𝑝,𝑎𝑎) , max
𝑎𝑎∈𝐴𝐴
min
𝑝𝑝∈𝑃𝑃
𝑑𝑑(𝑎𝑎,𝑝𝑝)�. 
For two of the eight normal structures (lungs and spinal cord) we performed the quantitative 
analysis using a modified structure which included only slices of the contours of the 
autocontour between the most superior and most inferior contours drawn by the physician. 
This analysis better represents the contouring accuracy of the algorithm (compared to whole-
structure quantitative analysis) as it eliminates errors that arise owing to differences in CT 
scan extent both between the test and atlas patients and among the atlas patients, and takes 
into consideration incomplete contouring of structures at distance far from the treated 
volumes, see Figure 14. 
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 Figure 14 - Modified structures considered for analysis of autocontour performance. For 
spinal cord and lung (shown), a modified autocontour was created for analysis. This structure 
only includes slices of the original autocontour between the most superior and most inferior 
slices of the corresponding physician drawn structures. In this example, the physician drawn 
lung structure (brown) was only contoured for part of the true lung. The original autocontoured 
lung (cyan) extended for many slices below the physician lung, when modified (lavender) the 
slices extended below the most inferior slices of the physician drawn lung were removed. This 
is appropriate for many reasons including, as shown in this example, often the autocontour 
will extend further even than the dose grid (green dash) and is therefore irrelevant in the 
treatment planning process. 
 
Physician Review of Autocontours 
A radiation oncologist was asked to rate the normal structures on a five-point scale, 
Table 8. For contours receiving a score indicating minor or major edit would be needed for 
use in dose volume histogram (DVH)-based planning (scores 1-3), the physician was asked 
Modified 
Autocontoured Lung 
Autocontoured Lung 
Physician Drawn Lung 
Dose Grid 
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to note the main failure mode. This allows for analysis of potential improvement of the 
algorithm. 
 
Table 8. Five point scale for physician rating of normal structures. For structures receiving a 
score of 1, 2, or 3, which indicates either minor or major edit is needed for use in DVH based 
treatment planning, the physician was asked to cite the main failure mode. 
Rating Description 
5 Perfect; indistinguishable from physician-drawn contours for DVH based planning 
purposes 
4 Within acceptable inter-physician variation for planning purposes, as described 
above 
3 Good; needs minor edits if normal structure is near a target 
2 Fair; needs significant edits to be used for the  planning purposes described above 
1 Poor; large areas need minor or major edit. Is unusable for planning purposes 
described above 
 
For the top performing algorithm the remaining 118 patients were rated on the same 
scale and, to assess the possibility of rater bias, contours from this top performing algorithm 
for 10 patients were reviewed by five additional radiation oncologists from four international 
institutions. Physician agreement was assessed by grouping each pair of ratings (one rating 
from the primary physician and one from an outside physician) into one of three categories. 
Category I agreement includes instances when the primary and outside physician agreed as 
to the degree of edit needed, Category II agreement indicates that the physicians agreed that 
the contour required either no more than minor edits or required major edits. The final 
category, Category III agreement, includes those contours where the physicians disagreed on 
the acceptability of the contour, with one physician indicating that the contour needed major 
edit with the other indicating no or minor edit for use. Additionally, inter-physician variability in 
ratings was assessed using a Wilcoxon signed rank test. 
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Additional Contour Analysis 
Exploratory analysis of the autocontouring of additional structures including optic 
chiasm, optic nerves, submandibular glands, esophagus, and lens using the previously 
described algorithms and others including a commercially licensed algorithm (108) using (1) a 
proprietary atlas (2) the same atlas used in MACS and (3) the proprietary atlas in combination 
with a shape model supplied by the vendor (only available for some structures) were also 
performed results of which can be found in the appendix. 
 The results of this first experiment are found on page 100. 
Clinical Use of Normal Tissue Autocontours 
In the second experiment we investigated the clinical use of an autocontouring 
algorithm for normal structures in the head-and-neck. 
Clinical Implementation  
After retrospective validation of the contouring algorithms, we began a limited 
introduction of the top performing algorithm, MACS, into our head-and-neck clinic. The 
automated contouring algorithm was already in use for a limited number of sites and 
structures in our clinic prior to the implementation of this atlas for normal structures in the 
head-and-neck. The software based on the MACS algorithm is accessible via a script in the 
Pinnacle3 Treatment Planning System (Philips Medical Systems, Milpitas, CA). Initially, use of 
the software was limited to a select number of radiation oncologists for review, which 
prompted standardization of the contour color to match that already in clinical practice, and 
inclusion of a script to overwrite empty structures already in the treatment plan (our clinical 
workflow involves the population of a standard set of empty structures through a script). 
Additionally, due to algorithm limitation as discussed, the inferior portion of the lung was often 
either not contoured or was contoured in many segments per slice, which prompted renaming 
of the lung structure to “lung_avoid,” indicating its use for treatment planning purposes rather 
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than anatomical definition.  After the automated contouring workflow was finalized, the 
software was released for use by all attending physicians. Typically, the clinical workflow of 
automated contouring involves the initialization of the algorithm by a dosimetrist using a script 
in the treatment planning system, import of the structures into the treatment plan, followed by 
review and any needed editing of the contours by the attending radiation oncologist. All final 
contours were reviewed and edited by the attending physician, see Figure 15, in the same 
way that initial resident contours would be reviewed. The final contours reflected approval by 
the physician, with or without editing as deemed appropriate. 
Quantitative Analysis of Autocontour Edit 
To assess the degree of edits made of the autocontours for clinical use, the contours 
generated by the algorithm were compared to the contours edited for treatment planning by 
the physician using the DSC (Equation 1), MSD (Equation 2), and HD (Equation 3). In 
addition to analysis of the eight clinically implemented normal structures, we also 
quantitatively compared edits of two modified contours, as previously described. 
Additionally, in order to elucidate possible planning margins needed if autocontours 
are used without edits, we determined the minimum uniform expansion to the autocontour 
needed to cover 95% or 100% of the edited contour for 90% or 95% of the population. These 
margins may reveal that for some structures a planning at risk volume (PRV) may be added 
to the autocontoured normal tissue in order to compensate for potential errors in contouring. 
This expansion may ensure the safety of using unedited structures in treatment planning. This 
may be especially true for structures with a maximum dose constraint for which, if the 
modified structure meets constraint, any structure completely encompassed would also meet 
constraints. 
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Finally, to assess the possible motivation for contour edits outside of anatomical OAR 
definition, we used a one-sided t test to assess the association between automatic contour 
edits and the minimum distance to target volume. 
 The results of this second experiment are found on page 107. 
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 Figure 15 - Example of physician edits to clinical autocontours. Shown for one patient are 
autocontours of the brain, brainstem and cochleae (panel A) and spinal cord mandible and 
parotid glands (panels B and C) in blue and the physician edits and/or approved structures 
which remained in the patient’s treatment plan in red. For this patient, no edits were made to 
the cochlea structures, and some boundaries of other structures remained unedited.  
Physician 
Edited/Approved 
Structures 
Autocontoured 
Structures 
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Machine Learning Model for Prediction of Autocontour Errors 
In the third experiment we sought to develop of a random forest model for assessment 
of anatomical errors in autocontours of normal structures in the head-and-neck 
Contour QA technique 
Necessary for implementation as part of a fully automated treatment planning 
approach is a method to detect autocontouring errors. Detection of gross and simulated errors 
represents a check of safety and catching of significant autocontouring errors. The detection 
of smaller, potentially necessary clinical edits to autocontours would allow for the possibility to 
flag to the user of an automated treatment planning approach that autocontours presented 
may require editing. Other investigations of contour QA have been reported using historical 
data with heuristically selected metrics and thresholds to predict simulated contouring errors 
(109), mislabeled contours, and the effects of noise (110). These studies introduce the 
important topic of contour QA and demonstrate the feasibility of automated techniques in 
detecting some errors. However a comprehensive or optimized prediction model was not 
used to differentiate cases of automatic contouring failure and manual detection of errors is 
still heavily relied upon. 
To predict contour errors, we implemented a random forest (RF) method in Matlab 
(Mathworks, Natick Massachusetts). RFs are machine-learning models proposed by Breiman 
(111) that do not require a priori information about any relationship between input metrics and 
output predictions (unlike, for example, regression models, which typically assume linearity) 
and provide a measure of predictor importance, and have low susceptibility to overfitting. 
Random forest models have proven successful in other contour QA approaches (49, 110) as 
well as non-linear approaches such as radiation toxicity (112-115). 
Three RF models were trained for each of the eight normal structures, one model for 
each of the three classes of automatic contouring errors (simulated errors, and two degrees of 
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true errors), as described below.  Each model was then tested on an independent dataset. 
The RF models were trained for 1,000 decision trees with a minimum leaf node size of three. 
The number of patients and error types for each training and testing dataset are detailed in 
the following sections.  
Engineered predictive metrics, developed to assess the contour accuracy, were 
extracted from each contour and corresponding CT dataset. A summary of the metrics can be 
found in Table 9. The predictive metrics included volumetric (e.g., Dice similarity coefficient) 
and distance agreement metrics (e.g., mean surface distance) with contours generated from 
three independent contouring techniques. For the first technique, a commercially licensed 
algorithm (108) (Varian Medical Systems, Palo Alto, CA) was implemented in a multi-atlas 
deformable image registration contouring approach, whereby contours from 11 atlas patients 
were deformably registered to the test patient and the resultant contours were fused using a 
majority voting algorithm, a schematic is shown in Figure 13. For the second technique, 
contours were generated using the heuristic algorithm Smart Detection®, as implemented in 
the Eclipse treatment planning software (Varian Medical Systems). Owing to algorithm 
limitations, only the brain, eyes, lungs, and mandible contours were generated and thus 
compared with the corresponding contour from the test patient. For the third technique, 11 
atlas patients were rigidly registered to the test patient and the most accurate registration (as 
measured by the mutual information between atlas and test patient data set over the whole 
image) was used for contour propagation.  
Other predictive metrics included the volume of the contour, metrics extracted from the 
Hounsfield unit (HU) distribution within the contour, and the spatial relationship of the contour 
with other automatically contoured structures (i.e., other normal structures). Additionally, we 
analyzed the highest order coefficient of first-, second-, and third-order polynomial fits to inter-
slice distance measures, both between adjacent slices and between bony tissues and the 
inter-slice area Figure 16. Because several of the available metrics were derived from the 
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same primary data (e.g., metrics from the HU distribution, agreement with secondary 
techniques, and polynomial fits to slice measures), a univariate selection was performed by 
choosing the metric within the group with the lowest average misclassification probability in a 
small (10-tree) forest using only the predictor in question. The full list of predictive metrics can 
be found in Table 9. 
 
Figure 16. Inter-slice metrics for autocontour error detection. Contour features for a 
representative patient are shown in panel A and include polynomial fits to inter-slice metrics 
such as the mean distance to bone (in panel B) and the slice area (panel C). 
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Table 9. Engineered metrics used for the prediction of errors to automatic contours.  
Shape metrics Size/Hounsfield unit (HU)-derived metrics Positional metrics 
Metrics showing agreement with 
independent automatic contours 
Metric/metric 
group Definition 
Metric/metric 
group Definition 
Metric/metric 
group Definition 
Metric/metric 
group Definition 
Inter-slice 
slice area 
statistics 
Mean, maximum, 
minimum, and 
standard 
deviation 
Volume 
(no. of voxels 
in contour) × 
[voxel size 
(cm3)] 
Inter-slice 
minimum 
distance to 
bone statistics 
Mean, maximum, 
minimum, and 
standard 
deviation 
Independent 
deformable atlas 
approach, 
volumetric 
agreement* 
Volume ratio, true 
positive ratio, 
false positive ratio 
Inter-slice 
slice area 
polynomial 
fits* 
Highest order 
coefficient of first-
, second-, and 
third-degree 
polynomial fits 
HU statistics 
Mean, 
standard 
deviation of 
HU of pixels 
within contour 
Inter-slice 
minimum 
distance 
polynomial fits* 
Highest order 
coefficient of first-
, second-, and 
third-degree 
polynomial fits 
Independent 
deformable atlas 
approach, distance 
agreement* 
Hausdorff 
distance, mean 
surface distance 
Inter-slice 3D 
Hausdorff 
distance 
Mean, maximum, 
minimum, and 
standard 
deviation 
Lower extreme 
of HU 
distribution 
within contour* 
HU at 1%, 2%, 
5%, and 10% 
cumulative 
probability 
Inter-slice 
maximum 
distance to 
bone statistics 
Mean, maximum, 
minimum, and 
standard 
deviation 
Independent 
heuristic approach, 
volumetric 
agreement* 
Volume ratio, true 
positive ratio, 
false positive ratio 
Inter-slice 3D 
Hausdorff 
distance* 
Highest order 
coefficient of first-
, second, and 
third-degree 
polynomial fits 
Upper extreme 
of HU 
distribution 
within contour* 
HU at 90%, 
95%, 98%, 
and 99% 
cumulative 
probability 
Inter-slice 
maximum 
distance 
polynomial fits* 
Highest order 
coefficient of first-
, second-, and 
third degree 
polynomial fits 
Independent 
heuristic approach, 
distance 
agreement* 
Hausdorff 
distance, mean 
surface distance 
Inter-slice 3D 
mean surface 
distance 
Mean, maximum, 
minimum, and 
standard 
deviation 
% of contour 
with HU below 
given HU 
values 
-500, -100, 0, 
40, 300, 500 
Separation of 
contour 
centroids in X, 
Y,  and Z 
directions 
Seven other 
automatic 
contours 
Independent single-
patient rigid 
approach, 
volumetric 
agreement* 
Volume ratio, true 
positive ratio, 
false positive ratio 
Inter-slice 3D 
mean surface 
distance* 
Highest order 
coefficient of first-
, second-, and 
third-degree 
polynomial fits 
    
Independent single-
patient rigid 
approach, distance 
agreement* 
Hausdorff 
distance, mean 
surface distance 
*Univariate selection was performed within the metric group. 
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Simulated failure models 
In the RF models for simulated errors, prediction classes included unedited clinical 
automatic contours and simulated failures, including automatic contours that had been shifted 
or expanded by amounts that varied by structure. Contours were expanded uniformly in three 
dimensions or shifted in a random direction by a known amount. The size of the shifts and 
expansions varied by structure according to the average volume of the structure. Contours for 
small structures (eyes and cochleae) were shifted and expanded to a lesser extent than those 
for medium-sized structures (brainstem, mandible, and parotid glands), which were shifted 
and expanded less than that for large structures (brain, lungs, and spinal cord). For RF 
training, eight shifted structures from each of four size shifts and 10 expanded contours from 
each of three size expansions were combined with 62 unedited clinical contours, providing a 
total of 124 contours. See Table 10 for details of the training data-set, including the sizes of 
shifts and expansions. Predictor importance was assessed by summing the change in the 
mean squared error due to splits on that predictor divided by the number of branch nodes 
after the split. 
For testing of the simulated error RFs, 50 contours from each of the aforementioned 
error types (shifts and expansions) were combined with contours propagated on 13 patient 
scans of other anatomical locations (seven patients with cervical cancer and six patients with 
breast cancer), and contours from nine patients in nonstandard positions for which the 
automatic contouring algorithm was grossly incorrect, as well as contours from one patient 
who had a very large primary tumor volume that impinged on nearby normal structures. 
Figure 17 shows representative examples of contours with simulated errors and for a patient 
not in a similar position to the atlas patients. 
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 Figure 17. Contouring errors for building and testing of QA models. Simulated errors included 
autocontours which had been shifted and expanded (left) and autocontours propagated on 
patients for which the atlas based technique is not suitable (right). The atlas used for the 
current study included patients positioned supine on the treatment table; when autocontours 
are propagated on patients in significantly different positons automatic contouring errors arise.  
Clinical Contour 
Automatic Contour 
Expanded Contour 
Shifted Contour 
Brain 
 
Left Eye 
Right Eye 
Mandible 
Right Parotid 
Spinal Cord 
Left Parotid 
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Table 10. Number of type of simulated failure modes used for building of the random forest models. In the prediction of simulated errors, 
four sizes of shifted contours and three sizes of expanded contours were used for each structures. The sizes of the shifts and 
expansions varied by structure in accordance with the structure size, classified into three groups. Contours for smaller structures (eyes, 
cochleae) were shifted and expanded less than those for medium-sized structures (brainstem, mandible, parotid gland), which were 
shifted and expanded less than those for large structures (brain, lung, spinal cord).  
Structure 
Shifted,  
size 1 
Shifted,  
size 2 
Shifted,  
size 3 
Shifted,  
size 4 
Expanded,  
size 1 
Expanded,  
size 2 
Expanded,  
size 3 
Size, cm No. Size, cm No. Size, cm No. Size, cm No. Size, cm No. Size, cm No. Size, cm No. 
Brain 1 8 2 8 3 8 5 8 3 10 5 10 8 10 
Brainstem 0.5 8 1 8 2 8 3 8 2 10 3 10 5 10 
Cochleae 0.2 8 0.3 8 0.5 8 1 8 1 10 2 10 3 10 
Eyes 0.2 8 0.3 8 0.5 8 1 8 1 10 2 10 3 10 
Lungs 1 8 2 8 3 8 5 8 3 10 5 10 8 10 
Mandible 0.5 8 1 8 2 8 3 8 2 10 3 10 5 10 
Parotid glands 0.5 8 1 8 2 8 3 8 2 10 3 10 5 10 
Spinal cord 1 8 2 8 3 8 5 8 3 10 5 10 8 10 
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Prediction of clinical edits 
For the prediction of true errors, a group of RF models (two for each of the eight 
OARs) were trained and tested on autocontours that were reviewed, and, if necessary, edited 
for clinical use. RF models were trained to differentiate contours that had been edited 
clinically from those that had not been edited. Two thresholds were chosen to determine 
whether the contour was edited: first, a Hausdorff distance (see Equation 3) between the 
edited contour and the contour in the patient’s final treatment plan greater than 0 (i.e., any 
clinical edit) and second, a Hausdorff distance between the edited contour and the contour in 
the patient’s treatment plan greater than 5 mm, classified as a “significant” clinical edit.  
To obtain the initial RF model, we used data collected from the first 104 patients 
during clinical implementation. Following the initial modeling, and as the automatic contouring 
software was used clinically, the results were collected and a prediction was obtained for 
each structure. After the prediction for 10 structures from at least five patients (because 
bilateral structures, if all are left in the treatment plan, accrue 10 structures from five patients), 
predictive metrics were calculated and the RF models were retrained to include the new 
clinical results. This iterative machine learning mechanism was implemented to determine 
whether model performance improved over time as the models learned from new failure 
modes; the process of model building and rebuilding is illustrated in Figure 18. The final 
analysis contained RF models tested on 120 independent patients. The number of 
autocontours used for training and testing varied by structure because predictions were 
generated only for structures that remained in the patients’ treatment plans upon treatment. 
Predictor importance was assessed by summing the change in the mean square error due to 
splits on that predictor divided by the number of branch nodes after the split. 
The results of this third experiment are found on page 112. 
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 Figure 18. Workflow of the machine learning framework for the prediction of clinical edits to 
automatic contours (i.e., true errors). After the initial model building (104 patients), the model 
was used to predict clinical edits, and after prediction on 10 successive structures, the new 
data were added and the models were updated. Data from 120 patients were used for this 
prospective model testing and model updating. 
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Dosimetric Impact of Normal Tissue Autocontours for Treatment Planning 
 In an ideal scenario, the autocontouring of normal structures would produce contours 
which do not need edit for treatment planning, as they would be anatomically correct. While 
we do not expect that we have achieved this ideal, we sought to investigate the possibility of 
using unedited autocontours from the MACS autocontouring algorithm for treatment planning 
and to assess the effect this may have on the treatment plan. Other investigations have 
shown that for salivary glands the use of autocontoured or even simplified geometric 
structures may be sufficient for treatment planning purposes(116) suggesting that the same 
may be true for other normal structures. 
Patient Cohort 
For this analysis, two cohorts of patients were considered. Patients were selected as 
to represent seven head-and-neck subsites; larynx, nasopharynx, oral cavity, oropharynx, 
paranasal sinuses and cavity, and salivary glands. Selection criteria included a maximum of 
three physician-drawn planning target volume dose levels and availability of the physician 
approved contours.  
In the first cohort, 54 patients treated at The University of Texas MD Anderson Cancer 
Center had clinical normal structures which were derived from autocontours and either edited 
to satisfaction or used with approval by the attending physician. The autocontouring of eight 
normal structures (brain, brainstem, cochlea, eyes, lung, mandible, parotid glands, and spinal 
cord) was implemented clinically and thus were considered in this analysis. 
In the second cohort, normal tissue contours were drawn independently by the 
attending physician who was blind to the autocontour. In this group, structures not included in 
the clinical autocontouring atlas for 54 patients treated at The University of Texas MD 
Anderson Cancer Center and for all structures from 30 patients from other institutions treated 
on a clinical trial were collected. The clinical trial data were retrospectively collected through 
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The Cancer Imaging Archive (75) and was originally derived from the Radiation Therapy 
Oncology Group 0522 study (76). 
Using a two sided t-test the distribution of differences of clinical structures compared 
to autocontours was compared to the larger group of clinically edited patients, as presented in 
the second aim (Page 43) to determine how they compare to a population of patients with 
clinically edited contours. 
Dosimetric Evaluation 
Using the planning strategy presented in Chapter 4 - A Single Optimization Treatment 
Planning Strategy in the Head-and-Neck – two treatment plans were created for each patient. 
The first treatment plan was developed using the clinical normal structures and the second 
plan was created using unedited autocontours of normal structures (including the brain, 
brainstem, cochleae, eyes, lens, lungs, mandible, optic chiasm, optic nerves, parotid glands, 
submandibular glands, spinal cord). For all patients, physician drawn PTVs were used for 
treatment planning. Additional autocontoured planning structures were created as needed per 
the treatment planning strategy. Treatment plans were normalized as in Chapter 4. A 
schematic describing this investigation can be seen in Figure 19. 
For both plans, dosimetric analysis at clinically relevant DVH points was performed 
using the clinical normal structures, regardless of which structure (clinical structure or 
unedited autocontour) was used for treatment planning. Comparisons were made only for 
structures included in the clinical treatment plan. A Wilcoxon signed rank test was used to 
compare the dosimetric impact at clinically relevant dosimetric endpoints.
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Figure 19. Experiment to identify the dosimetric impact of using autocontoured normal tissues for treatment planning. Using both the 
unedited autocontours (top) and clinical structures (bottom) the planning strategy described in Chapter 4 was used to create high quality 
head-and-neck treatment plans. Evaluation of the plans was carried out on the “true” physician edited/approved structures, any 
differences in the DVH curves identifiy the impact the chioce of planning structure may have on th treatment plan.
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Correlation Dosimetric Impact of Normal Tissue Autocontouring to Quantitative Predictors 
Given the expected distribution of clinical edits and the knowledge of their impact on 
treatment plan quality we wished to investigate the possibility of predicting, prior to plan 
optimization and dose calculation, the potential impact of edits to normal tissue autocontours 
for four key normal structures in the head-and-neck; the spinal cord, the brainstem, and the 
contralateral and ipsilateral parotid glands. It may be expected that the relative importance of 
edits to normal tissue contours is related to patient specific features. For example, if the 
brainstem is close to the target volume, than edits to this autocontour may be more impactful 
than if the brainstem was at a distance from the targets. The correlation of the patient and 
structure features to the dosimetric impact of planning on these structures could provide the 
user a pre-assessment of potential autocontour quality. 
To investigate this, three dosimetric metrics including; the absolute dose to the clinical 
structure, the absolute difference in dose to the clinical structure when planned on either 
unedited autocontour or the clinical structure, and the relative dose difference when planned 
on the two structures, were evaluated for correlation with several features of the structures.  
Predictive metrics included the clinical edits to the structure, the prescription dose 
levels of the (up to three) PTVs, the minimum distance between the autocontour and the 
PTVs, the maximum distance of the closest 10% of points of the autocontour and the PTVs, 
and the Dice Similarity coefficient between the autocontours and the PTVs analyzed in 3 
ways (1) the autocontour and the original physician drawn PTVs (2) the autocontours and the 
PTVs with a uniform expansion of 0.5cm and 1cm and (3) the convex hulls of the 
autocontours and the PTVs. Examples of these structures and metrics can be found in Figure 
20. The convex hull of the normal tissues are the smallest convex shape which encompasses 
the contour. They, for example, may provide insight when a target is within the concave 
region of a parotid contour. 
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The results of this fourth experiment are found on page 119. 
Figure 20. Patient specific metrics for correlation with the effect ofthe use of autocontoured 
targets for treatment planning. For four normal structures (brainstem, parotid glands, and 
spinal cord), in blue, metrics which quantify the spatial relationship to each of the patients’ 
target volumes were calculated and included the minimum distance and minimum 10% of 
distances to each PTV (in colorwash, by dose level), the DSC and MSD with the PTV and 
with expanded PTVs (solid line, corresponding color), shown here for 1 cm uniform 
expansions, and the DSC and MSD of the normal tissue hulls (in maroon) with the PTVs. 
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Results 
Analysis of Autocontouring Algorithms 
Pilot Test of 4 Contouring Algorithms 
Considering the 10 initial test patients, the in-house MACS contouring algorithm was 
best performing when considering all 8 normal structures. For some structures, the Smart 
Segmentation® approach with and/or without fusion was not investigated owing to the 
success of the other autocontouring techniques (see Table 11). For lung contours the Smart 
Detection® algorithm performed the best with an average rating of 4.6 and a minimum of 3, 
indicating minor edits. The lung was the worst performing structure for the in-house algorithm, 
with an average rating of 3.5 and a minimum rating of 1. The main failure mode noted was in 
the inferior portion of the lung, where, due to the deformation fields, the combining of several 
contours in the STAPLE algorithm and the varying scan extent (and thus portion of the lung) 
in each of the atlas patients, the contours often have small slices inferiorly or occasionally 
islands. For many patients this part of the lung is distant from the treated volume, and given 
that the whole lung is seldom included in the simulation scan and therefore whole lung DVH 
metrics cannot be quantitated may not be included in the dose calculation region. For these 
ten patients, the most inferior portion of the PTV was at an average distance of 11.5 cm from 
the slices of inferior lung with noticeable errors, and for the patient with the closest PTV-to-
inferior-lung distance the dose grid was 3cm superior to the lung region with errors, see 
Figure 21. Given these things, we feel that errors on these bottom few slices are acceptable 
and may either be ignored or removed on post processing. For all other structures including; 
brainstem, cochleae, eyes, mandible, parotid glands, and the spinal cord, the MACS 
algorithm had an average rating better than all other algorithms. 
Quantitative comparison of the autocontours from each of these 4 autocontouring 
algorithm on the same ten patients in shown in Table 12. For all structures MACS had a 
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higher average Dice similarity coefficient and lower average Mean surface distance and 
Hausdorff distance indicating that these structure agree more closely with independently 
drawn physician structures. 
 
Figure 21. Example of autocontouring errors at the inferior structure extent. This patient, with 
the lowest physician score had large areas for which the autocontoured lung (cyan) failed to 
contour, as shown in the red circles. However, the physician drawn/approved structure 
(brown) also had large areas of incomplete contour. However, these missed areas are at the 
most inferior portion, or outside of, the dose grid (dashed green) and far from the contoured 
planning target volumes (red color wash).  
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A reoccurring failure mode of the smart detection algorithm, as cited by the rating 
physician, was structures that the structures were too large or were offset. This feedback 
prompted the decision to provide a third contouring approach in which these contours were 
fused using a majority voting algorithm. Unfortunately, many of the fused contours were also 
reported as being too large or offset, indicating that neither method was suitable for automatic 
contouring purposes. For example, the average volume across the ten patients of the 
physician drawn brainstem was 25.0 cc, the average volume of the MACS autocontoured 
brainstems was 23.85 cc, the average volume of the single and fused Smart Segmentation 
brainstem contours was 30.72 cc and 31.26 cc, respectively.   
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Table 11. Physician ratings of four autocontouring algorithms on ten patients. The mean, standard deviation, and minimum and 
maximum are shown for four autocontouring algorithms for ten patients. Contours were rated on a five point scale by a single physician. 
For brain, spinal cord and lungs, due to the success of other algorithms, Smart Segmentation® with and/or without fusion were not 
analyzed. The smart detection algorithm was not available for the structures with no reported statistics. 
 Physician Ratings of Autocontouring Algorithms 
 Smart Detection Smart Segmentation Smart Segmentation + Fusion 
Multi Atlas Contouring 
Service 
Structure N mean ± std [min-max] N mean ± std 
[min-
max] N mean ± std 
[min-
max] N mean ± std 
[min-
max] 
Brain 10 4.9 ± 0.3 [ 4 - 5 ]                                     10 5.0 ± 0.0 [ 5 - 5 ] 
Brainstem                   91 3.1 ± 0.6 [ 2 - 5 ] 10 3.1 ± 0.7 [ 2 - 4 ] 10 4.6 ± 0.5 [ 4 - 5 ] 
Cochleae                   95 3.0 ± 0.4 [ 2 - 4 ] 20 2.8 ± 0.5 [ 1 - 3 ] 20 5.0 ± 0.2 [ 4 - 5 ] 
Eyes 20 3.4 ± 0.9 [ 2 - 5 ] 185 3.3 ± 0.9 [ 2 - 5 ] 20 3.6 ± 0.6 [ 2 - 4 ] 20 3.6 ± 0.6 [ 3 - 5 ] 
Lungs 10 4.6 ± 0.7 [ 3 - 5 ] 93 3.0 ± 1.0 [ 1 - 5 ]                   10 3.5 ± 1.1 [ 1 - 5 ] 
Mandible 10 2.8 ± 1.5 [ 1 - 5 ] 101 2.8 ± 0.8 [ 2 - 5 ] 10 2.9 ± 0.7 [ 2 - 4 ] 10 4.7 ± 0.5 [ 4 - 5 ] 
Parotid Glands                   172 2.9 ± 0.8 [ 1 - 5 ] 20 3.2 ± 0.9 [ 2 - 4 ] 20 4.5 ± 1.1 [ 1 - 5 ] 
Spinal Cord* 10 4.2 ± 0.4 [ 4 - 5 ] 93 4.1 ± 0.4 [ 3 - 5 ]                   10 5.0 ± 0.0 [ 5 - 5 ] 
*Smart detection only allowed for the contouring of spinal canal 
 
103 | P a g e  
 
Table 12. Quantitative comparison of four autocontouring algorithms with independently 
drawn physician normal tissue contours. The Dice similarity coefficient, the mean surface 
distance, and the Hausdorff distance were used to compare the normal tissue autocontours 
for 8 structures generated on the same ten patients rated by the physician. The in-house 
multi-atlas contouring algorithms most closely matched the physician drawn structures with 
the highest average DSC and lowest average MSD and HD. 
 Dice Similarity Coefficient 
 Smart 
Detection 
Smart 
Segmentation 
Smart 
Segmentation + 
Fusion 
Multi Atlas 
Contouring Service 
Structure N mean ± std N mean ± std N mean ± std N mean ± std 
Brain 10 0.98 ± 0.00         10 0.98 ± 0.00 
Brainstem     91 0.74 ± 0.05 10 0.79 ± 0.04 10 0.88 ± 0.04 
Cochleae     95 0.38 ± 0.09 20 0.38 ± 0.07 20 0.65 ± 0.09 
Eyes 20 0.75 ± 0.05 185 0.74 ± 0.08 20 0.78 ± 0.06 20 0.87 ± 0.03 
Lungs 10 0.96 ± 0.01 93 0.92 ± 0.06     10 0.92 ± 0.02 
Mandible 10 0.67 ± 0.07 101 0.68 ± 0.08 10 0.71 ± 0.06 10 0.90 ± 0.03 
Parotid Glands     172 0.67 ± 0.10 20 0.72 ± 0.10 20 0.84 ± 0.05 
Spinal Cord* 10 0.57 ± 0.05 93 0.67 ± 0.07     10 0.81 ± 0.03 
 Hausdorff Distance (cm) 
 Smart 
Detection 
Smart  
Segmentation 
Smart 
Segmentation + 
Fusion 
Multi Atlas 
Contouring Service 
Structure N mean ± std N mean ± std N mean ± std N mean ± std 
Brain 10 1.13 ± 0.24         10 0.80 ± 0.29 
Brainstem     91 0.98 ± 0.27 10 0.83 ± 0.17 10 0.68 ± 0.24 
Cochleae     95 0.84 ± 0.21 20 0.69 ± 0.19 20 0.30 ± 0.07 
Eyes 20 0.58 ± 0.11 185 0.70 ± 0.27 20 0.57 ± 0.09 20 0.44 ± 0.12 
Lungs 10 2.35 ± 0.89 93 2.30 ± 0.88     10 1.90 ± 0.66 
Mandible 10 2.40 ± 1.06 101 1.71 ± 0.48 10 1.13 ± 0.27 10 0.63 ± 0.19 
Parotid Glands     172 2.00 ± 0.76 20 2.00 ± 0.85 20 1.25 ± 0.75 
Spinal Cord* 10 5.27 ± 1.98 93 2.90 ± 2.04     10 1.48 ± 1.18 
 Mean Surface Distance (cm) 
 Smart 
Detection 
Smart  
Segmentation 
Smart 
Segmentation + 
Fusion 
Multi Atlas 
Contouring Service 
Structure N mean ± std N mean ± std N mean ± std N mean ± std 
Brain 10 0.08 ± 0.02         10 0.07 ± 0.02 
Brainstem     91 0.28 ± 0.05 10 0.24 ± 0.05 10 0.14 ± 0.04 
Cochleae     95 0.25 ± 0.05 20 0.23 ± 0.04 20 0.09 ± 0.03 
Eyes 20 0.20 ± 0.04 185 0.23 ± 0.07 20 0.20 ± 0.05 20 0.11 ± 0.02 
Lungs 10 0.10 ± 0.02 93 0.21 ± 0.22     10 0.25 ± 0.14 
Mandible 10 0.39 ± 0.18 101 0.29 ± 0.09 10 0.24 ± 0.06 10 0.08 ± 0.02 
Parotid Glands     172 0.38 ± 0.14 20 0.34 ± 0.14 20 0.18 ± 0.06 
Spinal Cord* 10 0.53 ± 0.17 93 0.31 ± 0.13     10 0.14 ± 0.06 
*Smart detection only allowed for the contouring of spinal canal 
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Further testing of in-house multi-atlas contouring service (MACS) 
The MACS contouring algorithm was best performing on initial review and was 
therefore selected for comprehensive analysis. Central to the MACS algorithms is the atlas of 
patients from which contours are propagated. Of the 12 patients in the contouring atlas, nine 
were male and 11 had primary oropharynx disease, one patient had unknown primary. The 
mean age was 72 years. Ten were AJCC 7th edition clinical stage IVa, one IVb and one stage 
III; all were treated with curative intent.  
For all 128 patients the distribution of physician ratings of the 8 normal structures on 
the same 5-point scale can be seen in Figure 22. One patient had a surgically removed 
parotid and for five patients the lungs were not visible in the patient CT, thus no rating was 
recorded for these structures. Of the eight normal structures, six were, on average, indicated 
as clinically acceptable for use without edits in DVH-based planning, scoring either a four or a 
five. The remaining two structures had ratings indicating the need for minor edits for use in 
DVH-based planning, depending on their spatial relation to the target volume. For all normal 
structures, 87% received ratings which indicate no need for edit for use in treatment planning 
(a score of 4 or five). Furthermore, 97% of normal structures received a rating which indicates 
that, at most, only minor editing is needed for use in DVH based planning. 
 
  
105 | P a g e  
 
 Figure 22. Distribution of the primary physician ratings of the in-house MACS algorithm. 
Contours of eight normal structures generated from the MACS algorthms were reviewed by a 
physician on a five point scale for 128 patients. The mean (± standard deviation) physician 
ratings are displayed in the graphs and the % receiving each rating overlaid on the bars 
 
Inter-observer variability 
To assess inter-observer variability, a subset of 10 randomly selected patients was 
reviewed by five additional radiation oncologists from four outside institutions. The radiation 
oncologists, per a self-reported questionnaire, had an average of 8.25 years of experience 
(range, 3.0-12.5 years) and contour and/or review an average of seven patients per week 
(range, 2-15 patients), spending an average of 95 minutes per patient on contouring (range, 
45-180 minutes). For all structures except parotid glands, the scores assigned to the 10 
patients differed significantly (Wilcoxon signed rank test, p<0.05) between the primary 
physician and at least one outside physician. However, no structure was significantly different 
between primary and all of the outside physicians. 
For all structures, 45% (245/547) of the ratings by the outside physicians matched 
those of the primary physician and were classified as Category I agreements. Considering 
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Category II agreements, the physicians assigned an additional 48% (262/547) of the contours 
to same group, either as needing no or minor edit for use (48%) or as needing major edit for 
use (0%). Finally, only 7% of contours received scores indicating the need for major edits by 
one physician while needing no or minor edits by the other physician. In Table 13 the 
percentage of contours classified into each of the three agreement categories can be found 
for the eight normal structures assessed. 
 
Table 13.  Percentage of normal tissue rating pairs in three agreement categories. Category I 
indicates the scores by the two physician matched, Category II indicates that the ratings did 
not match but the contours were rated into the same “group” (either as needing no or minor 
edit or as needing major edit) by both physicians. Category III represents disagreement 
between two revewing physicians. Due to rounding, not all rows sum to 100. 
 % of agreements in 
Category 
Structure I II III 
Brain 22 76 2 
Brainstem 48 32 20 
Cochleae 46 49 5 
Eyes 47 42 11 
Lungs 60 36 4 
Mandible 40 58 2 
Parotid gland 57 38 5 
Spinal Cord 22 68 10 
Total 45 48 7 
 
 
Clinical Use of Normal Tissue Autocontours 
Due to its success on retrospective evaluation, the MACS autocontouring algorithm 
was implemented into the head-and-neck clinic at MD Anderson. During 10 months of clinical 
implementation, 22 radiation oncologists used the automated contouring software to generate 
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normal structure contours for 166 patients treated at our institution. Inclusion criteria included 
availability of the approved treatment plan and record of the requesting of the autocontours 
through the script in the treatment planning system. The 7 attending physicians who used the 
tool the most accounted for 23, 15, 14, 9, 7, 7 and 5% of the total use. The mean (± standard 
deviation) time required for generation of the autocontours was 11.5 ± 3.1 minutes when run 
on a Windows 2012-based PC with an 8-core Xeon E5-2697 v3 2.6-GHz CPU and 16 GB of 
memory. Multithread computing was enabled in the deformable registration algorithm, and 2 
registration tasks were allowed to be run simultaneously on the server.  This time does not 
require oversight by a physician or dosimetrist and can therefore occur simultaneous to other 
required treatment planning tasks. The distribution of autocontour edits, as measured by the 
Dice similarity coefficient, mean surface distance, and Hausdorff distance is shown in Figure 
23. We measured edits only for structures which remained in the treatment plan at the time of 
treatment with the same naming convention as the automatically contoured structures. 
Notably, radiation oncologists did not edit 49.8% of the contours for treatment 
planning. As shown in Figure 2, 31%, 40%, and 48% of automatically contoured brainstems, 
parotid glands, and modified spinal cords were not edited for clinical use. The structures 
edited least often were the eyes (69% were not edited) and modified lungs (74% were not 
edited). The Dice similarity coefficient was lowest for the cochlea (0.79±0.26). The maximum 
mean surface distance edits were seen for the unmodified lung avoidance structure (3.29 
mm) and unmodified spinal cord (2.65 mm), due primarily to inferior CT scan extent 
discrepancy. However, considering edit to the modified lung avoidance and spinal cord 
structures, the maximum mean surface distances were decreased for lungs and spinal cord to 
0.33mm and 0.20mm, respectively. This reduction is shown in Figure 23 as a reduction in 
both the medians and interquartile ranges of edits to the modified lungs and spinal cord 
structures relative to those edits of the unmodified versions.  
108 | P a g e  
 
A non-paired, one-sided t test showed that for all structures, contours that were edited 
for clinical use were significantly closer to the target volume than contours that remained 
unedited in the treatment plan (p < 0.003).  
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 Figure 23. Distribution of the clinical edits to autocontours. The red line within the box plot 
represents the median and box edges represent the 25th and 75th percentile. Outliers are 
indicated by red crosses and are values outside the 25th or 75th percentile by more than 1.5 
times the interquartile range. Between the boxplots are the percent of unedited contours and 
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the means (± standard deviations) of the Dice similarity coefficients and the mean surface 
distances for each for the automatically contoured or modified structures. Abbreviations: DSC 
= Dice Similarity Coefficient, MSD = Mean Surface Distance, HD = Hausdorff distance. 
 
Given these clinical edits, we sought to identify the minimum uniform expansion to the 
autocontours needed to encompass either 95% or 100% of the clinically edited contour for 
90% or 95% of the patients. Table 14 lists the minimum uniform expansions needed for each 
of the eight normal structures examined in our study, including the inferiorly modified lung and 
spinal cord contours. If autocontours are used without edit, our findings show that a uniform 
expansion between 0 and 5 mm would provide coverage of 95% of the physician edited 
structure for 90% of the population. To cover 100% of the physician edited structure for 95% 
of the population the minimum uniform expansion needed ranges from 4mm (cochlea) to 
more than 15 mm (lungs, mandible, parotid). 
Table 14.  Minimum uniform expansion to autocontoured normal tissues needed to cover a 
given fraction of the structure for a given fraction of the population. 
 Patient population 
 90% 95% 
 Contour coverage 
Structure 95% 100% 95% 100% 
Brain 0.00 7.53 0.00 10.64 
Brainstem 3.55 7.22 4.51 8.88 
Cochlea 2.28 3.02 3.42 4.00 
Eye 1.64 3.34 2.06 5.28 
Lung (modified) 0.64 >15 4.20 >15 
Mandible 1.74 12.80 3.59 >15 
Parotid gland 4.67 >15 9.05 >15 
Spinal cord (modified) 0.98 3.74 1.63 4.81 
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Machine Learning Model for Prediction of Autocontour Errors 
As necessary for the implementation of autocontouring as part of a fully automated 
treatment planning approach a method to detect autocontouring errors was investigated. 
Detection of gross and simulated errors represents a check of safety and catching of 
significant autocontouring errors. The detection of smaller clinical edits represents the 
possibility to flag to the user of an automated treatment planning approach that autocontours 
presented may require editing. 
Simulated failure models 
The performance of the RF models to predict simulated and gross errors is 
summarized in Table 15. The overall sensitivity and specificity of the models to gross and 
simulated error prediction were greater than 0.85 for all structures. When considering 
simulated errors due to small shifts and expansions, we found that the sensitivity was greater 
than 0.9, and this improved with the size of the shifts and expansions.  
When considering patients in non-standard positions, we observed that the model 
sensitivity was slightly lower for some structures; a minimum sensitivity of 0.5 was seen for 
the cochlea, lungs, and mandible, although the size of the test set was small (2-14 patients). 
For one patient, a large primary gross tumor volume (637 cm3) resulted in substantial 
automatic contouring errors for the surrounding contours, and for contours with a Dice 
similarity coefficient of less than 0.8 compared with the clinically edited structure (right eye 
and mandible), the contouring errors were successfully detected by their respective RF 
models. When considering the test patients in nonstandard positions plus the patients with 
other scan sites, we observed that at least half of the structures were predicted to have some 
contour errors in all patients. This suggests that if automatic contouring is predicted to fail in 
more than half of the structures, the patient is not a good candidate for this in-house 
autocontouring technique.  
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Table 15. Random forest model performance for the prediction of simulated and gross errors. Sizes of shifts and expansions can be 
found in Table 10. 
Structure 
Overall model 
performance* 
Shifted, size 
1 
Shifted, 
size 2 
Shifted, 
size 3 
Shifted, 
size 4 
Expanded, 
size 1 
Expanded, 
size 2 
Expanded, 
size 3 
Nonstandar
d positions 
Other scan 
locations 
Sens Spec N, test set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
N, test 
set Sens 
Brain 0.88 0.95 50 1.00 50 1.00 50 1.00 50 1.00 50 0.94 50 1.00 50 1.00 7 0.71 13 0.46 
Brainstem 0.90 1.00 50 0.96 50 0.98 50 1.00 50 1.00 50 0.74 50 1.00 50 1.00 5 0.80 13 0.77 
Cochleae 0.87 1.00 50 1.00 50 1.00 50 1.00 50 1.00 50 0.84 50 1.00 50 1.00 14 0.50 26 0.38 
Eyes 0.89 0.94 50 0.98 50 1.00 50 1.00 50 1.00 50 0.84 50 0.98 50 1.00 16 0.94 26 0.77 
Lungs 0.88 1.00 50 0.98 50 0.98 50 1.00 50 0.96 50 1.00 50 0.98 50 1.00 2 0.50 13 0.54 
Mandible 0.90 1.00 50 1.00 50 1.00 50 1.00 50 1.00 50 1.00 50 1.00 50 1.00 8 0.50 13 0.77 
Parotid 
glands 0.85 0.98 50 0.92 50 0.96 50 1.00 50 0.98 50 0.96 50 1.00 50 1.00 15 0.60 26 0.69 
Spinal 
cord 0.91 1.00 50 0.96 50 0.98 50 0.96 50 0.98 50 1.00 50 1.00 50 1.00 3 0.67 13 0.77 
*Sens, sensitivity; spec, specificity. 
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For all structures a metric derived from the HU distribution or an agreement metric 
with the independent deformable image registration contouring technique was the most 
important predictor. Other important predictor classes were derived from the autocontour 
distance to bony structures and the quantitative comparison to an independently and 
heuristically derived autocontour. 
Prediction of clinical edits 
Table 16 shows results of the overall performance of the RF models for the prediction 
of clinical edits to automatic contours (i.e., true errors), in which the thresholds of Hausdorff 
distances greater than zero (any clinical edit) or greater than 5 mm (significant clinical edit) 
were considered for contour errors. On average, 40% of contours (including modified 
structures) were edited for clinical use and 26% were edited such that the Hausdorff distance 
was greater than 5 mm. Models were not trained to predict significant (≥5-mm Hausdorff 
distance) edits to the brain, lung, or spinal cord contours owing to the very small proportion of 
contours edited and available for model building and testing purposes. 
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Table 16. Random forest model performance for the prediction of clinical edits to 
autocontours. Two random forest models were trained for each structure, in which automatic 
contour error was defined as a Hausdorff distance (compared with the edited automatic 
contour) of greater than 0 (i.e., any clinical edit) or greater than 5 mm (i.e., significant clinical 
edit). 
Structure No. 
Any clinical edit Significant clinical edit 
No. 
edited Accuracy Sensitivity Specificity 
No. 
edited Accuracy Sensitivity Specificity 
Brain 113 63 0.56 0.71 0.36     
Brainstem 109 60 0.55 0.92 0.10 39 0.56 0.54 0.57 
Cochleae 220 79 0.57 0.39 0.67 31 0.57 0.48 0.58 
Eyes 205 58 0.68 0.07 0.92 16 0.73 0.75 0.72 
Lungs 71 14 0.79 0.00 0.98     
Mandible 113 36 0.62 0.36 0.74 29 0.57 0.59 0.56 
Parotid gland 214 102 0.61 0.80 0.44 96 0.63 0.63 0.63 
Spinal cord 108 38 0.53 0.68 0.44     
 
The model performance over time, both for any clinical edit and for large clinical edit 
can be seen in Figure 24 and Figure 25, respectively. Little model improvement was seen 
over time and performance plateaued for most structures after 10 rounds of testing. 
Generally, the RF models to predict any autocontour edits did not perform as well as 
expected, with an average accuracy of 0.61. The RF model for the prediction of edits to the 
lung contours did not correctly identify any edited contours, though only 14 of 71 were edited 
and had Dice values with an average and standard deviation of 0.96±0.04. 
The RF models to predict significant clinical edits performed, on average, better than 
those to predict any clinical edit; the best performing model for the prediction of significant 
clinical edits was for the eyes. Model performance improved when only contours that had 
significant clinical edits were considered. The RF models for the prediction of significant 
clinical edits were 100% sensitive to edits with Hausdorff distance greater 12 mm to the 
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brainstem, 7 mm to the cochlea, 6 mm to the eyes, and 22 mm to the mandible contours and 
were 76% sensitive to edits with Hausdorff distance greater than 2.2 cm to parotid contours. 
This indicates that the size of edit to which the models are sensitive may be larger than for 
edit size for which it was built. 
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Figure 24. Performance of QA models to detect any clinical edit. Models with high sensitivity 
(red) (e.g. brainstem, parotid) generally had low specificity (yellow). The accuracy (blue) of 
the detection of clinical edits to normal tissue structures was generally low, less than 0.6 for 4 
of 8 structures. (Previous page) 
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Figure 25. Performance of QA models to detect large clinical edits. Models were rebuilt after 
ten patients. Model accuracy (blue) was above 0.55 for all structure, with the model to detect 
errors in the eyes having the highest accuracy at 0.73. Model performance plateaued over 
time.(Previous page) 
 
Among the most important predictors were a quantitative comparison to the 
independent deformable image registration contouring technique and metrics from the HU 
distribution. After the initial RF was built, the models were updated after every 10 structures. 
The accuracy, sensitivity, and specificity of the models were tracked over time, although an 
improvement in model performance was not observed.  
Insight into model performance may be had by understanding the reasons for which 
contours were edited. A non-paired, one-sided t test showed that for all structures, contours 
that were edited for clinical use were significantly closer to the target volume than contours 
that remained unedited in the treatment plan (p < 0.003). For the RF models least sensitive to 
contour editing (lungs, eyes, and mandible), the edited contours were on average 1.9 cm 
(lungs), 1.9 cm (eyes), and 0.4 cm (mandible) closer to the target volume than contours that 
were not edited for clinical use. This result may indicate that reasons other than anatomical 
accuracy (e.g. potential dosimetric effect) are used for contour edit decision making.  
Dosimetric Impact of Normal Tissue Autocontours for Treatment Planning 
Patients Cohort 
For the eight structures implemented for autocontouring into our clinical practice, the 
distribution of clinical edits seen clinically were compared using a two sided t-test to both the 
group of 54 patients selected from this larger cohort and to the group of 29 patients treated on 
a clinical trial. The results are shown in Table 17. For all structures, except eye, we found no 
significant difference in the mean of the distribution of dice similarity coefficients or Hausdorff 
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distances between the cohort of 54 patients and all patients with clinically edited normal 
structures. For eye, the mean Dice similarity coefficient for 289 clinical edited eye structures 
was 0.96±0.11, for this cohort the edits were slightly less with a mean and standard deviation 
of DSC of 0.98±0.04. 
Considering the 29 patients treated on a clinical trial and when normal tissues were 
drawn independently there was a significant difference in the distribution of clinical and 
autocontour agreement. The difference between autocontours and physician structures was 
larger for this group of patients than for those with clinical edited autocontours indicating that 
the use of these for planning would represent a worst case scenario, as clinical edits would be 
expected to be smaller. 
 
Table 17.  Comparison of contour disagreement in the dosimetric cohorts with clinical edits to 
autocontours. A two sided t-test was used to test the hypothesis that the distribution of edits 
sizes for both the cohort of 54 patients with clinical edited autocontours and the cohort of 
patient with independently contours normal structures had the same mean as all patients with 
clinically edited normal structures, as described in the previous section. 
 p-value, two sided t test 
 Independently Drawn Contours 
(n=29) 
Edited contours  
(n=54) 
Structure Dice Hausdorff  Distance Dice 
Hausdorff  
Distance 
Brain 0.60 <0.01 0.28 0.38 
Brainstem <0.01 <0.01 0.43 0.16 
Cochleae <0.01 <0.01 0.48 0.68 
Eye 0.01 0.06 0.03 0.01 
Lungs No Structures 0.94 0.99 
Mandible <0.01 <0.01 0.56 0.23 
Parotid Glands <0.01 <0.01 0.87 0.83 
Spinal Cord <0.01 <0.01 0.33 0.89 
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Dosimetric Impact 
A paired Wilcoxon signed rank test was used to compare the treatment plans using 
the physician drawn/edited structures with those created on unedited normal tissue 
autocontours. The comparison was done independently for the two patient groups (1) clinical 
structures derived from autocontours and (2) structures drawn independently from the 
autocontours.  
Considering the group of patients from which physician structures were derived from 
autocontours, DVH metrics which showed a significantly worsening effect on the DVH metric 
included the mean doses to both the ipsilateral and contralateral parotid glands and the 
volume of the ipsilateral parotid gland receiving more than 30Gy (p=0.01). The p-values of the 
Wilcoxon signed rank test for all structures can be found in Table 18.  These results suggest 
that for most structures using unedited autocontours generated using the method described in 
Chapter 4, results in no significant dosimetric effect on the treatment plan. The exception to 
this is for the parotid glands which are often in very close proximity to targets in the head-and-
neck. 
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Table 18. Comparison of DVH metrics to true structures when planned on unedited structures 
and clinically edited structures for 54 patients with clinical edited normal structure 
autocontours. Shown are p-values of the paired Wilcoxon signed rank test. In green are 
parameters for which having planned on unedited autocontoured normal structures showed 
an improvement in the DVH metric compared to having planned on the true physician 
edited/approved structure. In red are metric for which planning on the unedited structures 
caused a significantly poorer performance at the clinical DVH point. All plans were evaluated 
on physician edited/approved structures.  
Clinically Edited /Approved Structures 
Structure N Test Point 
p-value, paired 
Wilcoxon rank 
sum 
Spinal Cord 54 
D_max 0.08 
V_45Gy 1.00 
Brainstem 53 
D_max 0.68 
V_54Gy 1.00 
Ipsilateral Parotid 53 
D_mean 0.01 
V_30Gy 0.01 
Contralateral Parotid 50 
D_mean 0.06 
V_30Gy 0.01 
Cochleae 106 
D_max 0.49 
V_35Gy 0.68 
Eyes 88 
D_max 1.00 
V_50Gy 0.13 
Brain 50 
D_max 0.16 
V_54Gy 0.95 
High Dose PTV 54 
D_1cc 0.18 
V_95% 0.68 
Intermediate Dose PTV 45 V_95% 0.98 
Low Dose PTV 42 V_95% 0.09 
Detriment to DVH Metric Improvement in DVH Metric 
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Considering the group of patients treated on a clinical trial, and for which normal tissue 
contours were contoured independently, there was also limited dosimetric impact due to the 
use of unedited autocontours compared to physician drawn contours, Table 19. A significantly 
worsening effect due to the use of the unedited autocontoured normal structures was seen for 
the maximum dose to the brainstem (p<0.01) and both the maximum dose (p<0.01) and the 
volume receiving more than the maximally allowed dose of 45 Gy (p<0.01) for the spinal cord. 
However, for some patients, there is a clear discrepancy in the naming of structure and its 
contoured anatomy, this is especially easy to detect for the spinal cord contour. Common 
were two errors, either the physician drawn spinal cord either more closely represents a 
spinal canal contour, or is clearly not  a contour of the spinal cord (i.e. includes part of the 
spinal column or brainstem. Examples of these errors can be seen in Figure 26. This analysis 
underlines the importance of assumptions which are made about the development of 
treatment plans and their retrospective analysis.  
  
123 | P a g e  
 
Table 19. Comparison of DVH metrics to true structures when planned on unedited structures 
and independently drawn physician contours. Shown are p-values of the paired Wilcoxon 
signed rank test. In red are metric for which planning on the unedited structures caused a 
significantly poorer performance at the clinical DVH point. All plans were evaluated on 
physician drawn structures. 
Independently Physician Drawn Structures 
Structure N Test Point 
p-value, paired 
Wilcoxon rank 
sum 
Spinal Cord 29 
D_max <0.01 
V_45Gy <0.01 
Brainstem 27 
D_max <0.01 
V_54Gy 1.00 
Ipsilateral Parotid 29 
D_mean 0.55 
V_30Gy 0.77 
Contralateral Parotid 26 
D_mean 0.12 
V_30Gy 0.08 
Ipsilateral Submandibular Gland 16 D_mean 0.21 
Contralateral Submandibular Gland 21 D_mean 0.57 
Cochleae 8 
D_max 0.84 
V_35Gy 1.00 
Optic Chiasm 21 
D_max 0.14 
V_54Gy 1.00 
Optic Nerves 46 
D_max 0.44 
V_54Gy 0.50 
Lens 56 
D_max 0.34 
V_7Gy 0.46 
Eyes 6 
D_max 0.44 
V_50Gy 1.00 
Brain 1 
D_max 1.00 
V_54Gy 1.00 
High Dose PTV 29 
D_1cc 0.38 
V_95% 0.87 
Intermediate Dose PTV 29 V_95% 0.17 
Low Dose PTV 14 V_95% 0.95 
Detriment to DVH Metric  Improvement in DVH Metric 
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 Figure 26. Ten patients with clinical spinal cords exceeding clinical constraints when planned 
using autocontours. For these ten patients, the maximum dose to the clinical spinal cord (red) 
exceeded 45Gy (cyan) when the autocontoured spinal cord (blue) was used for treatment 
planning; the maximum dose when the physician drawn spinal cord was used was less than 
45Gy. In panels A-C, the clinical contour exceeds more superiorly than the autocontoured 
spinal cord. In panels D-J, the clinical spinal cord more resembles a spinal canal. In panel F, 
the clinical spinal cord contour extends very far superior to include the brainstem, which was 
not included as a separate structure for this patient. 
Clinical Structures 
Autocontoured Structures 
45 Gy Isodose Line 
A 
H G 
F E D 
C B 
J 
I 
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In Figure 27, the dosimetric impact of the choice of planning structure can be seen. 
For 898 physician drawn normal structures, 474 showed a decrease in plan quality and 424 
showed a dosimetric improvement due to planning on unedited autocontours. For spinal cord, 
13 of 83 plans (12 of which were drawn independently from autocontours) had a spinal cord 
which exceeded clinical dose constraints when planning was done on autocontoured spinal 
cords. Though, as discussed, and shown in Figure 26, all of these structures have physician 
edited/approved/drawn spinal cords which are not reflective of their naming. Considering all 
other normal structures, in only five cases (three parotid gland, one optic nerve, and one eye) 
did planning on an unedited autocontour result in an exceedance of the corresponding clinical 
threshold. The relative percentage difference of these five structures can be found in Table 20 
and were all less than 15%, indicating that while the structure did exceed clinical thresholds, 
the relative difference as small.  
The results above should be considered with the understanding that comparisons 
were made only on structures which were included in the original treatment plan. It is likely 
that structures not included in the clinical treatment plan were not of significant dosimetric 
interest because, for example, the structure may be far from the target. In these cases using 
an unedited automatic structure in lieu of a clinically approved structure is likely to have very 
limited dosimetric impact and therefore results herein represent the expected dosimetric 
impact for a subset of patients for which accurate contouring is expected to be of 
consequence in the treatment plan and therefore these results may overestimate the impact 
on the population as a whole. 
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Table 20. Dosimetric Impact of structure which exceed clinical structure when autocontours 
are used for treatment planning. Of 815 structure s 5 exceeding corresponding clinical 
constraints when autocontours, instead of clinical structures, were used for treatment 
planning. 
Structure Dosimetric metric 
Clinical 
Threshol
d 
Dosimetric Value when planned on Relative 
Difference 
(%) 
Clinical 
Structures 
Automatic 
Structures 
Parotid 
Gland 
Mean 
Dose 26 Gy 
25.9 Gy 27.5 Gy 6.3 
24.7 Gy 26.0 Gy 5.5 
Parotid 
Gland V_30Gy 50% 47.0% 53.6% 14 
Eyes Max Dose 50 Gy 48.2 Gy 51.4 Gy 6.6 
Optic 
Nerve Max Dose 54 Gy 52.1 Gy 54.4 Gy 4.4 
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 Figure 27. Distribution of relevant dosimetric points when planned on clinical structures and 
autocontoured structures. Along the x-axis, the DVH metric to true physician approved 
structures when planning on autocontoured structures and along the y-axis for the same 
patients the DVH metric when planned on the true clinical structure. Shades of green indicate 
      Edited 
      Independently Drawn 
47 
19 
37 
44 
39 
33 
1 
13 
44 
25 
39 
35 
3 
1 
2 
49 
28 
128 | P a g e  
 
improvement in the dosimetric descriptor when planned on the autocontours, shades of red 
indicate poorer performance due to use of the autocontours for planning. Darker shades 
delineate common clinical thresholds for each dosimetric descriptor, with darker green 
indicating an improvement beyond the clinical threshold and darker red indicating a poorer 
performance beyond the clinical threshold. In cyan squares, for 54 patients, clinical structure 
originated from autocontours with physician approval/editing for clinical use. In magenta 
circles, other normal structures were independently drawn for clinical use (continued on 
following pages). 
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 Figure 27. (Continued from previous pages) 
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 Figure 27. (Continued from previous pages) 
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Correlation to Patient Features 
Considering four structures of particular importance to the treatment of head-and-neck cancer 
(spinal cord, brainstem, and contralateral and ipsilateral parotid glands), there were few 
examples when the use of unedited autocontoured structures impacted plan quality or dose 
delivered to true clinical structure as measured by clinically used dose metrics. However, 
variations in impact including positive and negative impact as well as a limited number of 
cases for which clinical constraints were exceeded in autocontours were used for planning 
indicate a possibility of detecting these patients for the warning to the user of a fully 
automated system or for further investigation. Three dosimetric metrics; the absolute dose to 
the clinical structure, the absolute difference in dose to the clinical structure when planned on 
either unedited autocontour or the clinical structure, and the relative dose difference when 
planned on the two structures, were evaluated for correlation with several features of the 
plans, as shown in Table 21. 
For the spinal cord, brainstem, and contralateral parotid the absolute dose to the 
clinical structure when planned on the unedited autocontour was significantly correlated to the 
size of clinical edit, quantified as the Dice similarity agreement, Hausdorff distance, and mean 
surface distance. This indicates that the degree of clinical edit is correlated to its relative dose 
region. Unfortunately this data, the size of clinical edit, would not be available for incoming 
patients for which the need for clinical edits partly motivates the model prediction itself. The 
dosimetric impact for these three structures was also positively correlated to the prescription 
dose level of all three PTVs, and both the minimum distance and the distance of the 10% 
closest points to one or more PTVs. These correlations indicate that the higher a prescribed 
dose and the closer a normal tissue is to the PTVs, the higher the dose to the true normal 
structure will be. 
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The dosimetric impact due to the use of unedited autocontoured structures for 
treatment planning was assessed using the two remaining metrics; the absolute and relative 
dose differences.  Significant correlation between features of the treatment plan and the 
dosimetric impact of the choice of planning structure was found for a limited number of plan 
features. For example, the absolute difference in the mean dose to the contralateral parotid 
was significantly correlation to both the minimum distance and the distance of the 10% 
closest points to the low dose PTV, this may be expected given that edits to the parotid may 
be more impactful if the target is near the structure. Considering the very limited impact the 
choice of planning structure had on the resultant plans, as presented in the previous section, 
strong correlations would not be expected. 
 
 
 
 
 
Table 21. Correlation between dosimetric impact of using unedited autocontoured normal 
structures and patient and plan features. P-values of the hypothesis that there exist no 
relationship between the dosimetric impact (rows) and plan features (columns), significant 
established at <0.05 and shown in green. The absolute dose to the clinical structure of four 
key normal structures in the head-and-neck were significantly correlated with the size of 
clinical edit (although not available for prediction of new patients), the PTV prescribed dose 
level and the minimum distance to the target. The absolute and relative dose difference were 
less often correlated to plan features. No dosimetric features were correlated with the DSC of 
the targets or target variations.
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p-values of Correlation 
Coefficient Clinical Edit 
Prescription Dose 
Level Minimum Distance 
Max Distance of 10% 
closest points 
 Structure Dice HD MSD PTV1 PTV2 PTV3 PTV1 PTV2 PTV3 PTV1 PTV2 PTV3 
Absolute 
Dose 
Spinal Cord <0.01 0.01 0.02 <0.01 0.03 <0.01 <0.01 0.01 0.02 <0.01 0.01 0.01 
Brainstem <0.01 <0.01 <0.01 0.01 0.03 <0.01 <0.01 0.05 0.07 <0.01 0.04 0.05 
Ipsilateral Parotid 0.68 0.72 0.74 0.35 0.71 0.86 0.98 0.66 <0.01 0.68 0.70 <0.01 
Contralateral Parotid <0.01 <0.01 <0.01 <0.01 0.01 <0.01 <0.01 0.24 0.09 <0.01 0.23 0.07 
Absolute 
Dose 
Difference 
Spinal Cord <0.01 0.01 0.04 0.04 0.19 0.08 0.01 <0.01 0.09 0.01 <0.01 0.05 
Brainstem <0.01 <0.01 <0.01 0.61 0.61 0.45 0.52 0.77 0.42 0.58 0.78 0.41 
Ipsilateral Parotid 0.23 0.55 0.43 0.97 0.54 0.46 0.36 0.09 0.81 0.34 0.09 0.90 
Contralateral Parotid 0.20 0.33 0.35 0.28 0.75 0.30 0.56 0.18 0.68 0.66 0.16 0.73 
Relative 
Dose 
Difference 
Spinal Cord <0.01 0.03 0.07 0.29 0.25 0.10 0.04 <0.01 0.10 0.06 <0.01 0.07 
Brainstem <0.01 <0.01 <0.01 0.48 0.87 0.28 0.47 0.76 0.64 0.53 0.75 0.65 
Ipsilateral Parotid 0.37 0.94 0.76 0.82 0.34 0.68 0.17 0.04 0.90 0.15 0.04 0.83 
Contralateral Parotid 0.17 0.21 0.23 0.07 0.38 0.15 0.46 0.24 0.87 0.56 0.25 0.92 
  Dice with PTVs Dice of Structure Hull with PTVs 
Dice with  0.5 cm 
expanded targets 
Dice with 1cm  
expanded targets 
 Structure PTV1 PTV2 PTV3 PTV1 PTV2 PTV3 PTV1 PTV2 PTV3 PTV1 PTV2 PTV3 
Absolute 
Dose 
Spinal Cord               0.81 0.49 0.23     
Brainstem             0.22 0.09 0.49 0.18 0.74 0.36 
Ipsilateral Parotid 0.03 0.22 0.99 0.03 0.18 0.98 0.03 0.04 0.15 0.30 0.54 0.36 
Contralateral Parotid 0.61 0.61 0.08 0.65 0.63 0.07 0.27 0.14 0.86 0.88 0.13 0.17 
Absolute 
Dose 
Difference 
Spinal Cord               0.54 0.94 0.58     
Brainstem             0.42 0.02 0.17 0.12 0.74 0.36 
Ipsilateral Parotid 0.26 0.19 0.73 0.31 0.25 0.75 0.26 0.26 0.30 0.23 0.94 0.83 
Contralateral Parotid 0.23 0.05 0.04 0.23 0.06 0.04 0.44 0.72 0.02 0.03 0.09 0.15 
Relative 
Dose 
Difference 
Spinal Cord               0.53 0.97 0.62     
Brainstem             0.45 0.05 0.24 0.17 0.69 0.44 
Ipsilateral Parotid 0.22 0.15 0.54 0.25 0.18 0.55 0.21 0.21 0.18 0.12 0.79 0.95 
Contralateral Parotid 0.14 0.13 0.06 0.14 0.13 0.06 0.39 0.72 0.05 0.06 0.14 0.26 
134 | P a g e  
 
Discussion 
We have investigated the use autocontoured normal structures in the head-and-neck 
for treatment planning purposes. We first evaluated retrospective and prospective algorithm 
performance including the clinical implementation of the 8 normal structures into our head-
and-neck clinic. In an effort to ensure the safe use of autocontoured for automated treatment 
planning, which may or may not include the careful review of contours, we developed an 
approach to QA autocontours in order to flag them to the user. Finally, we investigated the 
potential use of unedited autocontours for treatment planning. The results show that 
autocontouring is a viable method to save time, reduce required infrastructure, while 
maintaining a high standard of care, and that the use of unedited autocontours has limited 
dosimetric impact. 
In an analysis of four autocontouring algorithms, an in-house methods, MACS, was 
highest performing. Two commercial algorithms were also analyzed –Smart Segmentation® a 
deformable image registration technique which performance was not found to be adequate for 
clinical use and Smart Detection® a heuristic approach which worked well but is only 
available for a limited number of structures, and Smart Segmentation® a deformable image 
registration approach which performed poorly with or without the use of multiple atlas 
patients. While the heuristic approach slightly outperformed the in-house technique for a few 
structures, the advantages of using a single algorithm which include a reduction in the time 
needed to contour, a simplification in workflow, and the availability to modify the contours 
which is not possible using the commercial approach the in-house method alone was selected 
for further analysis. Interest in other automatic contouring methods are increasing, including 
the use of edge detection, image gradient, and voxel intensities, which do not require prior 
information or model building as well as shape model and machine learning techniques which 
use the contours of prior patients to inform the contour of new patients and have performed 
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well on select patient data sets (99). These techniques may offer advantages and the 
validation and assessment of these algorithms both in the clinic and for planning purposes 
may be evaluated using the principles presented here. 
Given the known inter-physician variability in contouring(88, 117) and as the atlas for 
contour generation was derived from patients from the primary rating physician we sought to 
present autocontours from MACS to 5 physicians and, as expected, the acceptability of the 
contours, especially for use without edit, varied among physicians, however only 7% of 
contours received contours which indicated physician disagreement (i.e. outside of their own 
opinion of acceptable inter-physician variability). We expect similar results for a larger group 
of physicians. 
We successfully implemented into routine clinical the autocontouring of 8 normal 
structures (11 total contours as three were bilateral). These 8 structures were chosen as they 
were the most often contoured structures in a sample of head-and-neck cancer patients. This 
clinical implementation provides ongoing data at the size of edits of autocontours and 
possible trends into normal tissue contouring practices. Other structures are also required and 
include the submandibular glands, optic structures, esophagus, and others (92). A limited 
analysis of these structures, presented in the appendix, show less success for their 
contouring compared to independently drawn physician structures and therefore these 
structures may warrant further analysis. 
While no formal analysis of time savings or systematic method for physician feedback 
was developed, we believe that, in line with previous findings, autocontouring saves time 
(118-120) and that the continued use of the software indicates that it has been well received, 
with over 1000 patients having had these contours requested through the script in the 
treatment planning system. Upon implementation a description of the tool as well as guidance 
for its use was sent to the attending physician, however due to software limitations we were 
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unable to track approval and/or editing of the structures on a patient-by-patient basis and it 
was assumed that if normal structures were requested for the patient and image set of the 
final treatment plan and if the contours remained in the final treatment plan with the same 
naming as the autocontours (which is the same as our clinical naming) then the contours 
were edited and/or approved for clinical use. These assumptions likely have an impact of the 
fidelity of the data, and a limited number of instances which highlight the impact they may 
have were encountered. In one such example, for the patient and image set in question, the 
contours were requested through the script in the treatment planning system and remained in 
the final treatment plan, however, upon analysis of the cochlea structure it was found that the 
naming was inconsistent with the structure location (i.e. the left cochlea was on the right side 
of the body, and the right cochlea on the left). These structures were removed from analysis 
but other, less obvious examples, may have remained. Generally, clinical implementation was 
considered a success as nearly 50% of structures were not edited for clinical use and 
physicians appreciate and use the tool. 
In the third experiment, a method to ensure the safe use of autocontours in automated 
treatment planning was investigated. Random forest models were developed such that a 
patient with grossly incorrect autocontours would not be allowed to continue in the automated 
treatment planning process. Additionally, the possibility of warning the user to suspected 
contour inaccuracies was investigated. Due to the success of the autocontouring algrotihm, 
there were few “true” autocontouring failures and simulated failures were therefore used to 
supplement. It is unlikely that these simulated errors (e.g. shifts and expansions) accurately 
represent the potential failure modes of an autocontouring algorithm. However, models to 
detect gross errors successfully identified patients in non-standard positions, for a patient with 
a very large gross tumor, and for a limited number of other gross contouring errors. For all 
patients in nonstandard positions and of other disease sites, at least half of the normal 
structures were flagged as failing by their respective models and therefore we suggest that if 
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more than half of the structures are flagged as failing by the gross error models then the 
patients should not continue in the autoplanning process.  
Unfortunately, efforts to detect smaller contour edits found only limited success, with 
average accuracy just over 60%. The reason for the poor performance is likely multifaceted, 
though a driving reason is likely the (mis)alignment of the data collected with underlying 
assumptions. During clinical implementation it was assumed that contours which remain in 
the treatment plan represent the anatomical structure which corresponds to their name. An 
extension of this is the idea that edit of an autocontour indicates autocontouring error and also 
the inverse; lack of contour edit indicates perfect anatomical agreement. However, numerous 
examples which do not support this idea were identified. Further, the significance of the 
correlation between contour edit and distance to target suggest that contours are not edited 
solely for the purpose of anatomical accuracy. If a model to detect anatomical accuracy of 
contours is desired then vetting and careful development of a data set which matches this 
desire should be curated. While strict adherence to anatomical boundaries of normal 
structures for treatment planning purposes is ideal, contours for the purpose of treatment 
planning may serve other purposes which are not tracked, noted, or otherwise identifiable. 
To investigate the impact that the use of unedited autocontours may have on the 
treatment plan we developed treatment plans on both clinically used structures (both edited 
and/or approved autocontours and independently drawn structures) and unedited versions. 
The results of this experiment indicate that the automated treatment planning strategy as 
presented in Chapter 4 is robust to edits on the size of those seen clinically and even larger 
differences seen when the contour is drawn independently and that using unedited structures 
for treatment planning, which may save up to an hour of editing time, may be a feasible 
option. Through this, again, we saw the impact of structures which do not align with their 
naming (121); for at least seven of ten patients with a spinal cord dose which exceeded 
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clinical constraint when the treatment plan was developed on unedited structures there was 
some error in the spinal cord contour. 
 There are several limitations and opportunities for further study. Generally, the 
curating of a data set which explicitly meets the needs of the hypothesis is desired, though 
the use of real clinical data exposes the purposes and methods with which a clinical tool may 
be utilized and therefore, should be considered. The structure set implemented clinically 
included only 8 normal structures, and though others were investigated including their impact 
of plan dosimetry, further investigation is needed. The study of the dosimetric impact of 
autocontours was completed for a cohort of only 54 patients, from 6 sub-sites in the head and 
neck, and the accrual of additional patients may reinforce the conclusions or may identify 
specific scenarios (e.g. groups of patients) for which the current conclusions may not apply. 
Finally, if we are to suggest that true anatomical structures are not required for high-quality 
treatment planning we must be cognizant of the impact or doing so. First, the naming of such 
structures should always be in line with their physician description (121). Second, normal 
tissue contours routinely serve purposes beyond that for treatment planning (e.g. for the 
analysis of normal tissue complications, in the case of retreatment, etc.), and if anatomically 
defined contours are not routinely generated there is a risk of losing new and clinically reliable 
data which may be used. 
 Over all, we believe this work represents the first comprehensive assessment of 
automatic contouring for a large set of normal structures in the head-and-neck, including over 
2 years of use. Further, we have developed a technique to identify contours with gross errors 
which may jeopardize the safety of a fully automated treatment planning approach. Finally, 
this is the first study to evaluate the potential of using unedited autocontours of normal 
structures for head-and-neck treatment planning, and the results show that unedited 
autocontours do not significantly impact plan quality at clinically relevant dosimetric endpoints, 
and compared to clinical edited or approved autocontours. The use of autocontouring in the 
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head-and-neck, with or without editing, could dramatically reduce the time needed to head-
and-neck treatment plan development, possibly allowing for the transition to advanced 
techniques in low-resource settings. 
Conclusion 
The automatic contouring of normal structures in the head-and-neck is a promising 
avenue, producing accurate contours which are suitable for use without edits for treatment 
planning. 
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Chapter 6: Automatic Contours of Intermediate and Low 
Dose Clinical Target Volumes and Their Use in an 
Automated Planning System 
In this chapter we describe the results for Specific Aim 4 in which, through three 
experiments we evaluate the feasibility of the use of automatically countered intermediate and 
low dose target volumes in the head and neck. Our working hypothesis is that automatically 
contoured clinical target volumes can safely be used for treatment planning purposes. 
Introduction 
Towards a fully automated treatment planning system for the head-and-neck, we have 
presented the validation of the planning technique and optimization algorithms in Chapter 4 
and the use of fully automated normal structure contours in Chapter 5. The next step towards 
full automation is the implementation of automatically contoured target volumes. Intermediate- 
and low- dose clinical target volumes are good candidates for automatic contouring as they 
are often based on anatomically defined tissues rather than, as for the high dose treatment 
volume, the cancerous tumor. 
In the treatment of head-and-neck cancer, the irradiation of subclinical disease in the 
lymphatic system of the neck to between 45 and 60 Gy has long been shown to improve 
patient outcomes (1, 2). Historical records of patient reoccurrence reveal likely patterns of 
disease spread of each sub-site in the head-and-neck (3-6) and advise physicians on the 
nodal levels which would benefit from prophylactic radiation coverage. While irradiated nodal 
levels and prescribed doses may vary between patients and physicians (7, 8) there is some 
consensus on which to base standardized nodal selection according to stage and disease 
sub-site (9, 10). An atlas of nodal levels on a contrast enhanced CT of one patients is 
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available on the RTOG website 
(https://www.rtog.org/CoreLab/ContouringAtlases/HNAtlases.aspx). 
Once the intended nodal volumes for irradiation have been selected, they must be 
delineated. Contouring of these elective targets in the head-and-neck faces the same burdens 
as does the contouring of normal structures; contouring is time consuming and even with 
published guidelines and publically available atlases of nodal volumes there exists significant 
inter-physician variability(11-14). Further, target definition represents a major contributing 
factor to geometric inaccuracy in radiotherapy (15). To reduce cntour variability as well as 
save time and standardize treatment, methods for the automatic delineation of these 
anatomically based nodal volumes have been investigated and are promising techniques (16-
19), though small patient cohorts and limited or patient specific nodal volume selections limit 
their applicability more broadly. 
We seek to provide a set of atlas based automatically contoured nodal volumes which, 
with post processing, can provide clinically usable clinical target volumes for elective neck 
coverage of many head-and-neck subsites and stages. In the context of an automated 
treatment planning system for the head-and-neck, we envision a process by which the 
attending physician is required to provide information about the location of gross disease (by 
identifying the head-and-neck subsite) and the location of gross nodal disease, if present. 
This information along with the physician drawn primary and nodal gross tumor volume (GTV) 
contours will be used to provide a preliminary clinical target volume, divided by dose level, 
which the physician will then have the opportunity for edit for treatment. This process can be 
seen in Figure 28. 
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Figure 28. Workflow of the propagation of automatically generated CTVs. Using 5 user 
provided inputs, patient specific CTVs are created. The patient CT is used in a multi-atlas 
autocontouring algorithm and information provided about the disease type and stage is used 
to select the appropriate nodal volumes based on templates. From the patient GTV, the high 
dose CTV is created and then combined with the nodal volumes to provide patient specific 
CTV contours. In a contouring workspace the physician then has the opportunity to edit and 
the obligation to approve the contours for clinical use. 
Nodal Volume Atlases  
(Left and Right) 
Physician Provided Information: 
1. Head-and-neck subsite 
2. Nodal involvement 
3. Prescription dose levels 
4. Patient CT 
Nodal Volumes on 
Patient CT 
5. Primary and  
Nodal GTVs 
Patient CTVs ready 
for physician 
editing/approval 
Automatic Contouring 
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Methods 
Autocontouring Algorithm 
Autocontours of four anatomically defined nodal level groupings, as described in Table 
22 and Figure 29, were created using the in-house multi-atlas deformable image registration 
approach known as MACS as described in Chapter 5. Two separate atlases were developed, 
one for left sided nodal volumes and one for right sided nodal volumes. The left and right 
sided atlases were comprised of 10 and 12 patients without gross disease on the 
corresponding side and who were previously treated patients at The University of Texas MD 
Anderson Cancer Center. Contours of the four target volumes were collected from the 
patients’ treatment plans or drawn by a resident radiation oncologist; all contours used in the 
atlas were reviewed and approved for use by an attending radiation oncologist with 13 years 
of experience. 
Retrospective Autocontouring Performance 
Physician Review 
For this study, 115 patients were selected from the most recent 128 patients stored in 
the database of patients treated at our institution for head-and-neck cancer; the remaining 13 
patients were used for atlas development. A radiation oncologist was asked to rate the nodal 
level contours as seen in Figure 29 on a five-point scale, Table 8, with a score of 1 indicating 
major edits are needed and a score of 5 indicating a perfect autocontour. To assess the 
possibility of rater bias, nodal level contours for 10 randomly selected patients were reviewed 
by five additional radiation oncologists from four international institutions. Physician 
agreement was assessed by grouping each pair of ratings (one rating from the primary 
physician and one from an outside physician) into one of three categories. Category I 
agreement includes instances when the primary and outside physician agreed as to the 
degree of edit needed, Category II agreement indicates that the physicians agreed that the 
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contour required either no more than minor edits or major edits. The final category, Category 
III agreement, includes those contours where the physicians disagreed on the acceptability of 
the contour, with one physician indicating that the contour needed major edit with the other 
indicating no or minor edit for use. Additionally, inter-physician variability in ratings was 
assessed using a Wilcoxon signed rank test. 
  
145 | P a g e  
 
Table 22. Anatomical definitions of individual nodal levels used in this study. Individual nodal 
levels were grouped allowing for four atlas derived volumes; the retropharyngeal nodes (red 
arrow), nodal levels II-IV (green), levels Ib-V (dark blue), and levels Ia-V (light blue). This 
table was adapted from published guidelines, Gregoire et al(9) 
 Anatomical Boundaries 
Nodal 
Level Cranial Caudal Anterior Posterior Lateral Medial 
Retropha-
ryngeal 
Nodes 
Base of skull 
Cranial edge 
of the body 
of hyoid 
bone 
Fascia under 
the pharyngeal 
mucosa 
Prevertebral 
m. (longus 
colli, longus 
capitis) 
Medial 
edge of the 
internal 
carotid 
artery 
Midline 
Ia 
Geniohyoid 
m., plane 
tangent to 
basilar edge 
of mandible 
Plane 
tangent to 
body of 
hyoid bone 
Symphysis 
menti, 
platysma m. 
Body of 
hyoid bone 
Medial 
edge of 
ant. belly of 
digastric m. 
n.a. 
Ib 
Mylohyoid 
m., cranial 
edge of 
submandibul
ar gland 
Plane 
through 
central part 
of hyoid 
bone 
Symphysis 
menti, 
platysma m. 
Posterior 
edge of 
submandibu
lar gland 
Basilar 
edge/inner 
side of 
mandible, 
platysma 
m., skin 
Lateral edge 
of ant. belly 
of digastric 
m. 
IIa 
Caudal edge 
of lateral 
process of 
C1 
Caudal edge 
of the body 
of hyoid 
bone 
Post. edge of 
sub-
mandibular 
gland; ant. 
edge of int. 
carotid artery; 
post. edge of 
post. belly of 
digastric m. 
Post. border 
of int. 
jugular vein 
Medial 
edge of 
sternocleid
omastoid 
Medial edge 
of int. carotid 
artery, 
paraspinal 
(levator 
scapulae) m. 
IIb 
Caudal edge 
of lateral 
process of 
C1 
Caudal edge 
of the body 
of hyoid 
bone 
Post. border of 
int. jugular vein 
Post. border 
of the 
sternocleido
mastoid m. 
Medial 
edge of 
sternoclei-
domastoid 
Medial edge 
of int. carotid 
artery, 
paraspinal 
(levator 
scapulae) m. 
III 
Caudal edge 
of the body 
of hyoid 
bone 
Caudal edge 
of cricoid 
cartilage 
Postero-lateral 
edge of the 
sternohyoid m.; 
ant. edge of 
sternocleidoma
stoid m. 
Post. edge 
of the 
sternocleido
mastoid m. 
Medial 
edge of 
sternoclei-
domastoid 
Int. edge of 
carotid 
artery, 
paraspinal 
(scalenius) 
m. 
IV 
Caudal edge 
of cricoid 
cartilage 
2 cm cranial 
to 
sternoclavic
ular joint 
Anteromedial 
edge of 
sternocleidoma
stoid m. 
Post. edge 
of the 
sternocleido
mastoid m. 
Medial 
edge of 
sternocleid
omastoid 
Medial edge 
of internal 
carotid 
artery, 
paraspinal 
(scalenius) 
m. 
V 
Cranial edge 
of body of 
hyoid bone 
CT slice 
encompassi
ng the 
transverse 
cervical 
vessels 
Post. edge of 
the 
sternocleidoma
stoid m. 
Ant-lateral 
border of 
the 
trapezius m. 
Platysma 
m., skin 
Paraspinal 
(levator 
scapulae, 
splenius 
capitis) m. 
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Figure 29. Examples of automatically contoured nodal level group. Shown for a representative 
patient are the retropharyngeal nodes (red), nodal levels II-IV (green), levels Ib-V (dark blue), 
and levels Ia-V (light blue), on five slices (Panels B-G) at locations as seen in Panel A. 
 
Quantitative Contour Performance 
 From the two patient cohorts as previously discussed, [1) 115 retrospectively collected 
patients with reviewed nodal levels and 2) 54 patients from various head-and-neck subsites 
and clinically edited normal tissues autocontours], inclusion criteria included clinical nodes 
which visually resembled anatomically defined nodal regions, and were treated for one of the 
7 head-and-neck subsites. This left 55 of the 115 retrospective patients and 24 of the 
prospective patient cohort, for a total of 79 patients included in this analysis. 
 Physician drawn CTVs served as the gold standard in this study and were created by 
combining physician drawn CTVs of all dose levels into a single “clinical CTV”. This was 
necessary as often the division of clinical target volumes among many prescription doses can 
vary dramatically among physicians and were not standardized according to our automated 
planning approach. Atlas derived CTVs were generated by a visual matching of the 
intermediate and low dose clinical CTV with one or more of the four autocontoured nodal level 
groups, Figure 29, or one of three additional nodal level groups (including nodal level groups 
Ia-IV, Ib-IV, or II-V), which were not included in the autocontoured structure set and were only 
used for 2, 2, and 4, patients respectively. The selected nodal levels were combined with the 
clinical high dose CTV which was copied directly from the clinical treatment plan to mimic the 
anticipated automated planning approach to create the “atlas derived CTVs”. Two quantitative 
comparisons of the clinical CTVs and atlas derived CTVs were assessed using the Dice 
similarity coefficient, mean surface distance, and Hausdorff distance, as previously described. 
First, the clinical CTV and atlas derived CTV were compared directly, as seen in Figure 30. 
Second, to eliminate the bias introduced by including the physician drawn high dose CTV in 
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the atlas derived CTV, the physician drawn high dose CTV was removed from both the 
clinical CTV and the atlas derived CTV to create atlas derived and clinical “nodal CTVs”, see 
Figure 31.  
The results of this experiment can be found on Page 156. 
 
 
Figure 30. Quantitative comparison of clinical and atlas derived CTVs. In panel A, all clinical 
CTVs (here three dose levels indicated in red blue and yellow) were combined to create a 
single clinical CTV (green). IN panel C, atlas derived nodal volumes (light blue) were 
combined with the physician drawn high dose CTV (red) to create atlas derived CTVs 
(orange). In panel C, these two volumes were compared using the DSC, MSD, and HD. 
Atlas derived CTVs 
Clinical CTVs 
CTV1 
Atlas 
Nodes 
CTV2 
CTV3 
CTV1 
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C 
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 Figure 31. Quantitative comparison of clinical and atlas derived nodal CTVs. The high dose 
physician drawn CTV was removed from the clinical CTVs (panel A) and the atlas derived 
CTVs (panel C). The two volumes were compared the DSC, MSD, and HD. 
 
Dosimetric Impact of Planning on Autocontoured Target Volumes 
For this study, of the 54 patients used for evaluation of the treatment planning strategy 
and impact of normal tissue autocontours, 40 were selected because they met the inclusion 
criteria of at least 2 physician drawn CTVs and or PTVs, bilateral treatment, and intermediate 
and/or low dose CTVs based on anatomical nodal levels. For comparison, two treatment 
plans were developed. In the first strategy, plans were optimized to deliver dose to two 
physician drawn planning target volumes. Clinical PTVs were reduced to two such that the 
high dose physician drawn target was copied form the original treatment plan and any lower 
dose PTV was combined into one target volume. For planning purposes the prescription to 
this volume was chosen to be either equal to the original volume (if there was only an 
intermediate dose target) or between the two remaining target volumes (if there were both 
intermediate and low dose target volumes). See Figure 32 for an example of the reduction of 
Atlas derived nodal CTVs 
Clinical nodal CTVs 
CTV1 
Atlas 
CTVs 
CTV1 
Clinical 
CTVs 
A 
B 
C 
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target volumes from three to two dose levels for two patients. In the second strategy, plans 
were optimized to deliver dose the atlas derived PTVs which were generated from atlas 
derived CTVs with either 3 or 5 millimeter margin. The atlas derived high dose CTV was a 
copy of the physician drawn high dose CTV. The second atlas derived CTV was derived by 
combining the selected nodal levels which best matched the physician drawn nodes and 
subtracting the high dose CTV, this volume was prescribed the same dose as the 
intermediate dose level in the first strategy. Atlas derived CTVs were expanded by a margin 
of either 3 mm or 5mm to create atlas derived PTVs. Both planning strategies used physician 
drawn normal tissues, when present, for optimization. If physician drawn normal structures 
were not included in the clinical plan MACS was used to generate these structures. For 
optimization, planning structures were also generated using the MACS software as needed 
for the planning strategy.  
The dose delivered to the clinical CTVs and PTVs was evaluated when the two 
planning strategies were used. In the first strategy, the clinical PTVs were the targets for 
which the plan was optimized, the second strategy aimed to deliver dose a different target, 
the one that would be used if atlas derived nodal volumes were used as target volumes 
without edit. Coverage at the 95%, 98% and 100% isodose levels were evaluated. 
The results of this experiment can be found on Page 161. 
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 Figure 32.Clinical and atlas derived targets used for treatment planning. In panels A (patient 
1) and C (patient 2) intermediate and low dose clinical PTVs (blue and yellow colorwash) 
were combined to create a single secondary PTV (pink line). The two physician derived PTVs 
were used for treatment planning and represent the true planning scenario. Atlas derived 
CTVs (orange lines panel B,C,E, and F) were used with 3 mm (lavender line, panels B and E) 
and 5 mm (blue line, panels C and F) for comparison. 
 
 
D 
A 
E 
B 
F 
C 
Patient 1 
Patient 2 
152 | P a g e  
 
Evaluation of an Independent Technique for QA of autocontoured Target Volumes 
If automatically generated targets are to be used for treatment planning, similar to the 
strategy proposed for normal structures, it is necessary that automatically generated target 
volumes be verified independently. Towards this, we assessed the use of a second 
independent target volume contouring approach as a QA check of atlas derived CTVs. 
Second Clinical Target Volume Contouring Approach 
As developed by a member of our group, a machine learning approach has been 
shown to be successful in the contouring of a combined target volume structure in the head-
and-neck (CARDENAS – In Submission – Segmentation of Oropharyngeal Clinical Target 
Volumes using a two-channel 3D U-Net Architecture MICCAI). This approach uses a 3D 
variant of a two channel U-Net architecture and requires the user to input the patient CT 
volume, the physician drawn gross tumor volume(s), an external body contour, and two 
anatomical landmarks, as seen in Figure 33. The anatomical landmarks are used to identify 
the extent of the area of interest in the machine learning algorithm and include the fusion of 
sphenoid bone and basilar part of the occipital bone and most cranial extent of the sternum; 
the landmarks were manually identified for this study but their identification could be easily 
automated. The model was developed using 210 head-and-neck cancer patients treated for 
oropharynx disease with bilateral treatment. Assessed on 85 patients not included in the 
training set, this machine learning approach agreed with independent drawn physician CTVs 
with an average and standard deviation in the Dice similarity coefficient of 0.78±0.05. In this 
study, to assess the quality of the CTVs generated using this approach, CTVs for 79 patients 
were compared with both the clinical CTV and the clinical nodal CTV as previously described 
and as shown in Figure 34 
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 Figure 33. Secondary technique for the generation of CTVs. This approach requires as input 
(panel A) the primary and nodal GTV, an external contour in the region of interest, and 
anatomical landmarks which define the superior and inferior region of interest. The technique 
outputs a combined CTV volume (panel B). 
 
Input: 
Sup-Inf Extent 
External 
Contour 
Primary GTV 
Nodal GTV 
Output: 
 CTV Result 
A B 
154 | P a g e  
 
  
 
 
 
Figure 34. Quantitative comparison 
of CTVs from the secondary 
technique to clinical and atlas derived 
CTVs. Shown for three slices are the 
CTVs from the independent 
technique which were compared to 
both the clinical CTVs (green) and 
atlas derived CTVs (blue) for both the 
whole CTV volume (left panels) and 
the nodal CTV only (right panels). 
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Independent Clinical Target Volumes as a QA Approach 
In order to assess the use of these secondary contours for QA purposes we evaluated 
the correlation between the quantitative agreement as measured by the DSC, MSD, and HD 
between 1) the atlas derived CTVs and the CTVs generated using the independent machine 
learning technique and 2) the atlas derived CTVs and the physician drawn CTVs. Correlation 
was established using the correlation coefficient with a p-value less than 0.05 establishing 
significant correlation. If correlated, the agreement of the contours generated for the 
automated planning approach (the atlas derived CTVs) could be compared with the 
secondary technique and this result provided to the user of the system to guide the need for 
edits. 
The results of this experiment can be found on Page 163. 
Results 
Retrospective Autocontouring Performance 
Physician Review 
For 115 patients with atlas derived nodal volumes, the distribution of physician ratings 
of the 4 nodal volumes on the 5-point scale according to Error! Reference source not 
found. can be seen in Figure 35. The average rating of the four nodal volumes was between 
3.5 and 3.9, and 75% of contours [686/920 contours (4 volumes bilaterally on 115 patients)] 
were rated as needing no edit for clinical use. One quarter of the nodal contours (230/920) 
were rated as needing minor edit and only 0.4% (4/920) received a score of a 2 and were 
indicated as needing major edit for use in treatment planning. 
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Figure 35. Distribution of physician scores of the atlas based nodal volumes. A score of 4 or 5 
indicates no edits are needed for use in treatment planning. 
 
To assess inter-observer variability a subset of 10 randomly selected patients was 
selected for review by five additional radiation oncologists from four outside institutions. The 
radiation oncologists, per a self-reported questionnaire, had an average of 8.25 years of 
experience (range, 3.0-12.5 years).  
For all nodal volumes the scores assigned to the 10 patients differed significantly 
(Wilcoxon signed rank test, p<0.05) between the primary physician and at least one outside 
physician. However, no volume was significantly different between primary and all of the 
outside physicians. The average score across the subset of 10 patients for each of the four 
nodal volumes and each of the 5 physicians can be seen in Table 23. Some systematic 
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differences in contour ratings are seen; for example the third outside physician rated on 
average, all volumes lower than the primary physician. The fifth outside physician, however, 
rated, on average, all volume as high as or higher than the primary reviewer. This supports 
the known presence of inter-physician variability in contouring studies.  
Of 399 total ratings by outside physicians (4 bilateral structures on 10 patients by 5 
outside physicians with one structure not rated by one physician) 49% (195/399) of the ratings 
matched those of the primary physician and were classified as Category I agreements. 
Considering Category II agreements, the physicians assigned an additional 47% (186/399) of 
the contours to same group, either as needing no or minor edit for use (47%) or as needing 
major edit for use (0%). Finally, only 5% of contours received scores indicating the need for 
major edits by one physician while needing no or minor edits by the other physician. In Table 
24 the percentage of contours classified into each of the three agreement categories can be 
found for the eight normal structures assessed.  
 
 
Table 23. Average scores of the four nodal volumes by the primary and 5 outside physicians. 
Three physicians rated at least half of the contours, on average, higher than the primary 
physician. Two physician rated all contours, on average, worse than did the primary 
physician.
 Average Contour Rating 
Nodal Volume Primary Physician 
Outside 
Physician 1 
Outside 
Physician 2 
Outside 
Physician 3 
Outside 
Physician 4 
Outside 
Physician 5 
Nodal Levels 
Ia-V 3.7 3.0 4.0 3.1 4.0 4.4 
Nodal levels 
Ib-5 3.9 3.1 4.0 3.1 4.0 4.4 
Nodal Levels 
II-IV 4.0 3.1 3.9 3.1 4.0 4.5 
Retropharyngeal 
Nodes 4.0 2.7 3.7 3.7 2.9 4.0 
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Table 24. Inter-physician agreement in the rating of automatically contoured nodal levels. 
Category I indicates the scores by the two physicians matched, Category II indicates that the 
ratings did not match but the contours were rated into the same “group” (either as needing no 
or minor edit, or as needing major edit)) by both physicians. Category II represents 
disagreement between the two physicians. Due to rounding, not all rows sum to 100. 
 % of agreements in Category 
Structure I II III 
Retropharyngeal Nodes 39 55 6 
Nodal Levels II-IV 55 41 4 
Nodal Levels Ib-V 54 42 4 
Nodal Levels Ia-V 47 48 4 
Total 49 47 5 
 
 
Quantitative Contour Performance 
Compared to clinical CTVs, atlas derived CTVs had an average (± standard deviation) 
DSC of 0.81±0.05. When considering only the nodal part of the CTVs (i.e. with the high dose 
CTV removed) the dice similarity coefficient decreaseD to 0.63±0.10. The results of both 
analyses are found in Table 25 and the distribution of value for all 79 patients are found in 
Figure 36. The analysis without the high dose CTV better represents the quality of the atlas 
contours in mimicking the clinical CTV contours, but the whole CTV analysis more closely 
represents the true treatment scenario in the RPA whereby the final treatment volume would 
include the physician drawn/edited high dose CTV. The results should be taken with some 
consideration given that chosen atlas derived nodal volumes may not have accurately 
reflected the attending physician’s intention when contouring the targets for each patient. 
Generally, the atlas contours agree well with physician drawn contours compared to 
previously published whole CTV agreement metrics (11, 19, 20). 
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Table 25. Quantitative agreement between atlas derived CTVs and clinical CTVs. 
Comparisons were made for both the whole CTV and the nodal CTV only, for which the high 
dose CTV was removed. 
 Dice Similarity Coefficient Hausdorff Distance (mm) Mean Surface Distance (mm) 
 Mean ± std [min - max] Mean ± std [min - max] Mean ± std [min - max] 
Nodal 
CTVs 0.63 ± 0.10 [ 0.34 - 0.85 ] 4.52 ± 1.56 [ 1.57 - 10.33 ] 0.55 ± 0.27 [ 0.04 - 1.53 ] 
Whole 
CTVs 0.81 ± 0.05 [ 0.69 - 0.91 ] 2.33 ± 0.82 [ 1.06 - 4.80 ] 0.30 ± 0.07 [ 0.14 - 0.46 ] 
 
 
 
 
 
 
Figure 36. Distribution of the quantitative agreement between clinical and atlas derived CTVs. 
Shown are the distributions of the Dice similarity coefficient (left) the mean surface distance 
(middle) and the Hausdorff distance (right) for both the whole CTVs (in blue) and the nodal 
CTVs only (red).Whole CTVs has better agreement due to the use of the original high dose 
CTV from the clinical plan in the autoplan. 
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Dosimetric Impact of Planning on Autocontoured Target Volumes 
Coverage of the clinical CTVs and PTVs was poorer if atlas derived PTVs were used 
for treatment planning (i.e. optimization and normalization) than if the clinical PTVs were used 
for planning. Coverage was improved, however, if 5mm margins were used when compared 
to 3mm margins for the expansion of atlas derived CTVs to PTVs. RTOG trial 1016, in which 
the investigators studied the benefit of adding a chemotherapy drug cetuximab to a 
radiotherapy treatment strategy for patients with oropharynx cancer, required that for the 
intermediate dose target, prescribed 56Gy in the trial, volume should receive at least 45Gy 
(80% of the prescribed dose) to 95% of the target volume(21). Considering this threshold of 
80% of the prescribed dose to 95% volume, if 3 and 5mm margins are used 32% and 54% of 
the 40 treatment plans considered here meet that constraint, respectively. The average and 
standard deviation of the volume of both the clinical CTVs and clinical PTVs receiving 95%, 
98% and 100% of the prescribed dose for each of the two margin values are shown in Table 
26. Coverage of clinical PTVs was significantly poorer as measured using a Wilcoxon sign-
rank test when comparing the volume receiving 95%, 98%, and 100% (p<0.001) of the 
prescribed dose when 3mm margins were used as compared to 5mm margins. In Figure 37 
are the average DVH curves to the high dose and intermediate dose CTVs and PTVs given 
the two margins While the curves are similar for doses above 100% of the prescribed dose, 
the DVH curve of the true physician drawn intermediate dose PTV has a noticeably rounder 
shoulder when using either a 3 or 5 mm margin as compared to when the true structure was 
used for planning. 
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Table 26. Average coverage of the clinical CTVs and PTVs when atlas derived PTVS were 
used for planning.
  3 mm Margin 5 mm Margin 
  mean±std [min-max] mean±std [min-max] 
PTV 
V95%(%) 81.1±13.4 [45.7-98.9] 86.9±11.1 [56.4-99.8] 
V98%(%) 78.0±14.0 [41.7-98.1] 84.7±12.0 [52.1-99.5] 
V100%(%) 74.9±14.1 [38.9-96.7] 82.3±12.5 [49.3-98.5] 
CTV 
V95%(%) 86.6±10.8 [58.4-99.2] 91.3±8.4 [67.1-99.8] 
V98%(%) 84.1±11.8 [56.0-98.4] 89.6±9.3 [64.8-99.5] 
V100%(%) 81.7±12.3 [53.7-97.1] 87.9±9.9 [63.0-99.1] 
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 Figure 37. Average DVH curves to clinical PTVS when using atlas derived PTVs for planning. 
Atlas derived CTVs with 3 mm (green line) and 5 mm (blue line) were used for expansion to 
the PTVs. Coverage of clinical PTVs is noticeably poorer when clinical PTVs are not used for 
treatment planning. 
 
Evaluation of an Independent Technique for QA of Autocontoured Target Volumes 
Quality of the Second Independent Target Contouring Technique 
The second independent target contouring technique performed well in the contouring 
of CTVs for 79 patients, see Table 27. The contours agreed with a mean (± standard 
deviation) Dice similarity coefficient of 0.80±0.07 when considering the whole target volume 
and with an average of 0.66±0.11 when considering only the nodal CTV. Using a Wilcoxon 
signed rank text, the atlas based technique had a significantly better DSC (p=0.02), MSD 
(p<0.01), and HD (p<0.01) when considering the whole target volume. 
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Table 27. Quantitative agreement of independently derived CTVs with clinical CTVs. Whole 
and nodal only CTVs were compared using the Dice similarity coefficient, mean surface 
distance, and Hausdorff distance. 
 
Dice Similarity  
Coefficient 
Hausdorff Distance (mm) Mean Surface Distance (mm) 
 Mean ± std [min - max] Mean ± std [min - max] Mean ± std [min - max] 
Nodal 
CTVs 0.66 ± 0.11 [ 0.35 - 0.89 ] 3.07 ± 1.25 [ 0.75 - 6.37 ] 0.35 ± 0.16 [ 0.09 - 0.83 ] 
Whole 
CTVs 0.80 ± 0.07 [ 0.64 - 0.94 ] 2.64 ± 1.10 [ 1.01 - 6.37 ] 0.35 ± 0.11 [ 0.11 - 0.63 ] 
 
Independent Clinical target Volumes as a QA Approach 
 In order for the independent target contours generated using a machine learning 
technique to be useful as a QA check of the atlas based targets we first sought to establish if 
the agreement between the two contours are correlated to the agreement of the atlas based 
targets to the physician target. In Table 28 are the correlation coefficient and corresponding p 
values for 3 quantitative metrics between the atlas based and physician targets and the atlas 
based and independent targets. Significant correlation was established for all metrics 
indicating that agreement between the two contouring techniques is correlated to the ultimate 
agreement of the atlas based technique to the physician technique. The distribution of values 
can be seen in Figure 38.  
 
Table 28. Correlation of the agreement between the atlas derived CTVs with the clinical CTVs 
and the independent CTVs. Correlation coefficients and p-values are shown for the 
agreement between both the whole volume CTVs and the nodal CTV only for three 
quantitative metrics. All metrics were significant, with the strongest correlation between for the 
nodal CTVs using the mean surface distance. 
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 Correlation of Atlas and Physician and Atlas and Independent 
Targets 
 Whole CTV Nodal CTV 
 Dice HD MSD Dice HD MSD 
Correlation 
Coefficient 0.44 0.21 0.27 0.60 0.78 0.83 
p-value 6.0E-05 6.8E-02 1.6E-02 5.7E-09 3.1E-17 1.3E-21 
 
The positive correlation coefficients indicate that the larger the disagreement between 
the two contouring techniques the larger the disagreement between the atlas-based 
technique and the physician CTVs is expected to be. This correlation was stronger for the 
nodal CTVs which is expected as the subtraction of the high dose CTV removes the biased 
introduced because the atlas based technique used this contour directly while the 
independent technique does not. As seen in Figure 38, the identification of thresholds in the 
agreement of the two contouring techniques may be selected in order to identify potential 
disagreement with the physician drawn CTVs. For example, a threshold of 6 mm Hausdorff 
distance between the two contouring techniques would identify all atlas based contours with a 
Hausdorff distance of greater than 8mm and 82% of contours with HD greater than 6mm 
compared to the physician drawn CTVs. These threshold represent this data set only and 
should be further evaluated. The significant correlation supports the use of this second 
independent technique for use a QA check of atlas based CTVs when , for example in Figure 
39, when the atlas based CTVs do not agree well with clinical contours nor do they agree with 
CTVs from the independent technique and which doesn’t agree well with the clinical CTVs 
either.  
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 Figure 38. Distribution of the CTV quantitative agreement. Shown are the distributions of the 
dice similarity coefficient (left), mean surface distance (middle) and the Hausdorff distance 
(right) between the whole volume CTVs (red) and nodal CTVs (blue) between the atlas 
derived CTVs with both the  clinical CTVs (x-axis) and the independent technique (y-axis). 
Clear trends are seen with the whole volume CTVs having better agreement. 
. 
Figure 39. Example of disagreement between atlas derived CTVs, clinical CTVs, and CTVs 
from the independent technique. This indicates that use of the independent contouring of the 
CTVs may be useful as a QA tool in cases, like the one here, where all three contours 
disagree 
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Discussion 
In this work we have investigated the use of atlas based automatically contoured 
nodal levels for the definition of intermediate and low dose target volumes in the head-and-
neck. Upon physician review we found that the four nodal volumes considered were well 
received by head-and-neck radiation oncologists with nearly half reviewed as needing no edit. 
In an inter-physician analysis we found that there exists inter-physician variability in the 
acceptability of these contours, though for only between 0.4% (as rated by the primary 
physician) and 4% (as rated by outside physicians) would be expected to need major edits for 
use in treatment planning. 
Compared to clinical CTVs, we found good agreement with an average Dice value of 
0.81, which is comparable to the agreement found in other studies (11, 19, 20). These results, 
however, should be taken with the understanding that the physician drawn CTVs used for 
comparison were copied from clinical plans directly, without consideration of the intent of the 
physician when drawing the target. There are known exceptions to the general guidelines for 
the treatment of elective nodal volumes in head-and-neck cancer and it is likely that for some 
of the plans considered here the choice of atlas-derived nodal CTVs simply did not match with 
what the physician delineated. Given this, this high DSC indicates that the atlas based 
technique for the delineation of intermediate and low dose target volumes in the head-and-
neck performed very well. 
Further, we sought to assess what impact planning on these atlas derived targets 
would have on the coverage of the clinical targets. As expected, if the target of interest (in this 
case, the clinical target) is not used for treatment plan optimization, then coverage suffers. 
We investigated the use of both 3 and 5 mm margins for CTV to PTV expansion in order to, in 
part, compensate for possible contouring errors. The CTV to PTV margin as used to 
compensate for uncertainties in CTV contouring on the initial treatment scan is often not cited 
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as a primary use, but, as it is to compensate for geometric uncertainties(22), if contouring 
uncertainties are expected it may be wise to err on the side of safety and use a larger margin. 
When a 5 mm CTV to PTV margin was used for atlas-derived intermediate dose targets, 
slightly more than half of plans met the RTOG 1016 coverage constraint to the intermediate 
dose physician drawn PTV. 
Finally, if automatically delineated target volumes are to be used for fully automated 
treatment planning, it is advisable to assess and, ideally, ensure contour quality before 
presentation to the user. Towards this, we investigated the use of an independent technique 
for the delineation of target volumes and the agreement between the atlas-based targets and 
this secondary technique to the agreement between the atlas-based targets and the physician 
targets. The two were found to be strongly correlated indicating that in a fully automated 
system, both techniques could be used to delineate the CTV contours, their agreement 
assessed and this result provided to the user as guidance for the need for editing. However, 
as before, the motivation behind the delineation of the physician drawn targets is not known 
and this may influence the results found here. There are a few clear examples of 
disagreement between all three contours, which would indicate promise for the use of this 
independent technique as a QA tool, however further investigation into the usefulness of this 
strategy should be conducted.  
There are general limitations of this analysis and potential utility of automatically 
delineated targets more broadly. First, given the prominence of extensive inter-physician 
variability in the delineation of target volumes it may be ambitious to expect very high 
agreement between any automatic contouring technique and single physician drawn volumes, 
especially, as in this case, if (1) the physician intent in target delineation is unknown or 
ambiguous and (2) the atlas derived volumes originated from contours approved by a single 
physician. A detailed record of physician intent in the delineation of CTVs and consensus 
contours which match that intent would reveal the true ability of automated techniques for 
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CTV contouring.  Further, for multi-atlas autocontouring techniques, the presentation of the 
atlas to multiple head-and-neck physicians or the development of a consensus atlas may 
further reduce inter-physician variability in the reviews of contours propagated from such an 
atlas and, ultimately, edits to such contours. Second, in the current strategy nodal levels are 
limited to the four discussed here, though upon retrospective assessment approximately 10% 
of patients required nodal levels not included in the currently available set of nodal volumes. 
The need for additional volumes in a larger cohort of patients should be evaluated and, if 
needed, the additional nodal level groups could be added to the atlas patients, but must be 
accompanied by comprehensive analysis. Third, while the current autoplanning strategy is 
limited to the use of three dose volumes, and the autocontouring supports this with the 
intermediate dose level assigned to the ipsilateral neck and the lower dose assigned to the 
contralateral neck, there exist examples where a fourth dose level may be required due to the 
location of the disease, including when the disease is close to the temporal lobe or brachial 
plexus. This division of the targets into multiple dose levels is likely to vary depending on 
patient factors and physician experience. Therefore, a check of the target location should be 
performed and the user made aware if an additional dose level is likely to be required. Fourth, 
the use of the presented secondary technique, while proven to be correlated with the 
agreement between the atlas-based targets and physician targets, needs adjustment in order 
to be used in a fully automated system.  In order to generate the contours a method to detect 
the superior and inferior landmarks must be developed. Additionally, the current model was 
intended and tested exclusively for patients with bilateral disease of the oropharynx by the 
original authors and would require further development for use for many sub-sites in the 
head-and-neck which systematically differ in the selection of nodal levels. Further, while the 
correlation between atlas-physicians CTVs and atlas-secondary CTVs was established here, 
the true ability of this technique to detect and warn physicians of possible inaccuracies in 
atlas-based nodal level contours and or their use in CTV contours needs further development. 
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Finally, for use in an automated treatment planning strategy it is our recommendation 
that atlas based nodal levels be generated using the presented autocontouring technique for 
the initiation of CTVs but are used with physician approval and with the the allowance of 
possible editing. The volumes, both prior to and after possible edits should be compared with 
the secondary independent technique in order to further examine the use of this strategy for 
QA purposes. Only true clinical implementation will reveal the extent to which these contours 
are edited clinically and the extent to which QA is possible.  
Conclusion 
We have examined the use of automatically contoured nodal volumes for use as 
intermediate and low-dose CTVs in the treatment of head-and-neck cancer with radiotherapy. 
The contours were well received by head-and-neck radiation oncologists and agreed well with 
independently drawn physician contours. An independent target contouring method proved 
promising in the identification of contours requiring edits. We suggest the careful use of these 
automatically derived nodal volumes as CTVs in a fully automated treatment planning system 
with physician approval and editing as needed. 
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Chapter 7:  Discussion 
The goal of this work as a whole was to investigate two initiatives which may help 
alleviate the burden of radiotherapy in low resource settings. The dire need for radiation 
therapy in low-resource settings, including for 135 of 139 LMICs whose population have 
inadequate access to radiation therapy and for 55 countries in which no radiotherapy facilities 
exist (1), demands attention. A multifaceted approach is necessary and collaboration with 
professionals in these regions is central to success.  
An Upright Radiotherapy Chair 
The first method aimed to make more accessible the necessary high energy external 
beam radiotherapy machines required for safe radiotherapy delivery. The concept involves 
the use of a rotating patient treatment chair which, when paired with a fixed treatment beam 
offers the same degrees of freedom as traditional treatment machines. 
In the first aim, we have investigated inter- and intra- fraction setup reproducibility of 
an upright radiotherapy chair with the hypothesis that an upright radiotherapy chair has 
clinically acceptable inter- and intra- fraction reproducibility. 
 The use of such a chair, combined with a fixed treatment beam could greatly reduce 
the upfront and ongoing cost of teletherapy machines and may be of interest in low-resource 
settings or LMICs. While treatments in this seated position are not new to the field, the use of 
treatment chairs has declined and are currently very rare due to the routine acquisition of 
treatment planning images from CT scanners which, except for in a few rare exceptions, only 
allow for horizontal or nearly horizontal acquisition. As technology improves and other 
methods for the acquisition of planning images emerge (2, 3)  the possibility of other 
treatment positions is becoming a reality. If treatment chairs are to be reconsidered their 
acceptability in the context of current treatment delivery must be re-examined. Accurate setup 
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reproducibility is an important part of a robust treatment position. We found that the inter- and 
intra-fraction reproducibility in the treatment chair was, on average, less than 3mm and this is 
comparable to that in the traditional supine position. Given patient feedback, we 
manufactured a second treatment chair which incorporates additional patient indexing 
measures, increases the depth of the seat, and is built to limit the potential dosimetric impact 
of inter and intra- fraction motion.  
Limitations of this study include the use of a small patient set, all of whom were 
relatively healthy and tolerated both the seated and supine positions well. Further, the 
assessment of set-up reproducibility under conditions of image guidance were simulated 
using pre-alignment of the images using select anatomy rather than true adjustment based on 
pre-treatment images as is clinical practice. The treatment chair was only evaluated for head-
and-neck patients, due primarily to the tight geometry of the set-up using a traditional linear 
accelerator.  
The ultimate goal of this work is to support the development of a fixed beam system, 
which would eliminate some of these challenges. Treatment of other sites in the seated 
position, for example the cervix or prostate, may bring other challenges due to a difference in 
patient anatomy in this seated positon. The current study, as it was limited to the head and 
neck, would be expected to have little impact of internal anatomy between the supine and 
upright positons. If a fixed beam-rotating patient system is to be developed, the impact of 
other aspects of the radiotherapy process must be evaluated, including treatment delivery, 
machine shielding, and patient throughput. Additionally, the compatibility of this treatment 
positon including the import of planning images acquired in this position with treatment 
planning systems and in concordance with DICOM standards must be evaluated. Finally, end-
to end testing of the entire treatment process must be completed both at the start and at 
reoccurring intervals. Clinical implementation should be accompanied by appropriate clinical 
protocols, FMEA and root cause analysis studies. 
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Towards the development of a fixed-beam and rotating seated patient treatment 
paradigm which could greatly reduce the cost of the teletherapy machinery necessary for the 
delivery of both life-saving curative and symptom alleviating palliative radiotherapy in low-
resource settings, we have shown herein that the set-up reproducibility of the treatment chair 
is comparable to that in the supine position. Members of our group have previously showed 
the capability of the onboard KV imagers to capture and reconstruct CBCT images (4), which 
as reported by other investigators, can be used for treatment planning. This technology, 
however, is not released for clinical use and represents the next step in the efforts to realize 
this treatment paradigm. Other investigators are moving forward with this type of treatment 
working towards commercialization of a fixed-beam upright system (LEO Cancer Care, 
http://leocancercare.com). 
Automated Treatment Planning 
Our second proposal for the improvement of radiotherapy in low-resource settings was 
that of a fully automated treatment planning process for head-and-neck cancers. Given the 
extreme shortage of and growing need for trained radiotherapy personnel including medical 
physicists in LMICs, methods and tools to reduce this burden are desperately needed. 
Technological improvements have the ability to both improve the quality of care while 
simultaneously reducing the required human involvement. However, the introduction of these 
advanced technologies has the risk of further dividing those who have the resources and 
infrastructure to encourage advancement and those who do not and therefore risk falling 
further behind. In the case of advanced treatment planning techniques, the introduction of 
IMRT and VMAT greatly improved outcomes for head-and-neck cancer patients, however the 
introduction of these advanced treatment techniques requires improved equipment (MLCs, 
availability of service personnel for complicated machinery, adequate dose rate to 
compensate for beam modulation, etc.) and staff capable of implementing the techniques 
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which include advanced treatment planning. Without the required infrastructure the gap in 
treatment techniques only increases.  
The aim of the second aspect of this work was to partially reduce the burden on staff 
by automating the treatment planning process. Automated methods are proving beneficial in 
many areas of radiation therapy and the automation of the treatment planning process would 
be applicable in all clinics but may be especially useful in low-resource settings. 
In Specific Aim 2, Chapter 4, we sought to develop and validate a treatment planning 
strategy for the head-and-neck with the hypothesis that single optimization head and neck 
treatment plans perform with equal quality to clinically acceptable plans and 90% are 
accepted by radiation oncologists for use without edit. We found that a fully automated 
approach can produce plans that perform as well as, and in some cases better than, those 
plans as treated on a clinical trial with XX% rated as acceptable without edit by a dedicated 
head-and-neck radiation oncologist. The automated approach utilizes the RapidPlan® tools 
available in the Eclipse Treatment Planning System (Varian Medical Systems, Palo Alto, CA) 
in conjunction with in-house algorithms and requires no user input outside of the patient CT 
and treatment details including prescription and fractionation. The results were based on 54 
patients treated for cancers of various head-and-neck subsites at The University of Texas MD 
Anderson Cancer Center and 30 patients treated on a clinical trial. 
In Specific Aim 3, Chapter 5, we sought to assess the feasibility of the use of 
automatically contoured normal structures in the head-and-neck in a fully automated 
treatment planning strategy with the hypothesis that automatically contoured normal 
structures can safely be used for treatment planning purposes without significant impact on 
plan quality. In an investigation of the use of four autocontouring algorithms we found that in-
house multi-atlas contouring approach performed well and upon its clinical implementation 
half of contours were not edited for treatment planning. Further, we found that unedited 
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autocontours can be used without edit for treatment planning with very limited impact on the 
treatment plan. While our hypothesis was confirmed, the use of contours without oversight is 
far reaching and represents a significant change in practice and should be of further 
investigation. Therefore, we conclude that automatically contoured normal tissues should be 
reviewed by the radiation oncologist and approved for use in treatment planning though the 
initialization of such structures will greatly reduce the manual input required and increase the 
time savings offered of an automatic system. 
Finally, in Specific Aim 4, Chapter 6, we sought to assess the feasibility of the use of 
automatically countered intermediate and low dose target volumes in the head and neck with 
the hypothesis that automatically contoured clinical target volumes can be safely used for 
treatment planning purposes. We investigated the use of automatic contours for the 
delineation of nodal levels which were then used as intermediate and low-risk clinical target 
volumes. We found that, generally, the automatically contoured nodal volumes, generated 
using the same in-house algorithm as the normal tissue autocontours, were well received by 
radiation oncologists from five institutions. Quantitatively, intermediate and low-dose CTVs 
agreed well with physician drawn targets. If automatic targets are used for treatment planning 
than the coverage of physician targets is reduced, the results however suffer from a 
fundamental difference in the intent of target delineation, for which the physician intent was 
unknown, and thus the analysis of these results is limited. Finally, we found significant 
correlation in the agreement between the atlas-based target contours with an independent 
machine learning contouring technique and the physician contours suggesting that this 
independent method may be a useful QA tool to aide users of the automated system in the 
review of automatically contoured targets.  We feel that the use of fully automatically 
contoured intermediate and low-dose CTVs is not yet suitable for safe use and should be of 
further investigation. We concluded that CTVs generated from the multi-atlas based 
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automatically contoured nodal volumes can be used in treatment planning but should be 
accompanied by physician editing and approval as deemed necessary.  
Together, through these three aims we sought to investigate the extent to which the 
development of head-and-neck treatment plans can be automated.  We found, similar to other 
investigators, that knowledge based planning approaches can be utilized successfully for 
automatic treatment planning. Our group took automation further through the identification of 
algorithms for the determination of treatment isocenter, collimator angles, and jaw settings 
and through the use of the Varian API, the combination of all steps from the import of patient 
DICOM files through to dose calculation without human intervention. We further automated 
the process by automatically contouring normal tissues and anatomically based intermediate 
and low dose clinical target volumes in the head-and-neck. We have showed that through 
automation we can reduce the time needed for treatment planning to 40 minutes, most of 
which time does not require supervision. The automation of normal structures represents an 
important step in the treatment planning process and the algorithm described herein was 
successful in the contouring structures which can be used without edit for treatment planning. 
It is unlikely that clinicians are currently amenable to the use of unedited autocontours but it 
has been shown that the review and editing of autocontours represents a significant time 
savings. Together, the strategy is ready for limited clinical use and should be done so under 
close supervision and with extensive data collection as to its impact on clinical workflow and 
patient treatments. 
The success of this work should be considered in the context of its limitations. First, 
we found that the planning approach outperformed clinical plans for a cohort of patient treated 
on a clinical trial, but, in general, did not perform as well as plans optimized by highly trained 
dosimetrists at our institution or for plans of all head-and-neck subsites. The availability of 
highly trained staff is limited to select clinics, however, and as the approach outperformed 
plans treated on a clinical trial, we believe the quality of plans is sufficient for patient 
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treatment. Improvement upon the clinical knowledge base used for treatment plan generation 
including the optimization of the templated constraints could improve resultant plan quality 
and should be of routine consideration. The development of multiple knowledge bases, for 
multiple treatment subsites, may be considered and plans for which the strategy did not 
outperform clinical plans may provide useful for the development of such a knowledge base. 
Second, considering the automatic delineation of normal tissues, while a strategy was 
presented which allowed for use of unedited contours in treatment planning it is not standard 
practice to use unapproved contours for treatment planning and the consideration of such use 
should be carefully considered, both in the context of the treatment of the individual patient 
and if questions are to be asked of the dataset in which the patient may be included. As big 
data and deep learning find use in radiation oncology it is essential that the data from which 
these approaches are built can be traced back to thoughtful implementation. As an example, 
unapproved contours should be tagged or named to indicate their use to future researchers. 
We found many examples of contour and naming mismatches which, while likely irrelevant in 
the individual patient treatment plan had an effect on the work herein. 
Finally, the use of automatically contoured targets represents the aspect of this work 
most in need of further investigation. There exist enormous variability in not only the 
contouring of targets among physician but also in the choice of target anatomy when given 
patient disease characteristics. These challenges will be underlined in a system for which a 
simplified approach is desired. It is likely that additional nodal level groupings may be 
required, the atlases may need further development for patients with gross disease, and/or for 
patients from other demographics. The use of a second contouring technique as a check of 
the atlas based contours represents a novel contribution but requires further investigations, 
specifically the extension of the secondary technique for additional head-and-neck subsites 
and stages. 
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As a system, we envision the use of the automated treatment planning strategy as 
follows; a user is required to submit an approved patient CT and patient plan order which 
includes information about the patient’s acceptability for treatment (pregnancy status, prior 
radiation, implants, etc) and treatment goals (prescribed dose and fractionation). This 
information is then used to generate automatic normal tissues and nodal level groupings. The 
process is then suspended for the manual delineation of primary disease. Then on a single 
button click clinical and planning target volumes are generated using rules and the atlas 
generated nodal volumes; the targets are then reviewed by the attending physician. At this 
time the physician will also be presented with the results of the results of the random forest 
models for the detection of normal tissue contour errors and should use this to aide in the 
approval and editing of these structures as deemed appropriate. The automatic process then 
resumes with the automatic identification of the marked and treatment isocenter, the selection 
of beam parameters, plan optimization, dose calculation and production of accompanying 
plan documentation. The whole process is estimated to take less than an hour, much of which 
time is unsupervised.  
Data concerning the editing of normal structures, targets, the results of the error 
prediction models, the timing of each step, the acceptability of the final plan, and others 
should be collected for all patients. This will allow in depth retrospect analysis of the 
performance of the automated planning technique and improvement of the system. 
We believe this system has the ability to greatly reduce the human effort needed for 
one of the most technical and tedious aspects of radiation oncology. Automation of this 
process, however, should be considered for use in low-resource settings in the context of 
radiation therapy as a whole. Notably, while advanced techniques have been shown to 
outperform older, simpler techniques for the treatment of head-and-neck cancer there exist 
downstream effects due to this transition. Quality assurance process including that of 
individual treatment plans as well as of the machines and even of the treatment planning 
178 | P a g e  
 
process itself must reflect the transition to these advanced techniques. Further, the tasks 
completed by an automated approach must be able to be accomplished by, ideally, a number 
of trained staff; in the case of head-and-neck treatment this requires knowledge not only of 
plan optimization but also of the contouring of normal tissues and targets. In circumstances 
where the autoplanner may not be appropriate for patient treatment plan development, when 
the system is not functional due to planned or unplanned circumstances, and for routine 
quality assurance checks it is essential that treatment planning skills not be lost, or never 
developed, in centers where autoplanning is used.  
Conclusions 
The work presented here represent efforts towards two solutions to reduce the great 
and growing disparity of radiation therapy around the world. In LMICs, where 84% of the 
world’s population lives and two thirds of the cancer population lives, there are only 30% of 
the worlds radiation facilities; 11 countries of more than a million people have not a single 
teletherapy unit. Improving access to radiation therapy is not a simple process, it requires 
innovation approaches, collaborative efforts, and consistent reassessment of the needs and 
status in the areas of interest. The approaches presented here represents efforts both to 
reduce the upfront and ongoing cost of radiotherapy machines through the introduction of a 
fixed-beam rotating patient paradigm and the automation of one of the most time-intensive 
and technologically complex aspects of advanced radiotherapy – treatment planning. We 
believe these efforts could benefit clinics in low-resource areas and partly address the 
growing need for radiotherapy around the world. 
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Appendix 
Appendix A – Specific Aim 1 
The following questionnaire was administered to patients after their participation in the inter- 
and intra- fraction setup study in the treatment chair. Participants were also encouraged to 
give verbal feedback.  
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This questionnaire evaluates your degree of comfort when in a treatment position.   
The first 15 questions refer to treatments in a seated position 
1. Getting on the chair was: Easy  Difficult (0-5) 
 
2. When initially positioned on the chair, I felt: Relaxed  Tense (0-5) 
 
DURING THE SIMULATED TREATMENT (ON THE CHAIR)… 
3. …I felt like I needed to move. Not at all  Constantly (0-5) 
 
4. …I felt: Restless  Calm (0-5) 
 
5. …My body felt tense. Strongly DisagreeStrongly Agree (0-5) 
 
6. …My breathing felt fluid and easy. Strongly Disagree Strongly Agree (0-5) 
 
7. …My neck was: Not at allPerfectly Comfortable (0-5) 
 
8. …My arms were: Not at allPerfectly Comfortable (0-5) 
 
9. …My back was: Not at allPerfectly Comfortable (0-5) 
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 10. …My legs were: Not at allPerfectly Comfortable (0-5) 
 
11. …Overall my body was: Not at allPerfectly Comfortable (0-5) 
 
12. …I could have fallen asleep. Strongly DisagreeStrongly Agree (0-5) 
 
13. …I had discomfort due to the chair I was positioned on. Strongly Disagree 
Strongly Agree (0-5) 
 
OVERALL (ON THE CHAIR)… 
14. I felt stable and supported on the chair. Strongly Disagree Strongly Agree (0-
5) 
 
15. I felt absolutely safe on the chair. Strongly Disagree Strongly Agree (0-5) 
 
 
The next 15 questions are about you regular actual treatments (lying down) 
16. Getting on the patient couch was: Easy  Difficult (0-5) 
 
17. When initially positioned on the couch, I felt: Relaxed  Tense (0-5) 
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 DURING TREATMENT (LYING DOWN, ON THE COUCH)… 
18. …I felt like I needed to move. Not at all  Constantly (0-5) 
 
19. …I felt: Restless  Calm (0-5) 
 
20. …My body felt tense. Strongly DisagreeStrongly Agree (0-5) 
 
21. …My breathing felt fluid and easy. Strongly Disagree Strongly Agree (0-5) 
 
22. …My neck was: Not at allPerfectly Comfortable (0-5) 
 
23. …My arms were: Not at allPerfectly Comfortable (0-5) 
 
24. …My back was: Not at allPerfectly Comfortable (0-5) 
 
25. …My legs were: Not at allPerfectly Comfortable (0-5) 
 
26. …Overall my body was: Not at allPerfectly Comfortable (0-5) 
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 27. …I could have fallen asleep. Strongly DisagreeStrongly Agree (0-5) 
 
28. …I had discomfort due to the chair I was positioned on. Strongly Disagree 
Strongly Agree (0-5) 
 
OVERALL (LYING DOWN, ON THE COUCH)… 
29. I felt stable and supported on the couch. Strongly Disagree Strongly Agree 
(0-5) 
 
30. I felt absolutely safe on the couch. Strongly Disagree Strongly Agree (0-5) 
 
FINAL: COMPARISON OF SEATED AND LYING DOWN POSITIONS 
31. I prefer sitting up to lying down for treatment: strongly agreestrongly disagree 
(0-5) 
 
 
 
Please note any comments or feedback below. 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
_________________________________________________________________________ 
Thank you for completing this survey; we appreciate your feedback.  
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Appendix B – Specific Aim 2 
The contouring of small structures is often more difficult, as indicated by lower Dice 
similarity coefficients and larger mean surface and Hausdorff distances, compared to larger 
structures. Cochlea, the smallest structures implemented into the clinic had the largest 
disagreement with the clinically edited structures and it was therefore decided that an 
“uncertainty margin” of 5mm, similar to a PRV, would be added to the autocontoured cochlea 
for treatment planning; In Table 14, we showed that a margin of 5mm would be sufficient to 
cover 100% of the edited cochlea for more than 95% of the population. 
Other smalls structures required for treatment planning but not implemented clinically 
include the optic chiasm, optic nerves, and lens. The accurate contouring of these structures 
is of particular importance with the tumor is close to the optic structures and because they are 
serial structures (chiasm and nerves) or have particularly low clinical dose constraints (lens, 
Dmax<7Gy). As data of the clinical edit to these autocontours was not available, we examined 
the agreement between autocontoured structures using the MACS algorithm and 
independently drawn physician contours for 37 patients. Occasionally, the MACS algorithm 
would result in an empty structure due to insufficient overlap of individual contours from the 
12 atlas patients, in this case automatic optimization could not continue and in the context of 
the automated planning approach manual delineation of these structures would be required. 
To compensate, for this we investigated the possibility of using structures which have been 
expanded on the atlas patients in order to increase their volume and increase the likelihood of 
overlapping anatomy as input into the staple algorithm. In Table 29 are the average volume, 
Dice Similarity Coefficient, true positive fraction and false positive fraction as well as the 
percentage of structure with true positive fraction of 100% and greater than 95% given pre-
MACS expansion of 0-2mm in 1mm increments and with post macs (PRV-style) expansions 
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of 1 to 5mm in 1mm increments. It was decided that structures with 1mm pre-MACs expansion would be used with 5mm post MACS 
expansions for treatment planning. 
Details of the final autoplanning strategy can be found in Table 30 
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Table 29. Agreement of autocontoured optical structures with pre- and post- contouring expansions.
  Volume (cc) True Positive Fraction False Positive Fraction 
Pre-MACS 
Expansion (mm) 
Post-MACS 
Expansion (mm) 
Optic 
Chiasm Lens 
Optic 
Nerves 
Optic 
Chiasm Lens 
Optic 
Nerves 
Optic 
Chiasm Lens 
Optic 
Nerves 
Physician Drawn 1.25 0.37 1.16       
0 0 0.70 0.12 0.50 0.27 0.27 0.37 0.52 0.24 0.17 
0 1 1.12 0.27 0.91 0.39 0.47 0.52 0.57 0.39 0.34 
0 2 2.41 0.66 2.27 0.58 0.75 0.81 0.70 0.57 0.58 
0 3 3.12 0.98 2.98 0.66 0.83 0.85 0.73 0.68 0.67 
0 4 5.25 1.81 5.29 0.82 0.95 0.90 0.80 0.80 0.80 
0 5 6.56 2.48 6.62 0.87 0.96 0.91 0.83 0.85 0.84 
1 0 1.26 0.34 1.10 0.45 0.56 0.59 0.56 0.44 0.38 
1 1 1.83 0.62 1.72 0.56 0.69 0.69 0.61 0.61 0.54 
1 2 3.62 1.26 3.94 0.72 0.85 0.93 0.75 0.75 0.73 
1 3 4.50 1.74 4.92 0.77 0.87 0.95 0.78 0.81 0.78 
1 4 7.26 2.97 8.29 0.90 0.95 0.98 0.84 0.88 0.86 
1 5 8.86 3.87 10.11 0.93 0.95 0.98 0.86 0.91 0.89 
2 0 2.99 1.08 3.63 0.66 0.85 0.92 0.72 0.70 0.71 
2 1 4.06 1.70 5.04 0.75 0.90 0.95 0.77 0.80 0.78 
2 2 6.58 2.81 8.72 0.82 0.93 0.99 0.84 0.87 0.87 
2 3 7.93 3.65 10.38 0.85 0.93 0.99 0.86 0.90 0.89 
2 4 11.63 5.57 15.44 0.95 0.99 1.00 0.89 0.93 0.93 
2 5 13.84 6.96 18.28 0.96 0.99 1.00 0.91 0.95 0.94 
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Table 29. Continued from previous page. 
 
  Dice % with TPF > 100% % with TPF >=95% 
Pre-MACS 
Expansion 
(mm) 
Post-MACS 
Expansion 
(mm) 
Optic 
Chiasm Lens 
Optic 
Nerves 
Optic 
Chiasm Lens 
Optic 
Nerves 
Optic 
Chiasm Lens 
Optic 
Nerves 
0 0 0.34 0.38 0.50 0.00 0.00 0.00 0.00 0.00 0.00 
0 1 0.39 0.49 0.57 0.00 0.00 0.00 0.00 2.63 0.00 
0 2 0.39 0.51 0.54 0.00 18.42 0.00 0.00 28.95 13.89 
0 3 0.37 0.44 0.47 0.00 34.21 0.00 3.45 52.63 25.00 
0 4 0.32 0.32 0.32 11.11 69.44 13.89 22.22 83.33 44.44 
0 5 0.28 0.25 0.27 14.81 86.11 22.22 33.33 88.89 50.00 
1 0 0.43 0.53 0.59 0.00 2.56 0.00 0.00 5.13 0.00 
1 1 0.44 0.48 0.54 0.00 20.51 0.00 0.00 23.08 2.78 
1 2 0.36 0.37 0.42 0.00 53.85 11.11 6.90 64.10 58.33 
1 3 0.33 0.30 0.36 6.90 69.23 30.56 20.69 76.92 66.67 
1 4 0.27 0.21 0.24 18.52 83.78 50.00 51.85 86.49 86.11 
1 5 0.23 0.17 0.20 29.63 86.49 72.22 66.67 89.19 86.11 
2 0 0.38 0.43 0.44 0.00 35.90 11.11 3.45 53.85 52.78 
2 1 0.35 0.32 0.35 3.45 58.97 38.89 13.79 79.49 66.67 
2 2 0.26 0.22 0.23 13.79 76.92 61.11 27.59 84.62 97.22 
2 3 0.23 0.17 0.20 17.24 84.62 86.11 51.72 89.74 97.22 
2 4 0.19 0.13 0.14 29.63 97.30 97.22 66.67 97.30 100.00 
2 5 0.16 0.10 0.12 48.15 97.30 100.00 77.78 97.30 100.00 
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Table 30. Planning constraints of automated planning strategy. The origin of the contours in the RPA, in the evaluation of the planning 
strategy and the constraints (if used for optimization) are listed. *Optic chiasm, nerves and lens are expanded by 1mm on the atlas 
patients prior to MACS contouring. * 
XXXXcGy indicates that the prescribed dose of the corresponding structure is embedded in the structure name and varies between 
patients. 
Structure Structure Name Origin (Prospective RPA Use) Origin Type Volume Dose Priority 
Primary and 
Nodal GTV GTVp, GTVn Physician Drawn Physician Drawn 
    
High Dose CTV zCTV1_XXXXcGy 
Physician Drawn or 
Edited and Approved 
GTVp+1cm and 
GTVn+0.5cm 
Physician Drawn     
Intermediate 
Dose CTV zCTV2_XXXXcGy 
Physician Drawn or 
Edited and Approved 
atlas derived nodes 
Physician Drawn     
Low Dose CTV zCTV3_XXXXcGy 
Physician Drawn or 
Edited and Approved 
atlas derived nodes 
Physician Drawn     
High Dose PTV zPTV1_XXXXcGy 
High Dose CTV + 
0.5cm, within 3mm 
Contracted BodyAuto 
Physician Drawn     
Intermediate 
Dose PTV zPTV2_XXXXcGy 
Intermediate Dose 
CTV + 0.5cm, within 
3mm Contracted 
BodyAuto 
Physician Drawn     
Low Dose PTV zPTV3_XXXXcGy 
Low Dose CTV + 
0.5cm, within 3mm 
Contracted BodyAuto 
Physician Drawn     
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High Dose 
Planning PTV zpPTV1_XXXXcGy High Dose PTV 
 
Upper 0 108% 400 
Upper 20 103% 400 
Lower 100 96% 400 
Lower 96  400 
High Dose PTV 
Ring zrPTV1_XXXXcGy 
PTV1 - PTV1 
contracted 5mm 
 Upper 0 103% 300 
5mm Ring 1 mm 
from PTV1 zWallPTV1_05 
PTV1+6mm - 
PTV1+1mm 
 Upper 0 100% 120 
PTV1 Minimum 
Dose 
assessment 
structure 
z8bodyPTV1 PTV1  within body contracted 8mm 
     
Intermediate 
Dose Planning 
PTV 
zpPTV2_XXXXcGy 
Intermediate Dose 
PTV pulled 5mm 
from pPTV1 
 
Upper 0 108%+1Gy 190 
Upper 0 103%+1Gy 190 
Lower 100 97%+1.5Gy 190 
Lower 97 100%+1.5Gy 250 
Low Dose 
Planning PTV zpPTV3_XXXXcGy 
Low Dose PTV 
pulled 5mm from 
pPTV1 and pPTV2 
 
Upper 0 108%+1Gy 190 
Upper 0 103%+1Gy 190 
Lower 100 97%+1.5Gy 190 
Lower 97 100%+1.5Gy 250 
Body BodyAuto Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) Upper 0 106 900 
Normal Tissue 
Avoidance zNT_avoid 
BodyAuto outside all 
PTVs on slices within 
1cm of PTV1 
 
Upper 0 45 70 
Upper 10 35 70 
Upper 20 30 70 
Non Target 
Tissue zNonPTVs 
BodyAuto outside all 
PTVs 
     
Brain Brain Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
Upper 0 45 130 
Line Model 75 
Brainstem BrainStem Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
Upper 0 45 200 
Upper 1 Model 35 
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Line Model 75 
Brainstem 7mm 
PRV zBrainStem_07 BrainStem + 7mm 
 Upper 0 50 300 
Brainstem 5mm 
PRV zBrainStem_05 BrainStem + 5mm 
     
Left Cochlea Cochlea_L Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Cochlea Cochlea_R Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Expanded Left 
Cochlea zCochlea_L_05 Cochlea_L + 5mm 
 Upper 0 45 75 
Expanded Right 
Cochlea zCochlea_R_05 Cochlea_R + 5mm 
 Upper 0 45 75 
Esophagus Esophagus Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Esophagus 
Avoidance 
Structure 
zEsophagus_avoid Esophagus + 5mm outside of all PTVs 
 Line Model 75 
Left Eye Eye_L Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) Upper 0 40 130 
Right Eye Eye_R Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) Upper 0 40 130 
Larynx Larynx Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Larynx 
Avoidance zLarynx_avoid 
Larynx + 5mm 
outside all PTVs 
 Line Model 70 
Left Lens* Lens_L_A1 Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Lens* Lens_R_A1 Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Lens 
Avoidance zLens_L_A1B2 Lens_R + 5mm 
 Upper 0 45 130 
Left Lens 
Avoidance zLens_R_A1B2 Lens_R + 5mm 
 Upper 0 5 130 
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Lung Avoidance Lungs_Avoid Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Mandible Mandible Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
Upper 2 105% 150 
Lines Model 75 
Left Optic 
Nerve* OpticNrv_L_A1 
Automatically 
Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Optic 
Nerve* OpticNrv_R_A1 
Automatically 
Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Optic Chiasm* Chiasm_A1 Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Optical 
Nerve 
Avoidance 
zOpticNrv_R_A1B2 OpticNrv_R + 2mm  Upper 0 45 130 
Left Optical 
Nerve 
Avoidance 
zOpticNrv_L_A1B2 OpticNrv_L + 2mm  Upper 0 45 130 
Chiasm 
Avoidance zChiasm_A1B2 Chiasm + 2mm 
 Upper 0 45 130 
Oral Cavity OralCavity Automatically Contoured 
     
Oral Cavity 
Avoidance zOralCavity_plan 
OralCavity outside all 
PTVs 
 Line Model  100 
Left Parotid 
Gland Parotid_L 
Automatically 
Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Right Parotid 
Gland Parotid_R 
Automatically 
Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Left Parotid 
Gland Planning 
structure 
zParotid_L_sub Parotid_L outside of all PTVs 
 Line Model  120 
Right Parotid 
Gland Planning 
Structure 
zParotid_R_sub Parotid_R outside of all PTVs 
 Line Model  120 
Posterior Neck fsPostAvoid Automatically Contoured 
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Posterior Neck 
Avoidance zPostNeck_avoid 
fsPostAvoid outside 
of all PTVs 
 Upper 0 35 120 
Shoulders Shoulders Automatically Contoured 
 Upper 0 25 40 
Spinal Cord SpinalCord Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
Upper 0 40 300 
Upper 1 Model 35 
Line Model 75 
Spinal Cord 
5mm PRV zSpinalCord_05 SpinalCord + 5mm 
     
Spinal Cord 
7mm PRV zSpinalCord_07 SpinalCord + 7mm 
 Upper 0 50 300 
Spinal Canal Spinal Canal Automatically Contoured 
     
Left 
Submandibular 
Gland 
Glnd_Submand_L Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Upper 10 35 70 
Upper 20 30 70 
Right 
Submandibular 
Gland 
Glnd_Submand_R Automatically Contoured 
Clinical Plan 
(if DNE, autocontoured) 
    
Upper 10 35 70 
Upper 20 30 70 
Vertebral 
Column VeterbalColumn 
Automatically 
Contoured 
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Appendix C – Specific Aim 3 
Additional analysis of autocontour algorithm performance was performed and is 
presented here.  The deformable image registration known as “Deeds” was presented in 2013 
and is currently licensed by Varian Medical Systems. This algorithm is used as the 
independent method for normal tissue contouring used in the machine learning models for the 
detection of autocontouring errors as presented in Chapter 5. In one version of the algorithm 
active shape models have been implemented for improved contouring(1). A physician review 
of the this algorithm, which includes the shape model and uses a Varian provided atlas, for 
ten patients was conducted and the results can be seen in Figure 40. The algorithm was also 
investigated for use with the same atlas as used in the MACS algorithm and with a second 
atlas generated from 11 patients treated at MD Anderson Cancer Center, this independent 
atlas was used for contour propagation for the machine learning models. The agreement to 
independently drawn physician contours of these three algorithms based on the Deeds DIR 
as well as for MACS can be seen in Table 31.  
In the smart segmentation software, as described, there are vendor provided ratings of 
the expected agreement between the test patient in question and each of the available atlas 
patients. We sought to investigate if there existed trends in these ratings relative to physician 
ratings or quantitative agreement with physician contours – no apparent trends were 
observed, the results can be seen in Table 32. We also sought to investigate if the physician 
ratings produced noticeable trends compared to both the average star rating and quantitative 
agreement with physician drawn structures – no apparent trend was observed, the results can 
be seen in Table 33. 
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Figure 40. Distribution of physician scores of Deeds based multi-atlas algorithm with shape models. 
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Table 31. Quantitative analysis of additional normal structure autocontouring algorithms.
 Contouring 
Method Structure N 
Dice Similarity 
Coefficient Hausdorff Distance (cm) 
Mean Surface Distance 
(cm) 
Mea
n Std Min Max 
Mea
n Std Min Max Mean Std Min Max 
Deeds MDA 
Independent 
Atlas vs Phys 
Brainstem 75 0.81 0.12 0.24 0.90 0.92 0.62 0.35 4.06 2.24 1.53 1.16 10.70 
Mandible 39 0.80 0.13 0.29 0.92 1.89 1.36 0.47 5.71 2.36 2.21 0.89 12.23 
Parotid Glands 140 0.72 0.10 0.33 0.90 1.74 0.55 0.70 3.68 3.03 0.97 1.46 6.74 
Brain 26 0.97 0.04 0.76 0.98 1.53 1.21 0.49 4.54 1.36 1.49 0.77 8.19 
Cochlea 94 0.59 0.17 0.11 0.85 0.45 0.22 0.16 1.27 1.46 0.63 0.66 3.95 
Esophagus 29 0.51 0.16 0.10 0.80 3.59 1.74 0.76 7.20 5.90 4.40 1.33 25.68 
Eye 58 0.79 0.08 0.63 0.93 0.46 0.11 0.22 0.72 1.75 0.57 0.83 3.03 
Lungs 12 0.88 0.09 0.74 0.97 3.75 2.42 1.39 7.94 4.33 4.15 1.01 13.04 
Spinal Cord 70 0.71 0.12 0.24 0.88 5.37 3.92 0.25 17.33 5.83 6.01 0.82 33.05                
Deeds MDA 
Original Atlas vs 
Phys 
Brainstem 75 0.79 0.13 0.24 0.90 0.97 0.69 0.43 4.06 2.47 1.65 1.19 10.46 
Mandible 39 0.81 0.13 0.27 0.91 1.92 1.29 0.59 5.62 2.28 2.11 1.00 12.76 
Parotid Glands 140 0.74 0.09 0.34 0.88 1.65 0.47 0.80 2.94 2.86 0.84 1.61 6.71 
Brain 26 0.98 0.01 0.96 0.98 1.37 0.94 0.50 3.81 1.01 0.17 0.80 1.51 
Cochlea 94 0.57 0.16 0.13 0.83 0.47 0.22 0.17 1.27 1.49 0.58 0.72 3.85 
Esophagus 29 0.51 0.14 0.12 0.76 3.54 1.46 0.94 5.96 5.45 3.50 1.98 20.07 
Eye 58 0.79 0.07 0.65 0.93 0.49 0.11 0.25 0.73 1.70 0.45 0.76 2.66 
Lungs 12 0.84 0.14 0.51 0.97 3.80 3.47 0.97 11.50 6.34 7.05 0.85 24.20 
Spinal Cord 70 0.74 0.11 0.28 0.87 3.90 3.23 0.37 13.47 4.29 5.32 0.90 28.89                
MACS vs Phys 
Brainstem 75 0.80 0.12 0.25 0.91 0.98 0.62 0.41 3.70 2.37 1.55 1.10 9.73 
Mandible 39 0.85 0.06 0.64 0.93 1.83 1.12 0.41 5.56 1.66 0.89 0.76 4.62 
Parotid Glands 140 0.79 0.07 0.44 0.89 1.47 0.64 0.59 3.60 2.37 0.76 1.30 6.16 
Brain 26 0.98 0.00 0.97 0.99 1.33 0.86 0.48 3.75 1.06 0.17 0.80 1.43 
Cochlea 94 0.50 0.17 0.06 0.88 0.48 0.19 0.14 1.41 1.61 0.68 0.42 4.27 
Esophagus 29 0.64 0.12 0.37 0.83 2.32 1.21 0.65 5.42 3.16 1.57 1.15 8.02 
Eye 58 0.84 0.07 0.56 0.93 0.47 0.15 0.25 1.06 1.42 0.39 0.72 2.36 
Lungs 12 0.76 0.21 0.39 0.94 4.56 4.23 1.24 14.08 9.09 9.47 1.49 29.89 
Spinal Cord 70 0.73 0.09 0.30 0.86 3.75 2.91 0.35 16.31 3.78 3.90 0.94 22.39                
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Deeds Varian 
Shape vs Phys 
Brainstem 75 0.78 0.13 0.23 0.90 1.09 0.71 0.49 4.26 2.59 1.73 1.26 10.54 
Mandible 39 0.80 0.14 0.27 0.92 2.16 1.31 0.52 5.63 2.51 2.40 0.87 12.30 
Optic Chiasm 21 0.47 0.13 0.13 0.62 0.88 0.34 0.47 2.00 2.16 0.73 1.27 3.74 
Optic Nerve 48 0.63 0.10 0.38 0.86 0.81 0.45 0.17 1.87 1.48 0.57 0.72 3.11 
Submandibular 
Glands 53 0.72 0.13 0.27 0.88 0.97 0.52 0.42 3.18 2.33 1.62 1.16 9.83 
Parotid Glands 140 0.74 0.08 0.38 0.87 1.94 0.60 0.68 3.62 2.95 0.85 1.52 6.73 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 32. Autocontour performance and Eclipse Star Rating. Mean and standard deviation of physician scores and agreement with 
physician contours divided by Eclipse Smart Segmentation star rating. 
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Structure Star N Physician Rating Dice Hausdorff Distance (cm) Mean Surface Distance (cm) Mean Std Mean Std Mean Std Mean Std 
Brainstem 
3 6 2.83 0.41 0.73 0.05 0.89 0.11 0.28 0.04 
4 77 3.17 0.59 0.74 0.05 0.96 0.25 0.29 0.05 
5 8 3.13 0.35 0.76 0.03 1.20 0.47 0.27 0.05 
Cochlea 
3 7 2.71 0.49 0.26 0.06 0.96 0.13 0.30 0.03 
4 80 3.04 0.37 0.40 0.08 0.81 0.20 0.23 0.04 
5 8 2.88 0.35 0.29 0.06 1.07 0.18 0.31 0.04 
Eye 
3 11 3.73 1.01 0.77 0.07 0.77 0.39 0.20 0.06 
4 158 3.28 0.90 0.74 0.08 0.69 0.27 0.23 0.07 
5 16 3.00 0.73 0.72 0.06 0.76 0.16 0.24 0.05 
Lung 
3 6 3.17 0.75 0.92 0.03 2.46 0.51 0.16 0.03 
4 79 2.95 0.99 0.92 0.05 2.28 0.87 0.20 0.19 
5 8 3.13 1.46 0.90 0.11 2.42 1.26 0.30 0.45 
Mandible 
3 6 2.50 0.84 0.61 0.05 1.69 0.21 0.37 0.06 
4 87 2.85 0.83 0.68 0.08 1.71 0.50 0.29 0.09 
5 8 2.88 1.13 0.69 0.09 1.74 0.41 0.29 0.11 
Parotid 
3 8 2.25 0.46 0.46 0.12 3.39 0.60 0.74 0.17 
4 148 2.91 0.82 0.68 0.09 1.94 0.72 0.36 0.12 
5 16 2.63 0.96 0.67 0.06 1.94 0.48 0.36 0.09 
Spinal Cord 
3 6 4.33 0.52 0.72 0.01 1.30 0.12 0.18 0.01 
4 79 4.04 0.41 0.67 0.07 2.95 2.13 0.31 0.13 
5 8 4.25 0.46 0.65 0.06 3.51 1.17 0.33 0.09 
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Table 33. Autocontour performance and physician rating. Mean and standard deviation of Eclipse Stars and agreement with physician 
contours divided by Physician Rating. 
Structure Rating N Star Dice Hausdorff Distance (cm) Mean Surface Distance (cm) Mean Std Mean Std Mean Std Mean Std 
Brainstem 
2 8 3.88 0.35 0.70 0.07 0.94 0.08 0.32 0.05 
3 63 4.03 0.44 0.74 0.04 1.02 0.31 0.29 0.05 
4 19 4.05 0.23 0.77 0.03 0.85 0.16 0.25 0.03 
5 1 4.00 0.00 0.79 0.00 1.00 0.00 0.24 0.00 
Cochlea 
2 7 3.86 0.69 0.33 0.06 0.99 0.17 0.28 0.03 
3 81 4.02 0.39 0.39 0.09 0.83 0.21 0.24 0.05 
4 7 4.00 0.00 0.40 0.07 0.83 0.11 0.23 0.03 
Eye 
2 41 4.07 0.35 0.69 0.11 0.90 0.44 0.27 0.11 
3 66 4.06 0.43 0.74 0.05 0.68 0.19 0.23 0.05 
4 63 4.02 0.34 0.76 0.06 0.62 0.12 0.21 0.05 
5 15 3.80 0.41 0.78 0.07 0.62 0.14 0.20 0.06 
Lung 
1 6 4.17 0.41 0.78 0.10 3.82 0.98 0.77 0.50 
2 25 4.04 0.35 0.91 0.06 2.72 0.51 0.23 0.17 
3 32 3.97 0.40 0.93 0.03 2.27 0.85 0.16 0.08 
4 25 3.96 0.35 0.94 0.02 1.74 0.58 0.14 0.06 
5 5 4.40 0.55 0.95 0.01 1.44 0.32 0.09 0.01 
Mandible 
2 41 4.00 0.45 0.61 0.07 1.92 0.52 0.36 0.09 
3 41 4.02 0.27 0.72 0.05 1.52 0.36 0.24 0.06 
4 14 4.00 0.39 0.71 0.06 1.67 0.36 0.27 0.08 
5 5 4.20 0.45 0.76 0.02 1.67 0.73 0.21 0.02 
Parotid 
1 1 4.00 0.00 0.29 0.00 2.57 0.00 0.68 0.00 
2 63 4.06 0.50 0.60 0.10 2.37 0.63 0.47 0.15 
3 75 4.01 0.26 0.70 0.07 1.86 0.75 0.34 0.10 
4 26 4.08 0.27 0.75 0.04 1.68 0.69 0.27 0.07 
5 7 4.14 0.38 0.76 0.08 1.39 1.01 0.26 0.14 
Spinal Cord 3 5 4.00 0.00 0.56 0.05 3.47 2.98 0.42 0.19 
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4 76 4.03 0.36 0.67 0.06 3.10 2.00 0.31 0.12 
5 12 4.00 0.60 0.73 0.04 1.37 1.23 0.21 0.08 
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